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Resumo  
 O cancro é uma doença complexa que envolve numerosas alterações na fisiologia da célula que 
conduzem, em última instância, a tumores malignos. Os processos biológicos através dos quais as células 
normais são transformadas em células cancerígenas malignas têm sido alvo de vasta investigação durante 
várias décadas (Seyfried & Shelton, 2010). Existem seis alterações essenciais na fisiologia celular que estão 
na base do crescimento celular maligno e são a auto-suficiência em termos de sinais de crescimento, a 
insensibilidade a sinais inibidores de crescimento, a evasão à morte celular programada (apoptose), um 
potencial replicativo ilimitado, a angiogénese sustentada e a invasão tecidular e metastização (Hanahan & 
Weinberg, 2000). Contudo, recentemente, têm sido propostos outros atributos distintos às células 
cancerígenas funcionalmente importantes para o desenvolvimento de cancro, que incluem a reprogramação 
do metabolismo energético celular, por forma a suportar o crescimento celular e a proliferação contínua, e a 
evasão ao controlo imunitário (Hanahan & Weinberg, 2011). Ao longo da última década, os tumores têm sido 
identificados como órgãos cuja complexidade pode exceder a dos tecidos saudáveis normais, contrastando 
com a anterior visão reducionista dos tumores como um conjunto relativamente homogéneo de células 
cancerígenas. Desta forma, a biologia de um tumor só pode ser entendida analisando os tipos celulares 
especializados que o constituem bem como a microambiente tumoral criado durante o processo de 
tumorigénese (Seyfried & Shelton, 2010) .  
Em termos de incidência global, estima-se que 12.7 milhões de novos casos de cancro e 7.6 milhões 
de mortes causadas por cancro ocorram por ano (Ferlay et al., 2010). 
 O cancro do colo do útero é o terceiro cancro mais comum entre as mulheres, e o sétimo 
globalmente (Ferlay et al., 2010; Yugawa & Kiyono, 2009), sendo a quarta causa de morte por cancro entre as 
mulheres, mundialmente (Jemal et al., 2011; Ferlay et al., 2010). Apesar de a incidência deste tipo de tumor 
ter diminuído nos países desenvolvidos, a incidência mundial estimada ronda os 500 000 novos casos por 
ano (Jemal et al., 2011; Yugawa & Kiyono, 2009). Em Portugal, o cancro do colo do útero surge como o 
quarto mais frequente entre as mulheres (Globocan, 2008). 
Em termos histológicos, existem duas variantes de cancro do colo do útero com significado clínico, 
os adenocarcinomas (AC) (que compreendem 10 a 25 % dos casos) e os carcinomas pavimento celulares 
(SCC) (que compreendem cerca de 85 a 90% dos casos) (Chan et al., 2003; Smith et al., 2000). Sabe-se que 
em algumas doentes, o tumor apresenta um crescimento endofítico, invadindo o endométrio, enquanto 
noutros casos, o tumor cresce exofíticamente para o canal da vagina (Nguyen & Averette, 1999). Além disso, 
neste tipo de tumor, a composição da flora vaginal, concretamente, a presença de Doderlein bacilli, bacilo que 
possui a capacidade de converter o glicogénio presente na mucosa vaginal em ácido láctico, contribui para a 
criação e manutenção de um microambiente rico em ácido láctico que pode desempenhar um papel na 
selecção das células cancerígenas e na progressão tumoral (Gupta, 2011; Redondo-Lopez et al., 1990). 
O virus do papiloma humano (HPV) é o agente etiológico do cancro do colo do útero, contudo, a 
infecção por HPV não é o único factor envolvido na carcinogénese do carcinoma do colo do útero (Yeasmin et 
al., 2011). Alterações genómicas em oncogenes e genes supressores de tumor nas células do colo uterino 
são também essenciais ao desenvolvimento de carcinoma do colo do útero (Yeasmin et al., 2011). A 
amplificação genética em certas regiões cromossómicas é um dos mecanismos de activação de vários  
oncogenes  e outros genes relacionados com o desenvolvimento e progressão tumoral (Schwab, 1999). 
Estudos em carcinoma do colo do útero, revelaram que os receptores do factor de crescimento epidérmico 
(EGF) e o proto-oncogene c-Myc estão frequentemente activados por amplificação e estão claramente 
associados ao fenótipo maligno (Hale et al., 1993; Pfeiffer et al., 1989). 
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 As células tumorais reprogramam o seu metabolismo energético de forma a sustentar as elevadas 
taxas proliferativas (Tennant et al., 2009; DeBerardinis et al., 2008). Além disso, esta reprogramação permite-
lhes resistir a alguns sinais de morte celular, particularmente aqueles mediados por danos oxidativos (King & 
Gottlieb, 2009). Para se dividir uma célula necessita de aumentar em tamanho mas também de replicar o seu 
DNA – processos que são altamente exigentes do ponto de vista metabólico e que requerem grandes 
quantidade de proteínas, lípidos e nucleótidos, tal como energia no forma de ATP, o que implica um aumento 
no consumo de glucose e aminoácidos (Tennant et al., 2010). O fenótipo metabólico melhor caracterizado que 
se observa nas células tumorais é o efeito de Warburg, que consiste no cancelamento do ciclo de Krebs e 
cadeia transportadora de electrões e aumento da taxa de glicólise na presença de concentrações normal de 
oxigénio (Vander Heiden et al., 2009; Warburg, 1956). Consequentemente, ao contrário da maioria das 
células normais, muitas células tumorais produzem quantidades substanciais da sua energia através da 
glicólise aeróbia, convertendo a maior parte da glucose a lactato ao invés de a metabolizarem mediante 
fosforilação oxidativa (Semenza, 2008; Warburg, 1956).  
Em suma, as células tumorais apesentam maior consumo de nutrientes e também maior produção 
de subprodutos do que os tecidos normais, resultando numa acumulação de metabolitos no interior da célula 
e na criação de um ambiente mais hostil no exterior da mesma.  
As alterações metabólicas e as adaptações desenvolvidas pelas células tumorais, extensivamente 
estudadas durante o último século, criam um fenótipo que é essencial ao crescimento tumoral e à 
sobrevivência da célula tumoral, alterando o fluxo ao longo de vias metabólicas chave, tais como a glicólise e 
a glutaminólise (Tennant et al., 2009). Estas alterações incluem a alteração da expressão (Semenza et al., 
1996), mutação e inactivação pós-traducional de uma enzima (Kim et al., 2006) ou a substituição de uma 
enzima por uma isoforma diferente (Atsumi et al., 2002). Por outro lado, embora os factores chave envolvidos 
na criação do fenótipo metabólico das células tumorais estejam por elucidar, a literatura actual indica que o c-
Myc, p53 o HIF-1 são cruciais neste processo e que existe uma acção combinada desta tríade de factores de 
transcrição na regulação do metabolismo tumoral (Yeung et al., 2008). 
Assim, as observações referidas anteriormente colocam a glicólise como contribuinte chave para o 
fenótipo maligno e suportam a procura de novos tratamentos para o cancro que têm como alvo esta via 
metabólica essencial. Na verdade, a maioria das adaptações metabólicas desenvolvidas pelas células 
tumorais são únicas e exclusivas relativamente aos tecidos saudáveis(Porporato et al., 2011). De forma a 
estabelecer novos alvos terapêuticos os transportadores de compostos carboxilatos, principalmente de 
glucose, lactato e piruvato devem ser estudados bem como as enzimas que catalisam passos chave em vias 
metabólicas centrais, como é o caso da lactato e da piruvato desidrogenase. 
A reacção reversível de redução do piruvato a lactato é catalisada pela família de enzimas lactato 
desidrogenases (LDH), formadas pelo rearranjo de até quatro cópias de duas subunidades diferentes: a 
subunidade LDH-H codificada no gene LDHB e a subunidade LDH-M codificada no gene LDHA para formar 
tetrâmeros activos que conduzem à formação de cinco enzimas, LDH1 a LDH5. A LDH5/LDH-4M (LDHA) 
catalisa preferencialmente a redução de piruvato a lactato e a LDH1/LDH-4H (LDHB) a conversão de lactato 
em piruvato (Porporato et al., 2011). A família de genes LDH também o gene LDHC, expresso nos testículos e 
espermatozóides, que codifica uma terceira isoenzima, a LDHC (Holmes & Goldberg, 2009).  
A reacção catalisada pela LDH5/LDH-4M produz concentrações equimolares de lactato e protões, 
então, de forma a evitar a acidificação intracelular e a morte, as células glicolíticas exportam protões através 
de sistemas adaptados ao transporte dos mesmos, em que se incluem os transportadores de 
monocarboxilatos (MCT), entre os quais o MCT1, MCT2, MCT3 e MCT4 efectuam o simporte passivo de 
lactato e protões (Halestrap & Meredith, 2004). 
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Tem sido reportada a sobre-expressão e activação do gene LDHA no tecido tumoral 
comparativamente com o tecido normal (Walenta & Mueller-Klieser, 2004; Lewis et al., 2000; Shim et al., 
1997).  Estudos anteriores revelaram transactivação do promotor deste gene pelo factor de transcrição c-Myc 
(Shim et al., 1997), aumentando directamente a sua expressão. Em relação ao LDHB não foi ainda 
estabelecida uma relação definitiva entre a expressão deste gene e o cancro, com alguns autores a 
reportarem o aumento (Chen et al., 2006) da mesma no tumor e outros, o seu silenciamento transcricional no 
tumor (Leiblich et al., 2006; Maekawa et al., 2003). Recentemente, tem sido também identificada expressão 
do gene LDHC num largo espectro de tumores (Koslowski et al., 2002). 
Sabe-se que o MCT4 transporta preferencialmente o lactato para o exterior da célula e o MCT1 
regula preferencialmente a entrada do mesmo em células tumorais (mas também o efluxo) e células 
endoteliais tumorais (Draoui & Feron, 2011). Existem estudos que demonstram a sobre-expressão de MCT1 
em carcinoma da mama (Pinheiro et al., 2010) e outros em que se verificou a sobre-expressão de MCT1 e 
MCT4 em neuroblastoma, cancro do colo do útero e colorectal (Pinheiro et al., 2009; Pinheiro et al., 2008; 
Sonveaux et al., 2008; Fang et al., 2006). 
 Com base no trabalho científico que vem sendo realizado na área do metabolismo tumoral, foi 
definido como objectivo desta tese a caracterização do perfil metabólico de duas linhas celulares de cancro de 
colo do útero de dois tipos histológicos diferentes, adenocarcinoma (HeLa) e carcinoma pavimento celular 
(SiHa), determinando a relevância das enzimas LDHA, LDHB e LDHC e dos transportadores MCT1 e MCT4. 
Especificamente, compreender o papel do factor de crescimento EGF e do lactato de sódio (NaLac) na 
regulação da expressão de LDHA, LDHB, LDHC, MCT1 e MCT4 nas linhas celulares HeLa e SiHa.  
 Os resultados revelaram que em células HeLa, a presença de NaLac promove a sobre-expressão de 
LDHA através da interacção do factor de transcrição c-Myc com o promotor do gene. Nesta linha celular foi 
também identificada amplificação genética de c-Myc. Em células SiHa a presença de NaLac promove 
igualmente um aumento na expressão de LDHA, a nível do mRNA, contudo não por intermédio da acção de 
c-Myc. Nesta linha celular, observou-se também um aumento no número de cópias de c-Myc, porém em 
resultado de aneuploidia, uma vez que estas células apresentaram mais de dois cromossomas 8, onde se 
localiza o c-Myc. 
Relativamente ao gene LDHB, verificou-se que, em ambas as linhas celulares, a presença de NaLac 
promove a sobre-expressão do mesmo. Em relação às células SiHa observou-se ainda que a estimulação 
com EGF promove a expressão de LDHB sendo este efeito activador potenciado pela presença de NaLac. 
Em termos de regulação da expressão de LDHB propõe-se que esta seja mediada pelo factor de transcrição 
STAT3. 
No que concerne à expressão dos transportadores de monocarboxilatos, verificou-se que a 
expressão de MCT1 em células HeLa na presença de NaLac é regulada pelo factor de transcrição c-Myc que 
actuará, neste cenário, como repressor. Já no que diz respeito às células SiHa os dados apontam para a 
existência de repressão da expressão do gene pelo c-Myc, em condições controlo, e para a sua activação na 
presença de NaLac. Em termos de perspectivas futuras, a elucidação do papel do c-Myc como activador ou 
repressor da expressão de MCT1 dependerá do estudo dos seus parceiros nos diferentes contextos. 
Em relação ao MCT4, este encontra-se sobre-expresso em ambas as linhas celulares quando 
expostas a NaLac. 
 Os resultados obtidos na análise de casos de AC e SCC do colo do útero evidenciaram o papel 
crucial do microambiente tumoral na selecção de células tumorais. No contexto oxidativo em que os tumores 
pavimentosos se desenvolvem, a sobre-expressão de MCT1 pode conferir vantagens às células tumorais, 
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dada a sua importância na importação de lactato. Além disso, esta sobre-expressão pode estar na base do 
switch do consumo de glucose para o de lactato neste tipo de tumor, tal como foi descrito em células SiHa. 
Nos casos de AC, as baixas concentrações de lactato que caracterizam o microambiente tumoral dos AC, 
parecem promover a diminuição da expressão de MCT1. Por outro lado, se considerarmos o papel do 
microambiente tumoral como agente de selecção, os menores níveis de lactato podem selecionar as células 
tumorais que expressam menos MCT1 dada a sua menor necessidade de importar lactato, comparativamente 
com as células tumorais de carcinomas pavimentosos. 
O estudo da migração e proliferação in vitro revelou que a estimulação com EGF e a presença de 
NaLac promove a migração e proliferação das células SiHa. Propomos que o factor de transcrição c-Myc 
possa estar implicado neste fenótipo via regulação da expressão de MCT1, cuja função permite fornecer à 
célula tumoral fontes de energia alternativas de modo a sustentar a sua avidez energética. Assim sendo, o 
factor de transcrição c-Myc pode estar implicado na regulação de vários genes alvo regulando processos não 
só relacionados com o metabolismo mas também com o controlo do ciclo celular. 
O estabelecimento de modelos in vivo, nomeadamente para estudo das consequências da inibição 
de MCT1 a nível do crescimento e progressão tumoral surge como futura abordagem. 
   
 
Palavras-chave: Lactato, EGF, cancro do colo do útero, c-Myc, microambiente tumoral, LDHs, MCTs 
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Abstract  
 
Emerging evidence indicates that impaired cellular energy metabolism is the defining characteristic of 
nearly all cancers regardless their cellular or tissue origin. Tumor cells have a remarkably different metabolism 
from that of the tissues from which they are derived. Although lactate is generally considered a waste product, 
several studies show that it is a prominent substrate that fuels the oxidative metabolism of oxygenated tumor 
cells. The study of the enzymes involved in lactate production (LDHA) and consumption (LDHB), as well as its 
transporters (MCTs), will help to define new therapeutic targets.  
The main objective of this thesis is to characterize the metabolic profile of two uterine cervix cancer 
cell lines from two different histological types, adenocarcinoma (HeLa) and squamous cell carcinoma (SiHa), 
namely LDHs and MCTs expression regulation by sodium lactate (NaLac) and Epidermal Growth Factor 
(EGF). 
Our findings suggested c-Myc activation of LDHA expression in HeLa cells grown in the presence of 
NaLac. Regarding SiHa cells, it was observed LDHA upregulation, at mRNA levels, by NaLac, however not c-
Myc mediated. NaLac promotes LDHB expression in both cell lines. In SiHa cells, EGF promotes LDHB 
expression too, being this activator effect increased by NaLac. We proposed NaLac-mediated c-Myc 
repression of MCT1 expression in HeLa cells. In SiHa cells, NaLac activates MCT1 expression, decreasing c-
Myc interaction with MCT1 promoter or promoting an alternative role of c-Myc as an activator. NaLac also 
promotes MCT4 expression.  
In the oxidative context where SCC cancer cells develop, the upregulation of MCT1 confer crucial 
advantages to these cells, given its importance in lactate uptake and could be in the basis of a switch from 
glucose to lactate consumption in SCC tumors, as described in SiHa cells. We suggested that c-Myc could 
also be involved in cell migration and proliferation in vitro, via MCT1.  
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1. Introduction 
 
1.1 Cancer  
Cancer is a complex disease involving numerous tempospatial changes in cell physiology, which 
ultimately lead to malignant tumors. Tumor cell invasion of surrounding tissues and distant organs is the 
primary cause of morbidity and mortality for most cancer patients. The biological process by which normal cells 
are transformed into malignant cancer cells has been the subject of a large research effort in the biomedical 
sciences for many decades (Seyfried & Shelton, 2010). 
Hanahan & Weinberg, 2000 suggested that six essential alterations in cell physiology could underlie 
malignant cell growth. These six alterations were described as the hallmarks of nearly all cancers and 
included, 1) self-sufficiency in growth signals, 2) insensitivity to growth inhibitory (antigrowth) signals, 3) 
evasion of programmed cell death (apoptosis), 4) limitless replicative potential, 5) sustained vascularity 
(angiogenesis), and 6) tissue invasion and metastasis (Hanahan & Weinberg, 2000). Genome instability, 
leading to increased mutability, was considered the essential enabling characteristic for manifesting the six 
hallmarks ( Seyfried & Shelton, 2010; Hanahan & Weinberg, 2000). 
Overall, an estimated 12.7 million new cancer cases and 7.6 million cancer deaths occur in 2008, with 
56% of new cancer cases and 63% of the cancer deaths occurring in the less developed regions of the world. 
The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% of the total), breast (1.38 
million, 10.9%) and colorectal cancers (1.23 million, 9.7%). The most common causes of cancer death are 
lung cancer (1.38 million, 18.2% of the total), stomach cancer (738 000 deaths, 9.7%) and liver cancer (696 
000 deaths, 9.2%) (Ferlay et al., 2010). 
 
1.2 Uterine cervix: Histology and microenvironment 
 
The uterine cervix protrudes into vagina (exocervix or ectocervix) and contains an endocervical canal 
that links the vagina with the uterus. The endocervical canal is lined by cells similar to the uterus – a single 
layer of tall, columnar, mucus-secreting cells. In areas where the cervix is exposed to the hostile 
microenvironment of the vagina, the cervix is lined by thick stratified squamous epithelia. The presence of 
Doderlein bacilli - gram-positive and rod-shaped bacilli which grows anaerobically on acid media - in the 
vaginal mucosa contributes to this hostile microenvironment. It is known that its presence is dependent on 
estrogen and that its function is to convert the glycogen present in the vaginal mucosa into lactic acid 
contributing to the acidification of vagina microenvironment (Gupta, 2011; Redondo-Lopez et al., 1990). 
At the point where the endocervical canal opens, the junction between the two types of epithelium 
exists (Brezinski, 2006). The stratified squamous cells in the ectocervix transition into mucinous columnar 
epithelium in the endocervix with the interface between the two tissues designated as the squamocolumnar 
(SC) junction (Havens & Sullivan, 2002). 
The natural history of the endocervical columnar epithelium is to undergo metaplastic transformation 
to a mature squamous epithelium, i.e. squamous metaplasia, this change being especially active during 
adolescence and pregnancy (Havens & Sullivan, 2002) (Figure 1). The area involved with this metaplastic 
change is designated the transformation zone and it’s dynamic throughout a woman’s reproductive life, 
migrating and changing location in the cervix in response to stimuli, including hormones and pH (Braun & 
Anderson, 2007). High estrogen levels, as experienced in the luteal phase of the menstrual cycle and during 
pregnancy, promote the gradual transition of squamous epithelium to columnar epithelium. Low estrogen 
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levels, as occur in menopause, cause the SC junction to recede into the endocervical canal. The adaptations 
that these cell types undergo are examples of metaplasia – the cellular response of changing from one type of 
epithelium to another in the face of an environmental stessor. Although the metaplastic changes of the cervix 
are not pathological, the squamous epithelia cell component of the transformation zone (Figure 1) is vulnerable 
to stressors, which may cause cell injury or damage (Braun & Anderson, 2007), being the tissue at risk of 
being influenced by oncogenic factors, principally Human Papillomavirus, to initiate neoplastic change 
(Brezinski, 2006; Havens & Sullivan, 2002). Accordingly to Burghardt & Ostör, 1983 a substantial majority 
(~87%) of uterine cervix squamous intraepithelial lesions (SILs) and cancers develop within the specific 
microenvironment of the cervix at the transformation zone (Burghardt & Ostör, 1983). In addition, recent data 
suggests that carcinogenic Human Papillomavirus-related cervical intraepithelial neoplasia (CIN) and uterine 
cervix cancers are linked to a small, discrete cell population that localizes to the SC junction of the cervix that 
expresses a unique gene expression signature (Herfs et al., 2012). 
 
 
 
Figure 1 - Uterine cervix cancer metaplasia. The endocervical columnar epithelium undergoes metaplastic transformation to a 
mature squamous epithelium during adolescence. 
 
 
1.3 Uterine cervix cancer  
 
1.3.1 Worldwide incidence 
Uterine cervix cancer is a major health problem worldwide; it is the third most common cancer in 
women, and the seventh overall (Ferlay et al., 2010; Yugawa & Kiyono, 2009), and is the fourth leading cause 
of cancer death in females worldwide, accounting for 9% (529 800) of the total new cancer cases and 8% (275 
100) of the total cancer deaths among females in 2008 (Jemal et al., 2011; Ferlay et al., 2010). 
Although the incidence of this cancer has declined in developed countries (Yeasmin et al., 2011) 
there is an estimated 500 000 new cases of uterine cervix cancer (the latest statistics are from 2008) per year 
worldwide with mortality of approximately one-third of these cases (Jemal et al., 2011; Yugawa & Kiyono, 
2009). 
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1.3.2 Histological types 
As previously referred, most uterine cervix cancers develop from the transformational zone where 
columnar epithelium undergoes physiological metaplasia to become squamous epithelium. This area is most 
vulnerable to neoplastic transformation. The neoplastic or dysplastic process may involve the entire thickness 
of squamous epithelium (CIS, carcinoma in situ) before penetrating the basement membrane (Nguyen & 
Averette, 1999). 
Uterine cervix cancer is characterized by a well-defined pre-malignant phase that can be suspected 
on cytological examination of exfoliated cervical cells and confirmed on histological examination of cervical 
material. There are different classification systems of precursor lesions of cervical squamous-cell carcinoma, 
World Health Organization (WHO) and Bethesda (Lax, 2011). Cervical intraepithelial neoplasia is categorized 
into 3 grades (CIN1-3). These pre-malignant changes represent a spectrum of histological abnormalities, 
designated as dysplasias, epithelial abnormalities in which the cells becomes disorganized, which are 
characterized by developmental changes in cell growth, shape and organization, ranging from CIN1 (mild 
dysplasia) to CIN2 (moderate dysplasia) to CIN3 (severe dysplasia/carcinoma in situ) (Woodman et al., 2007). 
Accordingly to Bethesda classification for cervical cytology this could be low- or high-grade squamous 
intraepithelial lesions (LSIL and HSIL, respectively) (Lax, 2011). 
Cytological and histological examinations cannot reliably distinguish the few women with abnormal 
smears who will progress to invasive cancer from the vast majority of those whose abnormalities will 
spontaneously regress (Woodman et al., 2007). 
There are two clinically significant variants of uterine cervix cancer. Squamous cell carcinomas that 
comprise around 85% to 90%, and adenocarcinomas/adenosquamous carcinomas that comprise 10% to 25% 
of uterine cervix cancer cases (Chan et al., 2003; Smith et al., 2000). 
Adenocarcinomas/adenosquamous carcinomas are often larger at the time of diagnosis than 
squamous carcinomas and frequently exhibit early lymphatic and hematogeneous metastasis, features that 
make them difficult to cure by conventional therapeutic measures. Moreover, the genetic alterations associated 
with cervical adenocarcinomas/adenosquamous carcinomas are unknown (Yeasmin et al., 2011). 
Squamous cell carcinoma typically presents as an ulcerated and exophytic lesion, while 
adenocarcinoma presents as an enlarged, barrel-shaped cervix with normal ectocervix  (Nguyen & Averette, 
1999). Besides that, locally advanced squamous cell carcinomas of the uterine cervix show a physiological 
microenvironment characterized by low oxygen tension (pO2), regions with hypoxic tissue (pO2 < 10 mmHg), 
elevated interstitial fluid pressure, high lactate concentration, low extracellular pH (pHe), and energy 
deprivation (Milosevic et al., 2004; Schwickert et al., 1995; Höckel et al., 1991). 
 
 
1.3.3 Human Papillomavirus (HPV) 
Human papillomavirus (HPV) is the etiologic agent of uterine cervix cancer; however, HPV infection is 
not the only factor in the carcinogenesis of cervix carcinoma (Yeasmin et al., 2011). In addition, the genomic 
alteration of oncogenes and tumor suppressor genes in uterine cervical cells is essential for uterine cervix 
carcinogenesis (Yeasmin et al., 2011). 
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HPVs are small, non-enveloped viruses that contain circular double-stranded DNA genomes of 
approximately 8000 base pairs (Figure 2) (Hebner & Laimins, 2006) that 
can cause most benign and malignant lesions in epithelial tissues (skin and 
mucosa) (de Villiers et al., 2004). HPV genomes replicate episomally, that is 
in an autonomous manner, in host cells, however HPV DNA is frequently 
found to be integrated into chromosomes in uterine cervical cancer cells  
(Yugawa & Kiyono, 2009). 
 
 
 
1.3.3.1 HPV genome 
HPV DNA has eight open reading frames (ORFs), namely E1, E2, E4, E5, E6, E7 (expressed in the 
early phase of infection), L1 and L2 (expressed in the late phase of infection) and control region designated as 
the long control region (LCR) or upstream regulatory region (URR) (zur Hausen, 2002; Yugawa & Kiyono, 
2009). Early genes have roles in viral replication and late genes encode viral capsid proteins (Yugawa & 
Kiyono, 2009). E6 and E7 ORFs are oncoproteins involved in proliferation-stimulating and transforming 
activities through the loss of E1 and E2 ORFs, allowing the integration of E6 and E7 ORFs within the host 
DNA. Once integrated, HPV DNA can immortalize human keratinocytes due to the interactions between the E6 
and E7 oncogenes with p53 and pRb tumor suppressor proteins, respectively, thus inhibiting the process of 
apoptosis. Moreover LCR regulates the transcription of the E6 and E7 viral oncogenes through the 
transcription factors of the virus and the host cells (zur Hausen, 2002). 
Over 100 different genotypes of HPVs have been identified of which about 40 are known to infect the 
genital tract (Yugawa & Kiyono, 2009). Epidemiological studies to date suggest that at least 15 
(16,18,45,31,33,52,58,35,59,56,51,39,68,73,82) of these, called oncogenic or high-risk (HR) types, (Roden & 
Wu, 2006) are significantly associated with progression to invasive cervical cancer (ICC) (Bosch et al.,1995). 
Most of these HR types are phylogenetically related to either HPV16 (31, 33, 35, 52 and 58) or HPV18 (39, 45, 
59 and 68) (Chan et al., 1995). 
Previous data revealed that high-risk HPVs are associated with more than 90% of uterine cervical 
cancers (Walboomers et al., 1999). Infection with these HPVs is considered to be the primary cause of uterine 
cervical dysplasia or low-grade CIN, and uterine cervical cancers are widely thought to arise from these 
lesions after long periods of time (Woodman et al., 2007; zur Hausen, 2002). Recent data suggest that high-
risk HPV types 16 and 18 are responsible for > 70% of cases of uterine cervix cancer (Boulet et al., 2008). 
Whereas HPV18 is the type most strongly associated with adenocarcinoma of the cervix, HPV16, followed by 
HPV18, are the types most frequently detected when squamous cell carcinoma is diagnosed (Clifford et al., 
2003; Muñoz et al., 2003). 
Accordingly to Woodman et al., 2007 the frequency with which HPV16 is found in integrated forms 
increases with the severity of uterine cervical neoplasia, although in some women with invasive disease only 
 
Figure 2 - HPV genome.The HPV genome is a circular double-stranded DNA of approximately 8000 base pairs. The genome 
contains an upstream regulatory region (URR) and eight open reading frames (ORFs) of six early genes (E1, E2, E4, E5, E6, 
E7) and two late genes (L1, L2). Early genes have roles in viral replication and late genes encode viral capsid proteins. E1 is a 
viral helicase and recruited to the viral replication origin located in URR by E2, where it forms the DNA replication machinery 
with cellular proteins. HPV genomes replicate episomally in their life cycle. Adapted from Yugawa & Kiyono, 2009. 
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episomal forms are detected. By contrast, HPV18 is almost always found in only integrated forms in women 
with high-grade cervical intraepithelial neoplasia (HGCIN) and invasive disease (Figure 3) (Woodman et al., 
2007). The timing of viral integration appears to correspond to the development of high-grade CIN as a 
consequence of high-level expression of E6 and E7 (Figure 3) (von Knebel Doeberitz, 2002). In fact, E6 and 
E7 are invariably expressed in HPV-positive uterine cervix cancer cells, and play important roles in 
carcinogenesis as well as maintenance of the transformed phenotype. Deregulated expression of E6 and E7 
can bring about substantial biological consequences, such as suppression of immunoresponse, 
immortalization, transformation and inhibition of differentiation, in addition to the previously referred inactivation 
of the major tumor suppressors, including p53 and pRB, inducing genomic instability that increases the risk of 
accumulation of cellular genetic and epigenetic changes (Yugawa & Kiyono, 2009). So, these two viral proteins 
do not merely immortalize normal human epithelial cells but confer some tumorigenic properties of transformed 
cells (Yugawa & Kiyono, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Nuclei with epissomal viral DNA 
Nuclei with integrated viral DNA 
Normal nuclei  
Figure 3 - HPV-mediated progression to uterine cervix cancer. Basal cells in the cervical epithelium rest on the basement 
membrane, which is supported by the dermis. Human papillomavirus (HPV) is thought to access the basal cells through 
micro-abrasions in the cervical epithelium. Following infection, the early HPV genes E1, E2, E4, E5, E6 and E7 are 
expressed and the viral DNA replicates from episomal DNA (purple nuclei). In the upper layers of epithelium (the midzone 
and superficial zone) the viral genome is replicated further, and the late genes L1 and L2, and E4 are expressed. L1 and L2 
encapsidate the viral genomes to form progeny virions in the nucleus. The shed virus can then initiate a new infection. Low-
grade intraepithelial lesions support productive viral replication. An unknown number of high-risk HPV infections progress to 
high-grade cervical intraepithelial neoplasia (HGCIN). The progression of untreated lesions to microinvasive and invasive 
cancer is associated with the integration of the HPV genome into the host chromosomes (red nuclei), with associated loss or 
disruption of E2, and subsequent upregulation of E6 and E7 oncogene expression. LCR, long control region. Adapted from 
Woodman et al., 2007. 
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1.3.3.2 HPV and uterine cervix cancer in Portugal  
Accordingly to Pista et al., 2011 the most frequent HPV genotype in Portugal is HPV16 (25.5%), 
followed by HPV 31, 53, 66, 58, and 51 (Pista et al., 2011). Data from Nobre et al., 2010 also indicate that the 
most prevalent type in Portuguese women is HPV16 (detected in 33.8% of women infected with HPV), but 
followed by HPV 58 (9.2%), HPV 33 (7.0%), HPV 18 (6.3%), HPV 53 (5.6%), HPV 31 and 56 (4.9% each), 
HPV 6 (3.5%), and HPV 66 and 81 (2.8% each). In addition, of 44 uterine cervix carcinoma samples, 71% 
were associated with HPV 16 (60%) and HPV 18 (11.1%), followed by the high-risk types 33 (11.1%), 35 
(4.4%), 45 (4.4%), and 56 (2.2%), the probable high-risk type 53 (4.4%) and the unknown-risk type 67 (2.2%) 
(Nobre et al., 2010). 
Accordingly to Globocan 2008 statistics, the estimated incidence of uterine cervix cancer in Portugal 
is 949, i.e. 4.9%. In addition, in Portugal, uterine cervix cancer is the fourth most frequent among female 
(ranking defined by total number of cases). 
1.3.4 Signaling pathways altered in uterine cervix cancer  
Chromosomal instability at a numerical or structural level is a hallmark of malignant tumors. Deletion, 
duplication and amplification of various genomic regions have been demonstrated to be present in many types 
of cancers (Duensing & Munger, 2004), including uterine cervix cancer . 
Amplification of proto-oncogenes and inactivation of tumor suppressor genes play an important role in 
the pathogenesis of many different tumors (Kersemaekers et al., 1999).  
The genomic alteration of oncogenes and tumor suppressor genes in uterine cervical cells is 
essential for uterine cervix carcinogenesis. Amplification of DNA in certain chromosomal regions is one of the 
mechanisms by which genes that are critical for the development and progression of human cancers are 
activated. Numerous oncogenes and other cancer-related genes have been identified in these amplified 
regions (Schwab, 1999). 
Studies in uterine cervix carcinomas have shown that the receptors for the epidermal growth factor  
and c-Myc are important for the prognosis of patients with advanced tumors (stages II–IV) (Kersemaekers et 
al., 1999). Particularly in squamous cell carcinomas proto-oncogenes such as epidermal growth factor receptor 
(EGFR) and c-Myc are often activated by amplification and are clearly associated with malignant phenotypes 
(Hale et al., 1993; Pfeiffer et al., 1989). 
 
1.3.4.1 Epidermal growth factor receptor (EGFR) and uterine cervix cancer  
The EGFR is a receptor belonging to the human epithelial growth factor response (HER) family of 
receptor tyrosine kinases. Receptor activation upon ligand binding leads to downstream activation of the 
PI3K/AKT, RAS/RAF/MEK/ERK and PLCγ/PKC pathways that influence cell proliferation, survival and the 
metastatic potential of tumor cells. This HER family comprises four structurally related transmembrane 
receptors: HER1 (EGFR or erbB1), HER2 (HER2neu or c-erb-B2), HER3 (c-erb-B3), and HER4 (c- erb-B4) 
(Lee et al., 2005).  
The oncogenic pathway of some cells is thought to be initiated as a result of HER family receptor 
mutation, overexpression, structural rearrangements, and/or relief of normal regulatory or inhibitory pathways 
(Anido et al., 2003; Witton et al., 2003; Woodburn, 1999) . 
EGFR plays an important role in the differentiation and morphogenesis of many organs and 
proliferation and survival in mammalian cells (Lynch et al., 2004). Increased activation by gene amplification, 
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protein overexpression or mutations of the EGFR has been identified as an etiological factor in a number of 
human epithelial cancers (Brand et al., 2011; Sarkis et al., 2010). Particularly, overexpression of EGFR has 
been reported to be frequent in uterine cervix cancer, ranging from approximately 50–70% (Shen et al., 2008; 
Kersemaekers et al., 1999; Hale et al., 1993).  
In certain studies, the expression of EGFR proved to be an independent predictor of poor prognosis 
for the uterine cervix cancer decreasing local tumor control after radiotherapy (Kersemaekers et al., 1999; 
Kristensen et al., 1996) while other studies did not confirm this result (Nagai et al., 2000). Lee et al., 2005 have 
reported that increased expression of HER2 and decreased expression of EGFR membranous staining 
correlate with improved overall survival in patients with carcinoma of the cervix (Lee et al., 2005). In addition, 
that overexpression of HER2 was correlated with adenocarcinoma, and overexpression of EGFR correlated 
significantly with squamous cell histology and is less frequent in adenocarcinomas (Lee et al., 2004; Hale et 
al., 1993) . Recently, it has been proposed that inhibiting EGFR during radiotherapy may be a promising 
therapeutic strategy in certain squamous cell carcinomas (Nagy et al., 2011). 
Epidermal growth factor (EGF) is single-chain polypeptide (6 kDa) that a wide spectrum of activities 
including mitogenic, angiogenic and chemotactic effects on normal and tumor cells (Price et al., 1996; Khazaie 
et al., 1993). EGF plays an important role in the regulation of cell growth, proliferation, and differentiation by 
binding to its receptor EGFR (Carpenter & Cohen, 1990). Besides that EGF family ligands promote tumor cell 
motility, adhesion and invasion (Lu et al., 2001; Price et al., 1996; Rosen & Goldberg, 1989). EGF is one of the 
potent stimulators for uterine cervix cancer cell invasiveness (Shen et al., 2006).  Data from Chiang et al., 
2008 revealed that Na+/H+ exchanger 1 (NHE-1) activity is necessary for this EGF-mediated uterine cervix 
cancer cell migration (Chiang et al., 2008) .  
 Additionally, EGF has also documented effects on metabolism, through stimulation of various 
intracellular responses in vitro, including Na+/K+ antiport activity, Na+-dependent phosphate transport, 
glycolysis, and glucose and amino acid uptake in a variety of cultured epithelial cells (Nowak & Schnellmann, 
1995). Accordingly to Nowak & Schnellmann, 1995 an increase in glucose consumption was accompanied by 
a rapid change in lactate metabolism in Renal Proximal Tubular cells (RPTC) treated with EGF. EGF treatment 
of these cells resulted in net lactate production that reached a maximum when net glucose consumption was 
the highest, while in not treated cells there as a net consumption of lactate. So, the authors proposed that EGF 
shifts glucose metabolism from gluconeogenesis to glycolysis and rapidly stimulates the pentose cycle (Nowak 
& Schnellmann, 1995).   
 
1.3.4.2 c-Myc and uterine cervix cancer 
 
The c-Myc proto-oncogene is closely associated with cellular proliferation. The gene is located at 
chromosome 8q24 and encodes two nuclear phosphoproteins with Mr 62,000 and 66,000 (Kersemaekers et 
al., 1999). c-Myc is a transcription factor normally involved in the regulation of cell metabolism and in the 
induction of cell proliferation (Grandori et al., 2000). 
Amplification or increased expression of c-Myc has been found in many tumors, most notably in 
lymphoid tumors and carcinomas, including uterine cervix carcinomas (Kersemaekers et al., 1999). 
Regarding uterine cervix carcinomas, amplification and/or overexpression of the c-Myc gene were 
frequently observed in advanced-stage uterine cervix cancers and were shown to be associated with tumor 
progression (Riou et al., 1990). Accordingly to Bourhis et al., 1990 overexpression of c-Myc (i.e., levels at least 
three times the mean observed in normal tissues) was present in 33% of invasive carcinomas of the cervix 
(Bourhis et al., 1990). 
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Accordingly to Brychtová et al., 2004 expression of c-Myc protein is increased not only in uterine 
cervix cancer but also in the premalignant lesions since that they found significantly higher levels of c-Myc 
protein in keratinocytes of high-grade dysplasias in comparison to low-grade dysplasias and control cases. 
However, the authors did not observe differences between low-grade CIN and a control group of patients. The 
same significant changes between above mentioned groups were seen in surrounding stromal cells 
(fibrocytes, fibroblasts, some endothelial cells and lymphocytes) (Brychtová et al., 2004). Other authors had 
also revealed that c-Myc amplification is frequently detected in precancerous cervical lesions with HPV 
infection (Chen et al., 2012).  
Recent data indicated that c-Myc positivity rates (that is c-Myc gain) in normal subjects, CIN1, CIN2, 
CIN3 were 5%, 26%, 96%, 100%, respectively, and increased in association with the severity of the 
histological diagnosis. In squamous cell carcinoma (SCC) c-Myc positivity rate was 100% (Policht et al., 2010). 
The mean of signals for specimens diagnosed as normal was approximately 2, for CIN1 was close to 2, CIN2 
revealed a probe signals means of 2.63, in CIN3 2.95. In cancer cases (SCC) it was verified and increase in 
mean c-Myc copy number to approximately 4 (Policht et al., 2010). 
 
1.4 Metabolic alterations in cancer 
Research into tumor cell metabolism has recently entered a new age (Cairns et al., 2011). Although 
this field was actively explored in the pre-genomics era, the discovery of tumor suppressor genes and 
oncogenes dampened interest in metabolism as a potential source of cancer cell specificities and related 
therapeutic targets. However, although the study of tumor-associated genes has led to the identification of 
oncoproteins as new therapeutic targets, a cure for cancer is still far away. Scientists in the cancer field are 
therefore reconsidering earlier metabolic discoveries using the molecular tools that are now available. This has 
led to cancer metabolism’s comeback to business (Draoui & Feron, 2011). 
In addition to the six recognized hallmarks of cancer (previously cited), aerobic glycolysis or the 
Warburg effect is also a robust metabolic hallmark of most tumors (Hanahan & Weinberg, 2011; Seyfried & 
Shelton, 2010). 
The view of cancer as a metabolic disease was gradually displaced with the view of cancer as a 
genetic disease. While there is renewed interest in the energy metabolism of cancer cells, it is widely thought 
that the Warburg effect and the metabolic defects expressed in cancer cells arise primarily from genomic 
mutability selected during tumor progression (Seyfried & Shelton, 2010; Hsu & Sabatini, 2008; Kim & Dang, 
2006; Shaw, 2006). But accordingly to Seyfried & Shelton, 2010 damage to cellular respiration precedes and 
underlies the genome instability that accompanies tumor development. Once established, genome instability 
contributes to further respiratory impairment, genome mutability, and tumor progression. In other words, 
effects become causes. This hypothesis is based on evidence that nuclear genome integrity is largely 
dependent on mitochondrial energy homeostasis and that all cells require a constant level of useable energy to 
maintain viability (Seyfried & Shelton, 2010). So, emerging evidence indicates that impaired cellular energy 
metabolism is the defining characteristic of nearly all cancers regardless of cellular or tissue origin (Seyfried & 
Shelton, 2010). 
Tumor cells have a remarkably different metabolism from that of the tissues from which they are 
derived. They exhibit an altered metabolism that allows them to sustain higher proliferative rates (Tennant et 
al., 2009; DeBerardinis et al., 2008) and resist some cell death signals, particularly those mediated by 
increased oxidative damage (King & Gottlieb, 2009). However, this means that they are more nutrient hungry 
and excrete more waste products than normal tissues, resulting in a build-up of metabolites inside the cell and 
the formation of a more hostile environment outside the cell. In order to divide, a cell needs to both increase its 
9 
 
size and replicate its DNA - processes that are hugely metabolically demanding and which require large 
quantities of proteins, lipids and nucleotides, as well as energy in the form of ATP. This anabolic drive requires 
cells to increase their uptake of the building blocks for this process, major factors being amino acids and 
glucose (Tennant et al., 2010).  
So tumor cells reprogramme their metabolic pathways to meet these needs during the process of 
tumor progression. The best characterized metabolic phenotype observed in tumor cells is the Warburg effect 
consisting in the abrogation of Krebs cycle and electron transport chain and increase rate of glycolysis even 
under normal oxygen concentrations (Vander Heiden et al., 2009; Warburg, 1956). As a result, unlike most 
normal cells, many cancer cells produce substantial amount of their energy from aerobic glycolysis, converting 
most of the incoming glucose to lactate rather than metabolizing it through oxidative phosphorylation 
(Semenza, 2008; Warburg, 1956). The evidence that most tumors seem to use glucose at similar or even 
higher rates than normal organs came from images recorded using [18F]-fluorodeoxyglucose positron 
emission tomography (FDG-PET), in which tumors often appear as PET-positive as some of the most 
metabolically active organs (such as the brain and heart) (Gambhir, 2002). 
 In sum, although cancer cells retain their ability to increase glucose uptake under anaerobic 
conditions (the Pasteur effect) they show an increased glucose uptake in the presence of oxygen (aerobic 
glycolysis). However, in contrast to normal tissues, a substantial amount of pyruvate is reduced to lactate 
instead of being directed into the mitochondrion, a phenotype first described by Otto Warburg (Warburg, 
1956). 
The metabolic alterations and adaptations of cancer cells have been extensively studied over the past 
century (Tennant et al., 2010). They create a phenotype that is essential for tumor cell growth and survival, 
altering the flux along key metabolic pathways, such as glycolysis and glutaminolysis (Tennant et al., 2009). 
Some of the mechanisms used by tumors to bring about these changes include the altered expression 
(metabolic adaptation to hypoxia through activation of glycolytic gene transcription (such as Lactate 
dehydrogenase A (LDHA) gene regulation by Hypoxia Inducible Factor-1 (HIF-1)) (Semenza et al., 1996), 
mutation (of the tricarboxylic acid cycle (TCA) cycle tumor suppressors, succinate dehydrogenase (SDH) and 
fumarate hydratase (FH)) and post-translational inactivation of an enzyme (Pyruvate dehydrogenase kinase 
(PDK1) phosphorylates and inactivates the mitochondrial pyruvate dehydrogenase (PDH) complex) (Kim et al., 
2006) or the substitution of a different enzyme isoform (high expression of inducible isozyme of 6-
phosphofructo-2 kinase (iPFK-2) in proliferating cancer cells) (Atsumi et al., 2002). On the basis of these 
observations, the development of treatments that target tumor metabolism is receiving renewed attention 
(Tennant et al., 2010) . 
Although the key factors behind the cancer metabolic phenotype still remain to be elucidated, the 
current literature shows that c-Myc, p53, and HIF-1 are crucial for the tumor cells’ aberrant metabolic behavior 
and that exists an interplay of this triad of transcription factors in the regulation of cancer cell metabolism 
(Yeung et al., 2008). Focusing on c-Myc, recent data pointed out that c-Myc overexpression is found in 10–
20% of all tumors and has been shown to increase glycolysis (Cairns et al., 2011). Besides that, it has been 
shown that this c-Myc overexpression also increases the cellular capacity to perform both glycolysis and 
oxidative phosphorylation, and thus provides the cell with metabolic flexibility (Graves et al., 2010). 
1.4.1 Advantages of aerobic glycolysis 
There is some debate about the selective advantages that glycolytic metabolism provides to 
proliferating tumor cells. Initial work pointed that tumor cells develop defects in mitochondrial function and that 
aerobic glycolysis is a necessary adaptation to the lack of ATP production through oxidative phosphorylation 
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(Cairns et al., 2011). However, it was later appreciated that mitochondrial defects are rare (Frezza & Gottlieb, 
2009) and that tumors retain the capacity for oxidative phosphorylation and consume oxygen at rates similar to 
those observed in normal tissues (Moreno-Sánchez et al., 2007; Fantin et al., 2006; Weinhouse, 1976). Other 
explanations include the concept that glycolysis has the capacity to generate ATP at a higher rate than 
oxidative phosphorylation and so would be advantageous as long as glucose supplies are not limited. 
Alternatively, it has been proposed that glycolytic metabolism arises as an adaptation to hypoxic conditions 
during the early avascular phase of tumor development, as it allows for ATP production in the absence of 
oxygen. Adaptation to the resulting acidic microenvironment that is caused by excess lactate production may 
further drive the evolution of the glycolytic phenotype (Gillies et al., 2008; Gatenby & Gillies, 2004). Finally, 
most recently, it has been proposed that aerobic glycolysis provides a biosynthetic advantage for tumor cells, 
and that a high flux of substrate through glycolysis allows for effective shunting of carbon to key subsidiary 
biosynthetic pathways (Vander Heiden et al., 2009). 
The aforementioned observations position glycolysis as a key contributor to the malignant phenotype 
and support the quest for new anticancer treatments targeting glycolysis. Indeed, most of the molecular 
adaptations supporting high-rate glycolysis are unique to cancer in an otherwise healthy tissue (Porporato et 
al., 2011).  In order to find these new anticancer therapies metabolic studies must consider all the intervenients 
in metabolomic plateau. The transporters of carboxylate compounds, namely glucose, lactate and pyruvate 
should be studied as well as the enzymes that catalyse key steps in metabolic pathways, namely lactate and 
pyruvate dehydrogenases and cytochrome c oxidase.  
 
1.4.2 Lactate as a signaling molecule 
Traditionally thought of as a glycolytic waste product, lactate may be one such signal. It has been 
found that inhibition of lactate dehydrogenase (LDH) can block tumor growth, most likely by multiple 
mechanisms. Much of the evidence for lactate as a multifunctional metabolite comes from work in exercise 
physiology and muscle metabolism (Philp et al., 2005). Transported by several monocarboxylate transporters 
(MCTs), lactate may be shared and metabolized among cells, although the idea is still controversial 
(Hashimoto et al., 2006). The interconversion of lactate and pyruvate might alter the NAD+/NADH ratio in cells, 
and lactate exchange may serve to coordinate the metabolism of a group of cells (Hsu & Sabatini, 2008).  
Recently, lactate has also been pointed out as a signaling molecule, since it stimulates the 
overexpression of mitochondrial monocarboxylate transporter 1 (MCT1) (increase both at mRNA and protein 
levels) and cytochrome c oxidase, components of mitochondrial lactate oxidation complex (Hashimoto & 
Brooks, 2008; Hashimoto et al., 2007). Besides that, accordingly to Hashimoto et al., 2007, in L6 muscle cells, 
lactate signaling cascade involves Reactive Oxygen Species (ROS) production and converges on transcription 
factors affecting mitochondrial biogenesis (Hashimoto et al., 2007). 
Data from Sonveaux et al., 2008 evidence oxidative preference of some tumor cells for lactate over 
glucose. Lactate, released as the end-product of glycolysis in the hypoxic tumor cell compartment, prominently 
fuels the oxidative metabolism of the oxygenated tumor cell subpopulation, thereby sparing glucose for 
glycolytic cells (evidence of metabolic symbiosis in cancer, described later) (Sonveaux et al., 2008). This 
mechanism involves a competition between lactate and glucose metabolism for the intracellular NAD+ pool. 
Existence of this feedback could provide several advantages to oxidative tumor cells. First, oxidation of lactate 
to pyruvate by LDH involves the sustained production of reducing equivalents that could buffer tumor oxidative 
stress  and activate prosurvival pathways (specifically Akt pathway) (Pelicano et al., 2006). Second, lactate 
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oxidation does not require the initial energy input that drives ATP production from glucose. Third, respiration of 
lactate yields 18 ATP per lactate molecule and spares energy normally intended for housekeeping glycolytic 
enzymes. Lactate oxidation is thus more concise and more effective than glucose in the tumor cell energy 
metabolism under aerobic conditions (Sonveaux et al., 2008). Finally, because ROS are natural by-products of 
mitochondrial respiration, it has been proposed that glucose to lactate conversion may protect cancer cells 
from oxidative stress, as previously referred, and considered an advantage of aerobic glycolysis (Brand & 
Hermfisse, 1997). 
Lactate release from tumor cells is a common endpoint of several metabolic alterations, raising the 
hypothesis of an association with tumor progression (Walenta et al., 2004). Some evidences support this 
hypothesis: low interstitial pH is associated with the upregulation of various angiogenic molecules, such as 
vascular endothelial growth factor (VEGF), which support tumor growth, invasion, and metastasis) (Pinheiro et 
al., 2008; Fukumura et al., 2001). In this line of evidence lactate accumulation in human tumors has been 
associated with metastasis, tumor recurrence and poor survival, particularly in squamous cell carcinomas of 
the uterine cervix cancer (Walenta et al., 2000; Schwickert et al., 1995). So, and like numerous recent reports 
show, there are various biological activities of lactate that can enhance the malignant behavior of cancer cells. 
These mechanisms include, beyond the upregulation of VEGF, the activation of hyaluronan synthesis by 
tumor-associated fibroblasts, upregulation of hypoxia-inducible factor 1α (HIF-1α), and direct enhancement of 
cellular motility that generates favorable conditions for metastatic spread. Thus, lactate accumulation not only 
mirrors but also actively enhances the degree of tumor malignancy (Walenta & Mueller-Klieser, 2004). 
1.5 Lactate dehydrogenases (LDHs) 
The reversible pyruvate reduction into lactate reaction is catalyzed by the LDH family of tetrameric 
enzymes and it also allows glycolytic cells to maintain the levels of pyruvate low enough to avoid cell death 
(Thangaraju et al., 2009; Thangaraju et al., 2006). LDHs are formed by the arrangement of up to four copies of 
two different subunits: subunit LDH-H is encoded by the LDHB gene and is ubiquitously expressed in healthy 
tissues, whereas subunit LDH-M is encoded by the HIF-1-target gene LDHA and is therefore induced by 
hypoxia (Porporato et al., 2011). LDHA expression is also induced by a variety of oncogenes, including c-Myc  
(Shim et al., 1997) and may therefore participate in the rapid consumption of pyruvate even when oxygen is 
available in the tumor cell environment  (Feron, 2009). 
Compared to LDH-H, LDH-M has a higher Km for pyruvate and a higher Vmax for pyruvate reduction 
(Markert et al., 1975). Consequently, LDH5/LDH-4M preferentially catalyzes the reduction of pyruvate into 
lactate and plays key roles in the maintenance of a high glycolytic flux and in resistance to apoptosis. Elevated 
LDH5 expression is of unfavorable prognostic significance to many human tumors  (Koukourakis et al., 2005; 
Koukourakis et al., 2003). Conversely, LDH1/LDH-4H is most commonly silenced in glycolytic cancer cells, a 
process involving hypermethylation of the LDHB gene promoter  (Thangaraju et al., 2009; Leiblich et al., 
2006).  
The LDH5 reaction yields equimolar concentrations of lactate (from pyruvate) and protons (from 
NADH). So, in order to avoid intracellular acidification and death, glycolytic cells must export protons. Several 
systems are adapted for the transport of protons among which MCT1, MCT2, MCT3, and MCT4 are passive 
lactate–proton symporters (Halestrap & Meredith, 2004).  
In addition to LDHA and LDHB, the LDH gene family includes LDHC gene (also known as LDHX) that 
encodes a third isoenzyme, the LDHC. While LDHA and LDHB are expressed in somatic tissues, LDHC is 
reportedly expressed in testis and sperm (Holmes & Goldberg, 2009). 
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1.5.1 LDHs and cancer 
Previous reports indicate that lactate dehydrogenase is the only glycolytic enzyme whose inhibition 
should allow a blocking of the aerobic glycolysis of tumor cells without damaging the normal cells which, in 
conditions of normal functional activity and sufficient oxygen supply, do not need this enzyme. Therefore, this 
enzyme it is a potential target for cancer therapy once that the inhibition of LDH could result in a selective 
depletion of ATP in tumor cells (Papaconstantinou & Colowick, 1961).  
In previous experiments, oxamic acid, a competitive inhibitor of LDH, was shown to hinder the growth 
of HeLa cultured in vitro (Papaconstantinou & Colowick, 1961). Recent studies show that aerobic glycolysis 
can be hindered by blocking LDH which causes a failing in the regeneration of NAD, reduced during the 
conversion of glyceraldehyde 3-phosphate to 1,3-diphosphoglycerate, and necessary to maintain the glycolytic 
flow (Fiume et al., 2011).  
It has been reported that LDHA is elevated and activated in many cancers compared with 
surrounding normal tissue (Walenta &  Mueller-Klieser, 2004; Lewis et al., 2000; Shim et al., 1997). In addition, 
LDHA is upregulated in solid tumors in response to hypoxia in a HIF-1α-dependent manner (Draoui & Feron, 
2011). 
Recent studies demonstrate that LDHA plays a key role in tumor maintenance of neu-transformed 
mouse mammary epithelial cells (Fantin et al., 2006) and that the reduction in LDHA activity resulted in 
stimulation of mitochondrial respiration and decrease of mitochondrial membrane potential. It also 
compromised the ability of tumor cells to proliferate under hypoxia. So, accordingly to them, the tumorigenicity 
of the LDHA-deficient cells was severely diminished, and this phenotype was reversed by complementation 
with the human ortholog LDHA gene (Fantin et al., 2006) .  
A definitive relationship between LDHB and cancer has not yet been established (Kinoshita et al., 
2011). Chen et al., 2006 concluded that in non-small cell lung cancer (NSCLC) the levels of LDHB were 
significantly elevated in NSCLC sera (Chen et al., 2006). Furthermore, the serum levels of LDHB correlated 
with the clinical stage of NSCLC  and LDHB protein expression was a predictor of very poor prognosis in 
medulloblastoma patients (Haas et al., 2008).  
Recent results from Kinoshita et al., 2011 indicated that mRNA levels of LDHB were elevated in 
cancer tissues. They concluded that the reduction of miR-375 and the increased expression of LDHB are 
frequent events in maxillary sinus squamous cell carcinoma (MSSCC) cancer cells and that by this way miR-
375 acts as a tumor suppressor and direct regulator of LDHB in MSSCC (Kinoshita et al., 2011). 
Transcriptional silencing of LDHB expression caused by aberrant methylation of the gene promoter 
region has been reported in gastric and prostate cancers (Leiblich et al., 2006; Maekawa et al., 2003), 
suggesting that tumors preferentially express LDH isoenzymes with a high LDHA gene product content (LDH 
5>LDH4>LDH3). In colorectal cancer, suppression of LDHB transcript in a more invasive phenotype was even 
proposed to account for a large part of the Warburg metabolic switch (i.e. independently of hypoxia-induced 
changes in LDHA expression) (Thorn et al., 2009). 
Recent reports suggest that LDHB suppression plays an important role in triggering or maintaining 
the mitochondrial defects and then contributes to cancer cell invasiveness by inducing claudin-1 protein (Kim 
et al., 2011). These results suggest the novel idea that glycolytic activation may itself cause mitochondrial 
defects and may actively promote cancer development. This idea differs from the prevailing theory that 
activated glycolysis is the consequence of cellular adaptation to overcome mitochondrial defects due to 
hypoxic condition during cancer development. Further, this idea suggests that mitochondrial dysfunction and 
glycolytic activation can result in a vicious cycle, that is independent of initiating events for those two 
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phenomena, and that oncogenic activation of aerobic glycolysis may be sufficient to trigger mitochondrial 
dysfunction without hypoxic stimulus in tumorigenesis  (Kim et al., 2011). 
Elevated expression of LDHB in tumor cells could indicate the occurrence of oxidative metabolism, 
while LDHA expression is likely to correlate with glycolytic metabolism (Nakajima & Van Houten, 2012). 
Recently, the germ cell–specific LDHC gene, was shown to express in a broad spectrum of tumors, 
with high frequency in lung cancer (47%), melanoma (44%), and breast cancer (35%) (Koslowski et al., 2002) 
but the mechanism for ectopic activation of this gene is unknown (Tang & Goldberg, 2009). 
1.5.2 Regulation of LDHs 
Previous data identified LDHA as a c-Myc responsive gene (Shim et al., 1997). Accordingly to these 
authors c-Myc is able to transactivate the LDHA promoter and directly increase LDHA expression (Shim et al., 
1997). It has also been described that HIF-1 increases the expression of genes involved in the enzymatic 
breakdown of glucose to pyruvate and the enzymes involved in the clearance of pyruvate. So, LDHA has been 
identified as a HIF-1 target (Denko, 2008). Additionally, it has been shown that highly expressed oncogenic c-
Myc collaborate with HIF in the activation of several glucose transporters and glycolytic enzymes, as well as 
LDHA  (Dang et al., 2008). 
Concerning LDHB expression, recent data revealed transactivation of LDHB gene expression by a 
signal transducer and activator of transcription 3 (STAT3), a key tumorigenic driver in many cancer that acts as 
a downstream mTOR effector in human cancer cells (Zha et al., 2011). 
For LDHC expression in cancer cells, it has been demonstrated that it was regulated by transcription 
factors Sp1 and CREB (Tang & Goldberg, 2009). 
1.6 Monocarboxylate transporters  (MCTs) 
Monocarboxylates, such as lactate and pyruvate, play a central role in cellular metabolism and 
metabolic communication between tissues  (Halestrap & Price, 1999). In cancer cells, a steady source of 
metabolic energy is required to continue the uncontrolled growth and proliferation of these cells (Airley & 
Mobasheri, 2007). 
  As previously referred, most cancer cells rely on a high rate of aerobic glycolysis to obtain sufficient 
ATP in a hypoxic microenvironment (Vander Heiden et al., 2009). As a result lactate is abundantly synthesized 
from pyruvate (Feron, 2009), what contribute to the acidification of the microenvironment through lactic acid, 
inducing cellular acidosis, which triggers apoptosis. So, in order to avoid apoptosis, cancer cells must transport 
the lactate out of the cell (Izumi et al., 2011). By this way only the interstitial pH of tumors is low, while the 
intracellular pH of tumors is either normal or higher than that of normal tissues (Helmlinger et al., 2002; Dang & 
Semenza, 1999).  Able to adapt to and even benefit from an acidic environment, cancer cells increase proton 
efflux through pH regulators such as proton pumps, sodium-proton exchangers, bicarbonate transporters, and 
H+-linked monocarboxylate transporters, which are described to be upregulated in tumor cells (Izumi et al., 
2003). Inhibition of these adaptive mechanisms can lead to decreased viability of cancer cells and increased 
sensitivity to chemotherapeutic agents (Fais et al., 2007; Fang et al., 2006). 
On the other hand, lactate is not just a waste product: it was recently identified as a major energy fuel 
in tumors (Feron, 2009). Lactate is transported by monocarboxylate anion transporters (MCT; also called the 
solute carrier family 16 (SLC16)) (Halestrap & Price, 1999). In tumor cells take up or export lactate according 
to the oxygen availability, lactate concentration and expression of the MCT subtype at the plasma membrane  ( 
Semenza, 2008; Brooks, 2000).  
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It is known that MCT4 (SLC16A3) preferentially transports lactate out of the cell and MCT1 
(SLC16A1) regulates preferentially the entry of lactate into both tumor cells and tumor endothelial cells. In 
addition, MCT4 isoform is largely involved in hypoxia-driven lactate release (Draoui & Feron, 2011).  
MCT4 (Km lactate =22mM) has the lowest affinity for lactate, is encoded by a HIF-1α-target gene 
(Ullah et al., 2006), and is therefore adapted for the export of lactic acid from glycolytic tumor cells (Dimmer et 
al., 2000). It plays an important contribution to the regulation of intracellular pH (pHi): although it has only a low 
affinity for lactate, its high turnover rate ensures efficient proton export  (Chiche et al., 2012).  
MCT1 (Km lactate =3.5–10mM) has an intermediate affinity for lactate and is ubiquitously expressed 
in healthy and cancer tissues. In cancer, it facilitates lactate uptake by oxidative tumor cells in a newly 
described metabolic pathway involving lactate oxidation into pyruvate to fuel the TCA cycle (Sonveaux et al., 
2008).  
MCT2 (Km lactate =0.5mM) and MCT3 (Km lactate =5mM) have the highest affinity for lactate and are 
specialized in the import of lactate in very specific tissues such as liver (Cori cycle), kidney, and retina (Philp et 
al., 2001; Garcia et al., 1995). 
Recent data suggest that MCT1 can transport lactate into and out of tumor cells. Whereas most 
oxidative cancer cells import lactate through MCT1 to fuel mitochondrial respiration, the role of MCT1 in 
glycolysis-derived lactate efflux remains less clear (Boidot et al., 2012). 
1.6.1 MCTs and cancer 
Pinheiro et al., 2010 showed that MCT1 is upregulated in breast carcinomas, which does not 
corroborate a previous report in breast cancer, pointing to a possible silencing of MCT1 expression by gene 
promoter hypermethylation (Asada et al., 2003). The identification of genes that have their promoter region 
hypermethylated (which results in gene silencing) or hypomethylated (which results in increased transcription) 
might lead to the discovery of new factors that are important for tumor initiation and progression (Baylin & 
Ohm, 2006). Multiple studies (Bachman et al., 2003; Fahrner et al., 2002; Koizume et al., 2002) have shown 
that the promoters of silenced genes, when compared with actively transcribed copies of the same genes, 
contain localized regions of transcriptional-silencing marks that include (in addition to DNA CpG-island 
methylation) the deacetylation and methylation of key H3 amino acids. Regarding these chromatin events, 
DNA methylation seems to be the dominant factor in gene silencing (Baylin & Ohm, 2006) . 
MCT1 seems to have an important role in tumor progression since it was shown that inhibition of 
MCT1, either pharmacologically or using RNA interference (RNAi), results in the inhibition of xenograft tumor 
growth and resensitization of tumor cells to radiation (Tennant et al., 2010; Sonveaux et al., 2008). 
Sonveaux et al., 2008 found that oxidative SiHa tumor cells, like oxidative muscle fibers, constitutively 
expressed MCT1 mRNA at a higher relative level compared with glycolytic WiDr cells. In SiHa cells, MCT1 
was more actively transcribed than MCT4, whereas MCT4 was preferentially expressed in WiDr cells. The 
plasma membrane expression of MCT1 in SiHa cells contrasted with the scattered cytosolic, almost 
undetectable expression of MCT4, suggesting that lactate uptake by these cells primarily depends on MCT1. 
To confirm MCT involvement in lactate uptake, the authors measured changes in intracellular pH in response 
to acute lactate exposure. A small but significant decrease in intracellular pH was observed in SiHa cells 
exposed to exogenous lactate, indicating activation of a lactate-proton symporter. In contrast, intracellular pH 
remained unchanged in WiDr cells after lactate treatment (Sonveaux et al., 2008). 
Other studies have shown that MCT1 and MCT4 are overexpressed in human neuroblastoma, cervix 
and colorectal cancers, providing evidence for bad prognosis of cancer (Pinheiro et al., 2009; Pinheiro et al., 
2008; Sonveaux et al., 2008; Fang et al., 2006). It was also recently shown that high expression of both MCT1 
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and MCT4 correlates with the invasiveness of lung cancer cells (Izumi et al., 2011). So, targeting MCT activity 
would not only induce apoptosis due to cellular acidosis, but would also lead to reduction in tumor 
angiogenesis, invasion, and metastasis. Thus, these transporters can constitute an attractive target for cancer 
therapy by preventing cancer maintenance and metastasis (Pinheiro et al., 2008). 
1.6.2 Regulation of MCTs 
Vegrán et al., 2011  identified  a lactate/nuclear factor-kB (NF-kB) signaling pathway in endothelial 
cells, the existence of a lactate-driven, feed-forward Interleukine-8 (IL-8) (also known as C-X-C chemokine 8 – 
CXCL8) autocrine loop driving angiogenesis in tumors and that MCT1 and MCT4 play key roles in lactate-
based dialog between cancer cells and endothelial cells. Accordingly to these authors lactate can also enter 
tumor endothelial cells through MCT1 (Végran et al., 2011). This study not only showed that lactate can favor 
the survival of serum-starved endothelial cells but also that lactate can directly initiate pro-angiogenic signaling 
through stimulation of this autocrine pathway which drives endothelial cell migration and tube formation. The 
authors had shown that IL-8-specific blocking antibodies and IL-8-targeted siRNA both prevented lactate-
induced angiogenesis (Végran et al., 2011). 
Recently, it was identified a direct link between p53 function and MCT1 expression. Under hypoxic 
conditions, p53 loss promoted MCT1 expression and lactate export produced by elevated glycolytic flux, 
both in vitro and in vivo. p53 interacted directly with the MCT1 gene promoter and altered MCT1 mRNA 
stabilization. In hypoxic p53−/− tumor cells, NF-κB further supported expression of MCT1 to elevate its levels. 
Following glucose deprivation, upregulated MCT1 in p53−/− cells promoted lactate import and favored cell 
proliferation by fuelling mitochondrial respiration (Boidot et al., 2012). 
Additionally, protein expression of uptake transporters such as MCT1 appeared to be upregulated by 
c-Myc overexpression (Kang et al., 2009).  
 
1.7 Metabolic symbiosis in tumor microenvironment 
Recently, it has been proposed a metabolic symbiosis in the tumor microenvironment as result of the 
inefficient formation of blood vessels during tumor growth producing areas of normoxia and hypoxia within the 
tumor (Nakajima & Van Houten, 2012). 
Hypoxic tumor cells depend on glucose and glycolysis to produce energy. Lactate, the end-product of 
glycolysis, diffuses along its concentration gradient toward blood vessels. By contrast, oxygenated tumor cells 
import lactate (a process mediated by MCT1 located at the cell plasma membrane) and oxidize it (instead or in 
addition to glucose) to produce energy, thereby sparing available glucose, which can, in turn, freely diffuses 
deeper into the tumor to fuel glycolysis of hypoxic tumor cells located farther away from tumor blood vessels 
(Sonveaux et al., 2008). The use of lactate as an energy source requires the conversion of lactate into 
pyruvate (and back) as well as the transport of lactate into and out of tumor cells by way of specific 
transporters. Consequently, LDH isoforms and MCTs family, respectively, regulate these processes (Draoui & 
Feron, 2011). 
Moreover, it has been considered that to define a tumor as metabolically symbiotic, several criteria 
must be met. It is expected that metabolically distinct populations will have unique protein signatures showing 
different expression levels of pertinent enzymes and carbohydrate transporters (Table 1). For example, the 
glycolytic cell population in a tumor, whether cancer or stromal cell, would be expected in hypoxic areas of the 
tumor and to express high levels of HIF-1α, HK, Glut-1, MCT4, and LDHA. The cell population performing 
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oxidative phosphorylation, on the other hand, would have decreased expression of the aforementioned 
molecules and elevated expression of PDH, MCT1, and LDHB (Nakajima & Van Houten, 2012). 
 
Table 1 - Predicted expression levels of the most relevant enzymes and metabolite transporters to metabolic symbiosis. 
Adapted from Nakajima & Van Houten, 2012. 
Protein 
Expression in hypoxic 
cells 
Expression in 
oxygenated cells 
Glucose transporter 1 (Glut-1) High Low 
Hexokinase (HK) High Low 
Monocarboxylate transporter 1 (MCT1) Low High 
Monocarboxylate transporter 4 (MCT4) High Low 
Lactate dehydrogenase subunit M (LDH-M)  High Low 
Lactate dehydrogenase subunit H (LDH-H) Low High 
Pyruvate dehydrogenase (PDH) Low High 
Pyruvate dehydrogenase kinase (PDK) High Low 
 
1.8 LDHs and MCTs as therapeutic targets  
The current findings establish a dual role for lactate in tumors: it acts as both a metabolic fuel and a 
signaling molecule, positioning lactate at the intersection of key processes in cancer progression, namely 
tumor metabolism and angiogenesis. Therefore, although lactate shuttles are physiologically active in some 
types of healthy tissue, the specific characteristics of some tumors make the regulators of cellular lactate 
handling, namely MCTs and LDHs, potential anti-cancer targets. Indeed, the metabolic symbiosis that have 
been described between oxidative and glycolytic tumor cells – and also between tumor cells and stromal cells, 
including endothelial cells and fibroblasts – offer diverse rationales to support the development of MCT and 
LDH inhibitory strategies (Draoui & Feron, 2011). However, the success of these new therapeutic approaches 
depends firstly on the extent to which tumors are addicted to these pathways (Feron, 2010) and also on their 
specificity to tumor cells. 
 
Data from in vitro models of uterine cervix cancer revealed that some tumors are able to produce 
lactate whereas others use lactate as fuel. Besides that, in some patients the tumor presents an endophytic 
growth, invading the endometrium, whereas in other cases the tumor grows exophytically into vaginal channel 
(Nguyen & Averette, 1999).  In this type of tumor the composition of the vaginal flora contributes, as previously 
referred, to the maintenance of lactic acid rich microenvironment that can play a role in cancer cells selection 
and tumor progression. However, tumor cells could have plasticity to switch on and off metabolic pathways 
instead of being exclusively selected. Our study aims to contribute to clarify if it is a question of selection, 
adaptation or even both. 
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2. Objectives 
 
The definition of the specific role of monocarboxylate transporters in uterine cervix cancer and the 
ability of cancer cells to produce or consume lactate will help to define therapeutic targets. Thus, the main 
objective of this work is to achieve the metabolic profile of two uterine cancer cells from two different 
histological types, adenocarcinoma (HeLa) and squamous cell carcinoma (SiHa).  
The objective will be accomplished according to three specific aims: 1) to determine the relevance of 
LDHA, LDHB, LDHC, MCT1 and MCT4 in the metabolic switch in an in vitro model of uterine cervix cancer; 2) 
to understand the role of EGF growth factor and sodium lactate in the regulation of expression of LDHA, 
LDHB, LDHC, MCT1, MCT4 and 3) to evaluate epigenetic regulation of LDHA, LDHB and MCT1 promoters 
and also to define a possible role of c-Myc transcription factor in the regulation of LDHA and MCT1 expression.  
Ultimately, the development of the current project could contribute to find a link between the 
expression of specific monocarboxylates membrane transporters and/or glycolytic enzymes and tumor cell 
features in order to propose therapeutical strategies to inhibit cell proliferation, migration, angiogenic 
stimulation and to activate apoptosis related pathways. Finally, contribute to the identification of specific 
therapeutic targets in tumor cells, which could be inhibited or downregulated in order to repress vital metabolic 
pathways in cancer cells.  
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3. Materials and methods 
 
3.1 Role of EGF growth factor in the regulation of LDHs (LDHA, LDHB, LDHC) and MCTs 
(MCT1 and MCT4) expression in the presence and absence of Sodium Lactate (NaLac)  
 
3.1.1 Cell culture 
 
Cell lines were obtained from American Type Culture Collection (ATCC): HeLa (CCL-2) and SiHa 
(HTB-35). 
HeLa and SiHa cell lines were maintained at 37°C in a humidified 5% CO2 environment in Dulbecco’s 
modified essential medium (DMEM) (41965-039,Gibco) containing 4500 mg/L of glucose supplemented with 
10% fetal bovine serum (FBS) (S 0615, Biochrom AG) and 1% Antibiotic-Antimycotic (15240062, Anti-Anti, 
Invitrogen). 
Cells were grown to 75 - 100% optical confluence before they were detached by incubation with 1X 
0.05% trypsin-EDTA (25300-054, Invitrogen) at Room Temperature (RT) for 5 minutes. Whenever necessary, 
the cell number was determined with the help of a Bürker counting chamber.  
Cells in culture were exposed to 50% Sodium Lactate (NaLac) (1.06522.2500, Merck) at 10 mM 
and/or stimulated with EGF (PHG0311, Gibco) at 25 ng/mL. SiHa cells chronically exposed to NaLac at 10mM 
were grown in the presence of 50% NaLac at 10mM for 32 days. Cells grown in control conditions were 
maintained in the absence of NaLac and without EGF stimulation. 
3.1.2 Gene expression  
 
The role of EGF in the regulation of LDHA, LDHB, LDHC, MCT1 and MCT4 gene expression in cells 
grown in the presence and absence of NaLac was evaluated by quantitative Real-Time PCR. Firstly, a reverse 
transcription-Polymerase Chain Reaction was performed. 
 
3.1.2.1 Reverse transcription–Polymerase Chain Reaction  
 
Reverse transcription polymerase chain reaction (RT-PCR) is a variant of polymerase chain reaction 
(PCR) which produces DNA copies of a RNA template. In RT-PCR a RNA strand is first reverse transcribed 
into its complementary DNA (cDNA), using the enzyme reverse transcriptase, and the resulting cDNA is 
amplified by PCR (Shiao, 2003). 
Total RNA was extracted using the RNeasy Mini Extraction kit (74104, Qiagen) from cultured cells, 
according to manufacturer’s protocol. The RNA concentration was determined spectrophotometrically in a 
Nanodrop 2000 (Thermo Scientific). 
RNA was reverse-transcribed using SuperScript III Reverse Transcriptase (18080-044, Invitrogen) 
from 1 µg RNA  to which 0.5 µL Oligo(dT)20 (18418-020, Invitrogen), 0.5 µL random hexamers (p(dN)6) (50 
A260 units) (11034731001, Roche), 1 µL deoxynucleotides (dNTPs) Mix (10 mM) (28-4065-22V, 28-4065-02V, 
28-4065-12V and 28-4065-32V, GE Healthcare) and sterile bidestilled water (ddH2O) to complete a total 
volume of 13 µL were added. The reaction mixture was then incubated at 65ºC, for 5 minutes, in order to 
occur the annealing between RNA and primers. Then the reaction tubes were chilled to 4ºC and the following 
mixture was added: 4µL 5X First-Strand buffer (P/N Y02321, Invitrogen), 1 µL 0.1M  Dithiothreitol (DTT) (P/N 
Y00147, Invitrogen), 1µL RNaseOUT™ Recombinant RNase Inhibitor (10777-019, Invitrogen) and 1 µL 
Superscript III Reverse Transcriptase (18080-044, Invitrogen) and the cDNA synthesis was performed in a 
T3000 thermocycler (Biometra), using the following conditions (Table 2).  
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Table 2 - Program used for cDNA synthesis 
Stage Temperature (ºC) Time  
Denaturation 65 5 min 
Cooling 4 10 min 
 Annealing 25  5 min 
cDNA synthesis 50 50 min 
Inactivation 70 15 min 
Cooling 4 ∞ 
 
After that, 1 µL of RT-PCR product (cDNA) was used in 25 µL PCR reaction mixture using 
quantitative Real-Time PCR primers (Table 13), as described in table 3, in order to assess cDNA quality and 
specificity of the primers. 
 
 
 
Table 3 - PCR program for cDNA amplification using quantitative Real Time-PCR primers 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 94 5 min 1 
Denaturation 94 50 sec 
34 Annealing 60 30 sec 
Elongation 72 1 min  
Final elongation 72 7 min 1 
Cooling 15 ∞  
 
 
PCR products were analyzed on a 2% (w/v) agarose gel (in 1X Tris-borate-EDTA  (TBE) buffer 
(diluted from 10X TBE, EC-860, National diagnostics)) stained with 0.05% (v/v) ethidium bromide and under 
UV transillumination (BioDocAnalyse Transilluminator, Biometra).  
 
3.1.2.2 Quantitative Real-Time PCR 
 
Quantitative Real-time PCR (qRT-PCR) is a powerful technique for gene expression studies due to its 
high sensitivity, specificity and broad quantification range for high throughput and accurate expression profiling 
of selected genes. Quantification of mRNA transcription can be either relative or absolute (Bustin, 2000). The 
data obtained by qRT-PCR is normalized with an endogenous control, often referred to as a housekeeping 
gene (Gubern et al., 2009). In relative quantification, data are secondly normalized to a reference sample. 
qRT-PCR reactions were carried out for all genes of interest in each sample using LightCycler 480 
SYBR Green I master (04707516001, Roche) and LightCycler 480 instrument (Roche). Each reaction mixture 
was performed on 25 µL containing 1µL cDNA diluted with ddH2O (1:2.5), 12.5 µL LightCycler 480 SYBR 
Green I master (04707516001, Roche), 10.5 µL LightCycler 480 SYBR Green II master (H2O) (04707516001, 
Roche) and 0.5µL of each primer (10µM) or on 7 µL containing 1 µL of cDNA diluted with ddH2O (1:2.5), 3.5 
µL LightCycler 480 SYBR Green I master (04707516001, Roche), 2 µL LightCycler 480 SYBR Green II 
master (H2O) (04707516001, Roche)  and 0.5 µL of both primers (5µM) (Table 13) as described in table 4. In 
the present thesis, relative quantification of gene expression was performed and the Hypoxanthine 
phosphoribosyltransferase (HRPT) gene (Table 13) was used as endogenous control.  
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Table 4 - Quantitative Real-Time PCR program 
Stage Temperature (ºC) Time Cycles 
Heat activation 95 10 min 15 sec 1 
PCR    
Denaturation 95 15 sec 
45 Annealing 60 15 sec 
Elongation 72 20 sec 
Melting 
60 
95 
14 sec 1 
Cooling 40 10 sec  
 
All samples were run in triplicate (biological triplicates). The results of qRT-PCR were analyzed in 
LightCycler 480 software (Roche). Expression levels were normalized to those obtained for cells grown in 
control conditions (culture conditions specified in 3.1.1). Average and standard deviation of the relative gene 
expression values were calculated and statistical analysis was performed. 
3.1.3  Protein levels 
 
The role of EGF in the regulation of LDHA, LDHB, (and LDHC in SiHa cells), MCT1 and MCT4 protein 
levels in SiHa and HeLa cells grown in the presence and absence of NaLac was evaluated through Western 
blot and Immunofluorescence. The designations, LDHA and LDHB protein levels, which were used in this 
thesis, correspond to the detection of LDH-M subunit and LDH-H subunit, respectively. 
3.1.3.1 Western blot  
 
Western blot is a widely used analytical technique used to detect specific proteins in the given sample 
of tissue homogenate or extract. It uses gel electrophoresis to separate native proteins by 3-D structure or 
denatured proteins by the length of the polypeptide. The proteins are then transferred to a membrane 
(typically nitrocellulose or PVDF), where they are detected using antibodies specific to the target protein 
(Renart et al., 1979; Towbin et al., 1979).  
This method was used to assess LDHA, LDHB, MCT1 and MCT4 protein levels in cells grown in the 
presence of NaLac and/or after EGF stimulation (culture conditions specified in 3.1.1) and to compare them 
with those obtained in cells grown in control conditions (culture conditions specified in 3.1.1). 
Briefly, cells were lysed in Radio-Immunoprecipitation Assay (RIPA) (Appendix I) buffer and stored at 
-20ºC Overnight (ON). The lysates were centrifuged at 14000 rpm for 5 minutes at 4ºC and the supernatants 
were collected for protein concentration determination through Spectrophotometric quantification (595 nm) 
based on Bradford method and using Bio-Rad Protein Assay Reagent (500-0006, Bio-Rad). After that, it was 
added 5X Loading buffer (Appendix I) with 10% β-mercaptoethanol (M3148, sigma) (at a final concentration ≥ 
1X) to the cell lysate and incubated at 100ºC for 20 minutes. The lysates were centrifuged at 14000 rpm for 2 
minutes and incubated on ice.  
Equal amounts of total protein were separated by 15% Tris-glycine SDS-Polyacrylamide gel 
(Appendix I) electrophoresis at 150V for 1h30 in 1X Tris-Glycine-SDS (TGS) buffer (10X TGS buffer, 161-
0772, Bio-Rad) in Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad) and then transferred to a 
nitrocellulose membrane in transfer buffer (Appendix I) with a Mini Trans-Blot® Electrophoretic Transfer Cell 
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(Bio-Rad), at 60V for 4hours to ON. Membranes were blocked with 3% skim milk in Phosphate buffered saline 
(PBS) 0.1% (v/v) Tween 20 (Appendix I) for 1 hour at RT.  Blots were incubated with specific antibodies anti-
MCT1 (AB3538P, Millipore), anti-MCT4 (AB3316P, Millipore), anti-MCT4 (SC-50329, Santa Cruz), anti-LDHA 
(SAB1100050, Sigma), anti-LDH (H-subunit) (L7016, Sigma) and anti-LDHC (AV53602, Sigma) at appropriate 
concentrations (1:1000 in 3% (w/v) skim milk in PBS 0.1% (v/v) Tween 20 (Appendix I)) at 4ºC ON.   
After rinsing 3 X 5 minutes in PBS 0.1% (v/v) Tween 20 (Appendix I), blots were then incubated for 2 
hours at RT with a IgG secondary antibody-conjugated Horse raddish peroxidase (HRP) (anti-rabbit (31460, 
Thermo Scientific) and anti-mouse (31430, Thermo Scientific)) diluted 1:5000 in 3% (w/v) skim milk in PBS 
0.1% (v/v) Tween 20 (Appendix I).  
After rinsing 3 X 5 minutes in PBS 0.1% (v/v) Tween 20 (Appendix I), immunoreactive bands were 
detected using ECL Western blotting substrate (SuperSignal West Pico Substrate (34080, Thermo Scientific)), 
followed by exposure to film and photographic development with ChemiDoc XRS System (Bio-Rad). Images 
were analyzed using ImageJ software (http://rsbweb.nih.gov/ij/). 
To confirm equal loading of protein lysates and in order to normalize the obtained protein levels, 
membranes were rinsing 3 X 5 minutes with PBS 0.1% (v/v) Tween 20 (Appendix I) and reprobed using anti-β-
actin (A5441, Sigma) at 1:1000 in 3% (w/v) skim milk in PBS 0.1% (v/v) Tween 20 (Appendix I) at 4ºC ON and 
then processed as above. 
 
3.1.3.2 Immunofluorescence 
 
Immunofluorescence uses the specificity of antibodies labeled with fluorochromes to target specific 
proteins within a cell, allowing their visualization in the sample (Robinson et al., 2009). The two main methods 
of immunofluorescent labeling are direct and indirect. Less frequently used is direct immunofluorescence 
whereby the antibody against the molecule of interest is chemically conjugated to a fluorescent dye. In indirect 
immunofluorescence, the antibody specific for the molecule of interest (called the primary antibody) is 
unlabeled, and a second anti-immunoglobulin antibody directed  toward the constant portion of the primary 
antibody (called the secondary antibody) is labelled with the fluorescent dye (fluorophore) (Robinson et al., 
2009). 
In the present work, indirect immunofluorescence was performed aiming to evaluate LDHA, LDHB, 
LDHC, MCT1 and MCT4 protein levels in the presence and absence of NaLac and the role of EGF growth 
factor on its regulation. 
From each cell line (HeLa and SiHa), 2x105 cells/well (in 24-well plate) (4x105 cells/mL) were grown 
on lamellae, previously coated in 0.2% (w/v) gelatin, until they reached approximately 80% of optical 
confluence. EGF (PHG0311, Gibco) at 25 ng/mL and/or NaLac (1.06522.2500, Merck) at 10 mM were added 
to cells and incubated 37ºC 5% CO2 ON. Cells were harvested and fixed in 2% (w/v) paraformaldehyde for 15 
minutes at 4°C, blocked with PBS 0.2% (w/v) BSA (Appendix I) for 1hour at RT and incubated with primary 
antibody at 4ºC ON (anti-MCT1 (AB3538P, Millipore), anti-MCT4 (AB3316P, Millipore) and anti-MCT4 (SC-
50329, Santa Cruz),  diluted 1:100 in PBS 0.2% (w/v) BSA (Appendix I); (anti-LDHA (SAB1100050, Sigma),  
anti-LDH (H-subunit) (L7016,Sigma), anti-LDHB  (WH0003945M1, Sigma) and anti-LDHC (AV53602, Sigma) 
diluted 1:100 in PBS 0.2% (w/v) BSA 0.1%TritonX-100 (Appendix I)). 
After rinsing 3 X 5 minutes with 1X PBS (Appendix I) cells were incubated with the secondary 
antibodies for 2 hours, at RT. The secondary antibodies used were Alexa Fluor® 488 anti-mouse (A-11001, 
Invitrogen) or Alexa Fluor® 488 anti-rabbit (A-11034, Invitrogen) diluted 1:500 in PBS 0.2% (w/v) BSA 
(Appendix I). After that, the slides were rinsed, once again, 3 X 5 minutes with 1X PBS (Appendix I), prior to 
be mounted in VECTASHIELD media with 4'-6-diamidino-2-phenylindole (DAPI) (H-1200, Vector Labs) which 
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produces a blue fluorescence when bound to DNA, with excitation at about 360 nm and emission at 460 nm, 
so staining the nuclear material and consequently cell nuclei . Cells were examined by standard fluorescence 
microscopy using an Axio Imager.Z1 microscope (Zeiss).  
The same procedures described above were performed for negative controls, with the exception of 
the incubation with the primary antibody.  
Images were acquired with AxioVision software (http://microscopy.zeiss.com/microscopy/en_de 
/products/software/axiovision-for-biology.html) and processed with ImageJ software (http://rsbweb. nih.gov/ij/). 
  
3.1.4 Epigenetic regulation and LDHA, LDHB and MCT1 promoters  
 
3.1.4.1 Methylation pattern  
 
3.1.4.1.1 Bisulfite DNA conversion 
 
The methylation status of a DNA sequence can be determined using sodium bisulfite. The bisulfite 
treatment introduces methylation-dependent sequence changes through selective chemical conversion of non-
methylated cytosine to uracil. After treatment, all non-methylated cytosine bases are converted to uracil but all 
methylated cytosine bases remain cytosine. These methylation dependent C-to-T changes can subsequently 
be studied using conventional DNA analysis technologies, like PCR and automate sequencing of bisulfite-
treated genomic DNA to determine methylation status at CpG dinucleotides (Ehrich et al., 2007). 
In the context of this thesis bisulfite DNA conversion was applied to evaluate the methylation pattern 
of LDHA, LDHB and MCT1 promoters in cells grown in the presence and absence of NaLac with or without 
EGF stimulation. 
DNA was extracted from cells in culture (culture conditions described in 3.1.1) using DNA Purification 
Protocol for 1-2 Million Cells (Citogene) accordingly to the manufacturer’s protocol. 
Bisulfite treatment of genomic DNA was performed with the commercial EpiTect Bisulfite Kit (59104, 
Qiagen) that combines bisulfite conversion and DNA cleanup accordingly to the manufacturer’s protocol. The 
conversion was done using 2 µg of DNA and was added 1 µL of RNaseOUT™ Recombinant RNase Inhibitor 
(10777-019, Invitrogen) before and after bisulfite DNA conversion. 
After the bisulfite reaction the converted DNA was amplified by PCR (Tables 5 and 6) using  specific 
primers (Methyl primers) (Table 13) and finally was performed the automate sequencing of CpG islands 
identified in LDHA, LDHB and MCT1 promoters (Table 7), and their methylation status was evaluated. 
 
Table 5 - PCR program for amplification of bisulfite treated DNA 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 95 5 min 1 
Denaturation 95 30 sec 
35 Annealing Tann1  30 sec 
Elongation 72 50 sec 
Final elongation 72 7 min 1 
Cooling 15 ∞  
 
1 Methyl LDHA For2Rev2 45ºC; Methyl LDHA For3Rev3 48ºC; Methyl MCT1 For2Rev2 51ºC 
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Table 6 - PCR program for amplification of bisulfite treated DNA 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 94 5 min 1 
Denaturation 94 50 sec 
35 Annealing Tann1  30 sec 
Elongation 72 1 min 
Final elongation 72 7 min 1 
Cooling 15 ∞  
1 Methyl LDHB For1Rev1 53.7ºC; Methyl LDHB For2Rev2 55.6ºC; Methyl LDHB For3Rev3 54.6ºC 
 
PCR products were analyzed on a 2% (w/v) agarose gel (in 1X TBE buffer (10X TBE, EC-860, 
National diagnostics)) stained with 0.05% (v/v) ethidium bromide and under UV transillumination 
(BioDocAnalyse Transilluminator, Biometra). The DNA fragments were extracted from agarose and purified 
with IllustraTM GFXTM PCR DNA and Gel Band Purification kit (28-9034-71, GE Healthcare).  
 
3.1.4.1.2 Automate sequencing of LDHA, LDHB and MCT1 promoters’ CpG islands 
  
DNA sequencing is the determination of the order of the nucleotides in a DNA molecule. The DNA 
sequence can be determined by dye-terminator (Sanger) sequencing. In this method, the double stranded 
DNA fragment to be analyzed is mixed with a single primer binding to a strand complementary to the strand to 
be sequenced, DNA polymerase and a nucleotide mixture containing ordinary dNTPs and dideoxynucleotides 
(ddNTPs) (nucleotides lacking a 3'-hydroxyl (-OH) group at the polymerization site, and labelled with a 
fluorescent molecule – a different fluorochrom specific for each nucleotide). In a reaction based on the same 
principle as PCR, insertion of ddNTP terminates the extension of that particular strand. The insertion of 
ddNTPs is random, but, after a series of cycles, the sequencing reaction contains a mixture of copies of one 
strand ended at each base (Shendure et al., 2004). Strands are separated by size in a capillary 
electrophoresis. During the electrophoresis, the dyes of strands of equal length are excited passing a laser and 
the specific light emission is detected, generating nucleotide sequence of the DNA fragment (Swerdlow & 
Gesteland, 1990). One of the sequencing reaction mixtures contained the forward primer and the other one the 
reverse primer, so that both strands of the DNA fragment could be sequenced. 
In this particular setting, DNA sequencing was performed in order to evaluate the methylation pattern 
of the CpG dinucleotides of specific CpG islands identified at LDHA, LDHB and MCT1 gene promoters. 
Automate sequencing reaction mixtures of the amplified DNA fragments were performed as described 
as follows: 12µL of ddH2O, 1µL of reverse methyl primer (at 3.33 µM) (Table 13), 2 µL of DNA and 2µL of 5X 
Big dye sequencing buffer and 3 µL of Big dyeTM Terminator v1.1 (BigDye® Terminator v3.1 Cycle Sequencing 
kit, 4337456, Applied Biosystems).The automate sequencing reaction (Table 7) took place in a T3000 
thermocycler (Biometra).  
 
Table 7 - Automate sequencing program 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 96 5 min 1 
Denaturation 96 10 sec 
24 Annealing Tann1  5 sec 
Elongation 60 4 min 
Cooling 4 ∞  
1 Tann of Methyl LDHA Rev2 47°C; Methyl LDHA Rev3 48°C; Methyl LDHB Rev1 57.3ºC; Methyl LDHB Rev2 53.9ºC; Methyl LDHB Rev3 57.3ºC; Methyl MCT1 Rev2 51°C  
 
Automate sequencing reaction products were then purified with Illustra AutoSeq G-50 GFX (27-5340-
03, GE Healthcare) accordingly to manufacturer’s and analyzed in ABI Prism 3130 Genetic Analyzer. 
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3.1.5 Activity of LDHA, LDHB and MCT1 promoters 
  
In order to evaluate the activity of LDHA and LDHB and MCT1 promoters after EGF stimulation of 
cells grown in the presence and absence of NaLac, several deletion constructs (LDHA f1, LDHAf2 and LDHA 
f3; LDHB f1 and LDHB f2; MCT1 f1 and MCT1 f2) were generated using conventional molecular cloning 
techniques.  
3.1.5.1 Amplification of LDHA, LDHB and MCT1 promoter sequences 
 
Firstly, PCR amplification (Table 8) of genomic DNA (from HCT15 cell line) was done using specific 
primers with and without restriction enzyme (MluI and HindIII) sites designed for the LDHA, LDHB and MCT1 
promoter sequences (Table 13). 
Table 8 - PCR program used for amplification of LDHA, LDHB and MCT1 promoter sequences 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 94 5 min 1 
Denaturation 94 50 sec 
15 
Annealing Tann 1 30 sec 
Elongation 72 1 min 
20 
Denaturation 94 50 sec 
Annealing Tann 2 30 sec 
Elongation 72 1min 
Final elongation 72 7 min 1 
Cooling 15 ∞  
1 Tann of primers without restriction enzyme sites: LDHA For1Rev1 55ºC; LDHA For2Rev2 58ºC; LDHA For3Rev2 59.4ºC; LDHB For1Rev,For2Rev 55ºC; MCT1 For1Rev 
59.4ºC; MCT1 For2Rev 58ºC 
2 Tann of primers with restriction enzyme sites: LDHA For1Rev1 65ºC; LDHA For2Rev2 67.4ºC; LDHA For3Rev2 68.1ºC; LDHB For1Rev,F2R 65ºC; MCT1 For1Rev 68.1ºC; 
MCT1 For2Rev 67.4ºC 
 
PCR products were analyzed on a 2% (w/v) agarose gel (in 1X TBE buffer (diluted from 10X TBE, 
EC-860, National diagnostics)) stained with 0.05% (v/v) ethidium bromide and under UV transillumination 
(BioDocAnalyse Transilluminator, Biometra). The fragments were extracted from agarose and purified with 
IllustraTM GFXTM PCR DNA and Gel Band Purification kit (28-9034-71, GE Healthcare). After that DNA deletion 
fragments were sequenced through automate sequencing. 
 
 
3.1.5.2 DNA automate sequencing of LDHA, LDHB and MCT1 promoter sequences 
 
 
Each sequencing reaction mixture contained: 3 μL of Big dye™ Terminator v1.1 and 2 μL of 5X Big 
dye sequencing buffer (BigDye® Terminator v3.1 Cycle Sequencing kit, 4337456, Applied Biosystems), 1 μL 
of forward or reverse primer (at 3.33 µM) (Table 13), about 100 ng of template DNA and sterile bidestilled 
water up to 20 μL. Sequencing reaction was carried out in a T3000 thermocycler (Biometra), according to the 
program described in the table 9.  
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Table 9 - Automate sequencing program 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 96 5 min 1 
Denaturation 96 10 sec 
24 Annealing Tann1  5 sec 
Elongation 60 4 min 
Cooling 4 ∞  
1 Tann of primers without restriction enzyme sites: LDHA For1, Rev1 55.5˚C; LDHA For2, Rev2, For3 58˚C; LDHB For1, Rev, For2  55ºC; MCT1 For1, Rev1, For2, Rev2 58˚C 
 
Sequencing reaction products were then purified with Illustra AutoSeq G-50 GFX (27-5340-03, GE 
Healthcare) accordingly to manufacturer’s and analyzed in ABI Prism 3130 Genetic Analyzer. 
 
3.1.5.3 Plasmids generation and cloning 
 
 
Luciferase plasmids pGL3-Basic (Figure 4) and pGL3-Control (Figure 5) (pGL3 Luciferase Reporter 
Vectors, Promega) were used as negative and positive control, respectively. The pGL3-Basic vector lacks 
eukaryotic promoter and enhancer sequences, allowing maximum flexibility in cloning putative regulatory 
sequences. Expression of luciferase activity in cells transfected with this plasmid depends on insertion and 
proper orientation of a functional promoter upstream from luc+ (Figure 4). The pGL3-Control Vector contains 
SV40 promoter and enhancer sequences (Figure 5), resulting in strong expression of luc+ in many types of 
mammalian cells. This plasmid is useful in monitoring transfection efficiency, in general, and is a convenient 
internal standard for promoter and enhancer activities expressed by pGL3 recombinants (pGL3 Luciferase 
Reporter Vectors, Promega). 
 
 
Figure 4 - pGL3-Basic Vector. Adapted from pGL3 Luciferase Reporter Vectors, Promega. 
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Figure 5 - pGL3-Control Vector. Adapted from pGL3 Luciferase Reporter Vectors, Promega. 
 
DNA deletion fragments (LDHA f1, LDHA f2, LDHA f3, LDHB f1, LDHB f2, MCT1 f1 and MCT1 f2) 
(Table 13) and the pGL3 basic vector (Figure 4) were digested with MluI (ER0561, Fermentas) and HindIII 
(ER0501, Fermentas) restriction enzymes. The digestion reaction took place in a T3000 thermocycler 
(Biometra), at 37°C ON. The digestion products were purified with IllustraTM GFXTM PCR DNA and Gel Band 
Purification kit (28-9034-71, GE Healthcare). After that the deletion fragments were inserted into pGL3-basic 
vector that contains a modified coding region for firefly (Photinus pyralis) luciferase that has been optimized for 
monitoring transcriptional activity in transfected eukaryotic cells (Figure 3). The ligation reaction was prepared 
as follows: 2µL 10X T4 DNA ligase buffer (B69, Fermentas), 1µL T4 DNA ligase (EL0011, Fermentas), 1µL 
pGL3 basic vector previously digested and 16µL of digested DNA and was performed at 22ºC for 5 hours and 
65ºC 10 minutes in a T3000 thermocycler (Biometra).  
The recombinant plasmids were cloned into chemically competent Escherichia coli (C4040-10, 
Invitrogen) and colonies were selected by ampicillin resistance (Figure 4). Following, the recombinant plasmids 
were purified using Plasmid DNA Minipreps Kit (SP-PMN-250, Easy Spin, Citomed) according to 
manufacturer’s protocol. Plasmid DNA concentration was determined spectrophotometrically in Nanodrop 
2000 (Thermo Scientific). The deletion constructs were digested again with MluI and HindIII restriction 
enzymes  in order to confirm deletion fragments insertion and a third PCR amplification was done using 
plasmid DNA and RVprimer3 and GLprimer2 primers (pGL3 sequencing primers – table 13) (Table 10). 
 
 
Table 10 - PCR program for plasmid constructs amplification 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 94 5 min 1 
Denaturation 94 50 sec 
35 Annealing 56.9 30 sec 
Elongation 72 1 min  
Final elongation 72 7 min 1 
Cooling 15 ∞  
 
Finally, in order to sequence the DNA inserted into pGL3 vector automate sequencing was performed 
using pGL3 sequencing primers (at 3.33 µM) (Table 11) to determine the exact position of generated deletion 
constructs. Each sequencing reaction mixture contained: 3 μL of Big dye™ Terminator v1.1 and 2 μL of 5X Big 
dye sequencing buffer (BigDye® Terminator v3.1 Cycle Sequencing kit, 4337456, Applied Biosystems), 1 μL 
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of forward or reverse pGL3 sequencing primer (at 3.33 µM) (Table 13), about 100 ng of plasmid DNA and 
sterile bidestilled water up to 20 μL. Sequencing reaction was carried out in a T3000 thermocycler (Biometra), 
according to the program described in the table 11. 
 
Table 11 - Automate sequencing program 
Stage Temperature (ºC) Time  Cycles 
Initial denaturation 96 5 min 1 
Denaturation 96 10 sec 
24 Annealing 56.9 5 sec 
Elongation 60 4 min 
Cooling 4 ∞  
 
Sequencing reaction products were then purified using Illustra AutoSeq G-50 GFX (27-5340-03, GE 
Healthcare) accordingly to manufacturer’s and analyzed in ABI Prism 3130 Genetic Analyzer. 
A second transformation of chemically competent Escherichia coli (C4040-10, Invitrogen) was done, in 
order to increase the amount of plasmid DNA. All recombinant plasmids were purified with Plasmid DNA 
Midipreps Kit (12143, Qiagen) according to manufacturer’s protocol. Plasmid DNA concentration was 
determined spectrophotometrically in Nanodrop 2000 (Thermo Scientific). 
 
3.1.5.4 Transient transfection of promoters’ deletion constructs into HeLa 
and SiHa cell lines 
 
Transient transfection assays have been developed and broadly used to define transcriptionally 
regulatory elements, such as promoters, enhancers, and silencers. In a transient transfection assay, a DNA 
fragment of interest is placed upstream from a reporter gene and the regulatory potential of the sequence can 
be assessed by measuring transcription activity of the reporter gene. The firefly (Photinus pyralis) luciferase 
gene is one reporter used commonly in transient transcription assays (Yin et al., 2005). 
A transient transfection assay is the delivery of the plasmid DNA into cultured cells in order to 
measure the activity of the reporter gene in transfected cell lysated (Yin et al., 2005). Cell type, delivery 
method, and properties of the vector (e.g., size, quality, and amount) might influence transfection efficiency. 
Bioluminescence analysis could be affected by several factors, such as cell lysis efficiency, cell viability. To 
correct these systematic errors, a commonly employed strategy is to introduce a control plasmid carrying a 
second reporter gene driven by a constitutively active promoter (Yin et al., 2005). 
In the Dual Luciferase reporter system, for example, Renilla (Renilla reniformis) luciferase expressing 
plasmid is used as control. After co-transfection of two luciferase plasmids, both Firefly and Renilla luciferase 
activities are measured sequentially from a single aliquot of the cell lysate. The firefly luciferase activity 
normalized by Renilla luciferase activity represents a more accurate quantitation of transcription rates (Yin et 
al., 2005; Ho & Strauss, 2004).  
One day before transfection cells were trypsinized with 1X 0.05% trypsin-EDTA (25300-054, 
Invitrogen) and seeded into 24-well plates (2x105 cells/well) (4x105 cells/mL) in DMEM supplemented with 10% 
FBS and 1% AA. NaLac (1.06522.2500, Merck) at 10mM was added to cells. Cells were incubated at 37ºC 5% 
CO2 ON. Transfection was performed using Lipofectamine 2000 (11668, Invitrogen) and 0.5 µg of each 
deletion construct (LDHA f1, LDHA f2, LDHA f3, LDHB f1, LDHB f2, MCT1 f1 and MCT1 f2) (Table 13) per well 
at 3:1 ratio and 1X Opti-MEM medium (31985, Gibco).  
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pGL3-Control vector (that contains SV40 promoter and enhancer sequences) (Figure 5) was used as 
positive control and pGL3-Basic vector (the promoterless firefly plasmid) (Figure 4) as negative control. The 
control plasmid expressing Renilla luciferase was mixed with the Firefly luciferase deletion constructs at 1:5 
ratio. The plasmids and liposome were mixed at 1:3 ratio and incubated at RT for 20 minutes. The 
DNAp/liposome complex was added to each well (100µL/well) followed by incubation at 37ºC 5%CO2 for 4h-
6h. 4h-6h after transfection 500 µL of DMEM supplemented with 10% FBS and 1% AA medium were added to 
the cells (DMEM supplemented with 10% FBS and 1% AA with 10 mM NaLac to the cells grown in the 
presence of NaLac) followed by incubation at 37ºC ON. EGF (PHG0311, Gibco) at 25 ng/mL was added to the 
cells 24 hours post-transfection. Cells transfected in control conditions were maintained in DMEM 
supplemented with 10% FBS and 1% AA in the absence of NaLac and without EGF stimulation. Cells were 
harvested 48h post-transfection and lysed with 1X Passive lysis buffer (5X Passive lysis buffer, E194A, 
Promega) and frozen at -80ºC. 
 
3.1.5.4.1 Luciferase activity of LDHA and LDHB and MCT1 promoters’ deletion 
constructs  
 
In order to evaluate the luciferase activity of LDHA and LDHB and MCT1 promoters’ deletion 
constructs  Firefly and Renilla luciferase activity were measured sequentially from a single cell lysate on 
Victor3 1420 Multilabel Counter Luminometer (Perkin Elmer) by using the Dual Luciferase Assay System 
(E1910, Promega) according to the manufacturer’s protocol. The results were expressed as a ratio of Firefly 
luciferase activity to Renilla luciferase activity and then normalized to the pGL3-Basic vector activity. Once 
data were collected from three experiments (triplicates) average and standard deviation were calculated and 
statistics analysis was performed. 
 
3.1.6 c-Myc-antibody chromatin Immunoprecipitation (ChIP)  
 
Chromatin immunoprecipitation (ChIP) is a technique that allows the analysis of the association of 
specific proteins with particular genomic regions in the context of intact cells. ChIP is used to determine 
changes in epigenetic signatures, chromatin remodeling and transcription regulators binding (Collas, 2010; 
Kuo & Allis, 1999). The basic steps of this technique are cell fixation, chromatin shearing (by sonication), 
immunoselection, immunoprecipitation and analysis of the immunoprecipitated DNA by qRT-PCR (Das et al., 
2004). Chromatin is fragmented by sonication of whole cells and nuclei, into fragments of 200–1000 base pair 
(bp), with an average of 500 bp (Collas, 2010). 
In the present thesis ChIP was used to study c-myc transcription factor interaction with LDHA and 
MCT1 promoters in cells grown in the presence and absence of NaLac with or without EGF stimulation. 
HeLa and SiHa cells were grown in tissue culture flasks in DMEM supplemented with 10% FBS and 1% 
AA until they reached ~70-80% of optical confluence (100-120 million cells) and then were stimulated with 
EGF (PHG0311, Gibco) (25ng/mL) in the presence and absence of NaLac (1.06522.2500, Merck) (10 mM) at 
37ºC 5% CO2 for 12-16 hours. After that 37% formaldehyde (Merck) was added to cells to a final concentration 
of 1% (v/v) and incubated for 10 minutes at RT (to cross-link DNA and proteins) and then formaldehyde was 
quenched by addition of glycine to a final concentration of 125 mM and incubated for 5 minutes at RT. Then 
cells were harvested through scraping in 1X PBS (10X PBS, D1408 Sigma) centrifuged at 1200 rpm for 2 
minutes and 500 µL of ChIP lysis buffer (kch-onedIP-060, Diagenode) were added to cell pellets and stored at 
-20ºC. Cell pellets were thawed on ice and sonication was performed (10 cycles of 30 seconds each one). In 
order to check chromatin fragmentation, 2 µL of chromatin were separated by a 1.2% (w/v) agarose gel 
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electrophoresis (in 1X TBE buffer (diluted from 10X TBE, EC-860, National diagnostics)) stained with 0.05% 
(v/v) ethidium bromide. Fragmented chromatin (between 500-1000 bp) was stored at -20ºC. ChIP was 
performed using OneDay ChIP kit (kch-onedIP-060, Diagenode) accordingly to manufacturer’s protocol. c-Myc 
antibody (A-14) (sc-789, Santa Cruz Biotech) (target) and a rabbit non-immune IgG (kch-onedIP-060, 
Diagenode) were used. Amplification and analysis of Immunoprecipitated (IP’d) DNA was done through qRT-
PCR, accordingly to manufacturer’s protocol, in an ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems) (Table 12) using specific primers (Myc LDHA and Myc MCT1 primers) (Table 13). Data were 
analyzed in SDS 2.4.1 software (Applied Biosystems) and relative occupancy of the immunoprecipitated factor 
at specific loci was calculated using the following equation: 
 
                      
 
where CtNegCtl and CtTarget are the average threshold cycles of PCR done in triplicates on DNA 
samples from negative control ChIP (rabbit non-immune IgG) and targeted ChIP (using c-Myc antibody), 
respectively. 
 
 
Table 12 - IP’d DNA quantitative Real-Time PCR program 
Stage Temperature (ºC) Time  Cycles 
Activation 50 2 min 1 
Initial denaturation 95 10 min 1 
Denaturation 95 15 sec 
40 
Annealing; Elongation  60 1 min 
Dissociation curves 
95 
60 
95 
15 sec 
15 sec 
15 sec 
 
 
 
 
3.2 Detection of c-Myc copy number by Fluorescent in situ hybridization (FISH)  
 
Fluorescent in situ hybridization (FISH) is a cytogenetic technique used to detect and localize the 
presence or absence of specific DNA sequences on chromosomes thus allowing the detection of numerical 
and structural abnormalities in interphase nuclei (Policht et al., 2010). FISH uses fluorescent probes that bind 
to those parts of the chromosome with which they show a high degree of sequence complementarity (Policht 
et al., 2010). 
In the context of this thesis FISH was used to identify, firstly, c-Myc copy number in HeLa and SiHa 
cells and also to understand if c-Myc copy number variations result from genetic or chromosomal (such as 
aneuploidy) alterations. 
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 Vysis LSI MYC Dual color, Break Apart Rearrangement Probe (32-191096, Abbott Molecular) was 
used to detect c-Myc copy number (Figure 6a). Vysis LSI IGH/MYC, CEP8 Tri-color, Dual Fusion 
Translocation Probe (32-191020, Abbott 
Molecular) (Figure 6b) was used to detect c-
Myc copy number and the number of 
centromeres once inclusion of the 
SpectrumAquaTM CEP 8 serves as a control for 
chromosome 8 and is located at centromere.  
 
 
 
 
 
SiHa and HeLa cells (1x106 cells/mL) were grown on Millicell EZ slide (PEZGS0416, Millipore) 
previously coated with 0.2% (w/v) gelatin, in DMEM supplemented with 10% FBS and 1% AA until they 
reached ~70% confluence. Cells were harvested and fixed with 3:1 Methanol (106009, Merck): Glacial Acetic 
acid (100063, Merck) for 15 minutes at RT. Slide preparation, probe hybridization and post-hybridization 
washes were carried out using standard methods described in Vysis LSI (Locus Specific Identifier) DNA 
probes kit manual (Abbott Molecular). At least 100 nuclei were analyzed using microscopic visualization and 
images were acquired to verify the number of target and control signals and probe location. The frequency (in 
percentage) of the different number of signals of target (8q24 LSI MYC) and control probe (8p11.1-q11.1 
CEP8 alpha satellite) (located at the centromere), contained in Vysis LSI IGH/MYC, CEP8 Tri-color, Dual 
Fusion Translocation Probe (32-191020, Abbott Molecular) (Figure 6b), were calculated. The information 
provided by 14q32 LSI IGH probe (Figure 5b) was not used in this context.    
 
3.3 Histological analysis 
 
3.3.1  Tissue microarray 
 
Cylindrical cores are obtained from a number (up to 1000) of individual formalin-fixed, paraffin-
embedded tissue blocks. These are transferred to recipient tissue microarray (TMA). Each TMA can be 
sectioned up to 300 times. All resulting TMA slides have the same tissues in the same coordinate positions. 
The individual slides can be used for a variety of analyses saving labor and reagent costs while maintaining 
the uniformity of assay. Typically a minimum of 3 cores for each case are used (Kumar & Rudbeck, 2009). 
In the present thesis TMAs of adenocarcinoma and squamous cell carcinomas of the uterine cervix 
cases were performed. The total number of cases included was 44 squamous cell carcinoma cases, 14 
adenocarcinoma cases and 3 cases of cervical intraepithelial neoplasia. These tissue microarrays were 
analyzed by immunohistochemistry and FISH. 
 
 
  
Figure 6 - LSI MYC Dual color, Break Apart Rearrangement Probe (a) 
and LSI IGH/MYC, CEP8 Tri-color, Dual Fusion Translocation Probe 
(b) ideograms. Adapted from Vysis product catalog, Abbott Molecular. 
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3.3.2 Immunohistochemistry for MCT1 
 
Immunohistochemistry has emerged as a powerful investigative tool that can provide additional 
information to the morphological assessment of tissues. The use of immunohistochemistry to study cellular 
markers that define specific phenotypes has provided important diagnostic, prognostic and predictive 
information to disease status and biology (Kumar & Rudbeck, 2009). 
 Tissue specimens are fixed in formalin and subsequently embedded in paraffin in the majority of the 
cases. While formalin fixation preserves tissue morphology, it also alters the three-dimensional structure of 
tissue proteins. This alteration can result in a modification of the antigen’s epitopes. So, the first step of the 
immunohistochemistry is the demasking of antigens (Kumar & Rudbeck, 2009). In the present thesis this was 
performed using a water bath method in a Dako PTLink device – a module for tissue specimens for pre-
treatment process of deparaffinization, rehydration and antigen retrieval – for 20 minutes at 94ºC accordingly 
to manufacturer’s protocol. After that, a polymer-based immunohistochemistry (EnVision+System-HRP (DAB), 
K4011, Dako) was performed accordingly to manufacturer’s protocol. 
Briefly, after the antigen retrieval the tissue microarray slides were rinsed 2 X 5 minutes with 1X Tris 
Buffered Saline (TBS) (Appendix I) and then samples were incubated with primary antibody (anti-MCT1) 
(AB3538P, Millipore) diluted 1:400 in Bond Primary Antibody Diluent (AR9352, Leica bond) for 1 hour at RT. 
Then slides were rinsed 2 x 5 minutes with 1X TBS and incubated with Peroxidase Block (K4011, Dako) for 10 
minutes at RT to block endogenous peroxidase activity. Slides were rinsed once again and incubated with 
Labelled Polymer-HRP anti-rabbit (K4011, Dako) for 30 minutes at RT. After that slides were rinsed and 
incubated with DAB+substrate buffer (K4011, Dako) plus DAB+ chromogen (K4011, Dako) (For each 1 mL of 
buffer one drop (20µL) of DAB+chromogen) for 8 minutes at RT. Then the slides were rinsed in warm water 
and specimens were immersed in Mayer’s Hematoxylin for 1 minute. After that slides were rinsed again in tap 
water, in order to neutralize the acid and form an insoluble blue aluminium haematin complex, a procedure 
known as blueing. Finally specimens were immersed in alcoholic solutions with crescent percentage of ethanol 
and lastly in xylol to dehydrate. After that slides were mounted with Entellan (1079610500, Merck) mounting 
medium and examined under the optical microscope (Zeiss).  
The same procedures described above were performed for negative controls, with the exception of 
the incubation with the primary antibody. With the information provided by immunohistochemistry analysis for 
MCT1 the cases in the TMA were classified as negative or positive for MCT1, and for the positive ones, a 
degree of MCT1 immunodetection intensity (+-, +, ++, +++) was established.  
 
3.3.3 Detection of c-Myc copy number by FISH  
 
c-Myc copy number detection in tissue microarray slides were done using FISH. Pre-treatments of the 
specimen target (includes digestion of tissue), slide preparation, probe hybridization and post-hybridization 
washes were carried out using standard methods described in Vysis LSI (Locus Specific Identifier) DNA 
probes kit manual (Abbott Molecular). The probe mixture used for c-Myc detection was Vysis LSI IGH/MYC, 
CEP8 Tri-color, Dual Fusion Translocation Probe (Abbott Molecular) (Figure 6b) that contains a target probe 
(8q24 LSI MYC) and a control probe (8p11.1-q11.1 CEP8 alpha satellite) located at the centromere. The 
information provided by 14q32 LSI IGH probe (Figure 6b) was not used in this context.  
With the information provided by FISH analysis the cases in the TMA were classified as normal 
(disomy), aneusomy, trisomy, aneusomy and amplification for chromosome 8 and c-Myc, accordingly to the 
chromosome 8 and c-Myc copy number detected. 
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3.4 Role of NaLac and EGF in cell migration, cell cycle regulation and proliferation in vitro  
 
3.4.1 Cell migration - In vitro wound healing assay  
 
In vitro wound healing assay is a commonly used model to study directional cell migration in vitro 
once to a certain extent this method mimics the migration of cells during wound healing in vivo (Lee & Kay, 
2006) . 
In the present work this assay was performed to identify a possible role of NaLac by itself or in 
association with EGF stimulation of SiHa cells on their migration rate. 
SiHa cells were plated in six-well tissue culture dishes at a concentration of 2x105cells/well 
(1x105cells/mL) and maintained in DMEM supplemented with 10% FBS and 1% AA. When cells reached 90 to 
100% of optical confluence, they were treated with 5 µg/mL Mitomycin-C (M4287, Sigma) for 3 hours at 37ºC 
5% CO2 in order to inhibit cell proliferation. After the incubation time a tip of a micropipette (P200 tip) was used 
to wound the cell layer, creating linear scrapes. After the scratch the culture medium was replaced to remove 
floating cellular debris and medium with NaLac (1.06522.2500, Merck) (10mM) and/or EGF (PHG0311, Gibco) 
(25ng/mL) was added to cells. Culture medium was replaced after approximately 16-18 hours. Wound closure, 
corresponding to cell migration, was photographed when the scrape wound was introduced (t=0h) and at 
designated times after wounding (t=8h, t=24h, t=32h). Images were analyzed with ImageJ software 
(http://rsbweb.nih.gov/ij/) in order to estimate wound closure. 
 
Once Mitomycin-C was used in in vitro Wound Healing assay to inhibit cell proliferation a proliferation 
curve of SiHa cells grown in the presence and absence of this anti-proliferative agent was performed. SiHa 
cells were plated in twelve-well plate tissue culture dishes at a concentration of 2x105cells/well (2x105cells/mL) 
and maintained in DMEM supplemented with 10% FBS and 1% AA and incubated at 37ºC 5% CO2 ON. 5 
µg/mL of Mitomycin-C (M4287, Sigma) was added to cells and an incubation period of 3 hours at 37ºC 5% 
CO2 was performed. After that period of time cell number per mL was determined using a Bürker counting 
chamber (t=0h) and the culture medium was replaced by medium without Mitomycin-C and cells were 
incubated at 37ºC 5% CO2 for more 8, 24 and 32 hours and cell number/mL was determined at each time 
point, as described before. Average and standard deviation of cell number per mL were calculated (n=4) and 
compared to those values obtained for cells grown in the absence of Mitomycin-C. 
 
3.4.2 Cell cycle analysis by Flow Cytometry  
 
Flow cytometry enables the determination of the relative cellular DNA content of cells stained with 
propidium iodide (PI) – a fluorescent DNA intercalating dye – and also the identification of the cell distribution 
during the various phases of the cell cycle. Four distinct phases could be recognized in a proliferating cell 
population: the G1-, S- (DNA synthesis phase), G2- and M-phase (mitosis). However, G2- and M-phase, which 
both have identical DNA content, could not be discriminated based on their differences in DNA content 
(Cecchini et al., 2012; Nunez, 2001). The basic steps of this methodology are cell fixation with ethanol, 
staining and analysis by flow cytometry (Cecchini et al., 2012). 
In the context of the present thesis cell cycle analysis was performed to identify a potential role of 
NaLac by itself or in association with EGF stimulation of SiHa cells in the regulation of cell cycle. 
SiHa cells were plated in six-well plate tissue culture dishes at a concentration of 5x105/well (2.5x105 
cells/mL) and maintained in DMEM supplemented with 10% FBS and 1% AA. After ~8hours (when cells 
adhere) the medium was replaced by medium without FBS and incubated 37ºC 5% CO2 ON. Some cells were 
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harvested at 0h (control) and the others were stimulated with NaLac (1.06522.2500, Merck) (10mM) and/or 
EGF (PHG0311, Gibco) (25ng/mL) and harvested 6 and 24 hours after stimulation and fixed in 70% ethanol 
and incubated at 4ºC. Then cells were stained with PI solution (Appendix I). Firstly, cells were centrifuged at 
1500 rpm for 5 minutes and the cell pellet was resuspended in 500 µL of 50 µg/mL PI solution (Appendix I) 
and incubated at 37ºC for 40 minutes. After the incubation time it was added 3 mL of 1X PBS (Appendix I) and 
cells were centrifuged at 1500 rpm, 5 minutes at 4ºC. The supernatant was removed and the cells were 
resuspended in 500 µL PBS 0.1% (w/v) BSA (Appendix I) and analyzed through flow cytometric (FACScalibur 
- Becton Dickinson). Percentage of cells (death cells and cell aggregates were excluded) in each cell cycle 
phase was assessed. Average and standard deviation were calculated and statistical analysis was performed. 
 
3.4.3 Cell proliferation in vitro 
 
A proliferation curve of SiHa cells was done to evaluate a possible role of EGF in the proliferation of 
this cell type in the presence and absence of NaLac. 
SiHa cells were plated in twelve-well plate tissue culture dishes at a concentration of 2x105cells/well 
(2x105 cells/mL) and maintained in DMEM supplemented with 10% FBS and 1% AA at 37ºC 5% CO2 for 
approximately 8 hours (to adhere) and then culture medium was replaced by DMEM without FBS and 
incubated at 37ºC 5% CO2 ON (to synchronize cells). Cell number per mL was determined using a Bürker 
counting chamber (t=0h) and the culture medium was replaced by medium with NaLac (1.06522.2500, Merck) 
(10 mM) and/or EGF (PHG0311, Gibco) (25 ng/mL) and cells were incubated for 3 hours at 37ºC 5% CO2. 
After this period of time cell concentration (cells/mL) was determined as described before. The same 
procedure was done after 6, 12, 24 and 30 hours of incubation at 37ºC 5% CO2. The average and standard 
deviation of cell number per mL were calculated (n=4) and statistical analysis was performed. 
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Table 13 - Primers used during the experimental work 
Reference/Target Primer (5’-3’) Tm (ºC) Technique 
MluIpLDHA 
 
For1:ATGACGCGTCCTTTCAACTCTCTTTTGGC 75.6 
PCR; Automate sequencing 
For2:ATGACGCGTCTGGACACTGAGAAACAGG 75.9 
For3ATGACGCGTGACTCGAGATGAGATGCCAG 79.0 
HindIIIpLDHA 
Rev1:ATGAAGCTTGACTTGGAACCAAAAGGAATC 72.2 
Rev2:ATGAAGCTTGTGGAACAGCTATGCTGACG 74.4 
MluIpLDHB 
For1:ATGACGCGTCTTTTGAGACGGAATCGCTC 78.0 
For2:ATGACGCGTCAGAGTAGAAGAATCAGTCC 71.5 
HindIIIpLDHB Rev :ATGAAGCTTGCACTGCAAGGAAAGAATC 72.1 
MluIpMCT1 
For1:ATGACGCGTGATTGCCTAGAGCTCGTCAG 77.7 
For2:ATGACGCGTGGACATCAAAGACACTCCATG 78.2 
HindIIIpMCT1 Rev :ATGAAGCTTCTGCCTCGTTTGCTTGTTCC 75.7 
    
LDHA f1 
For1: CCTTTCAACTCTCTTTTGGC 
Rev1: GACTTGGAACCAAAAGGAATC 
60.4 
61.3 
PCR; Automate sequencing 
LDHA f2 
For2: CTGGACACTGAGAAACAGG 
Rev2: GTGGAACAGCTATGCTGACG 
58.3 
63.5 
LDHA f3 
For3: GACTCGAGATGAGATGCCAG 
Rev2: GTGGAACAGCTATGCTGACG 
62.7 
63.5 
LDHB f1 
For1: CTTTTGAGACGGAATCGCTC 
Rev: GCACTGCAAGGAAAGAATC 
63.8 
60.0 
LDHB f2 
For2: CAGAGTAGAAGAATCAGTCC 
Rev: GCACTGCAAGGAAAGAATC 
52.8 
60.0 
MCT1 f1 
For1: GATTGCCTAGAGCTCGTCAG 
Rev: CTGCCTCGTTTGCTTGTTCC 
61.7 
67.0 
MCT1 f2 
For2: GGACATCAAAGACACTCCATG 
Rev: CTGCCTCGTTTGCTTGTTCC 
62.0 
67.0 
    
RVprimer3 CTAGCAAAATAGGCTGTCCC 57.0 PCR; Automate sequencing 
GLprimer2 GGAAGACGCCAAAAACATAAAG 56.0 PCR; Automate sequencing 
    
Myc LDHA 
For1:CTTCTGTGGTTGGAGGGCAGCA 
Rev1:GCGCAGCCAGACAACCGA 
72.7 
71.4 
qRT-PCR 
For2:TCGGTTGTCTGGCTGCGC 
Rev2: GTGGAACAGCTATGCTGACG 
71.4 
63.5 
Myc MCT1 
For1:GCCCCACATATGCATCGTCC 
Rev1:ATTAAAGACGAGTCGGGAAAGAAG 
69.6 
64.4 
For2:GATTGCCTAGAGCTCGTCAG 
Rev2:CCTCCACACGCTTTCAGCC 
61.7 
68.3 
    
LDHA 
For: CTTGCTCTTGTTGATGTCATCG 
Rev: CAGCCGTGATAATGACCAGC 
64.6 
65.5 
qRT-PCR  
LDHB 
For: GAGCCTTCTCTCTCCTGTG 
Rev: CTGATAGCACACGCCATACC 
59.3 
63.1 
LDHC 
For: GGATCTTCAGCATGGCAGTC 
Rev: CTATTCTGGAGTTTGCAGATACAC 
64.8 
60.6 
MCT1 
For: GCTGGGCAGTGGTAATTGGA 
Rev: CAGTAATTGATTTGGGAAATGCAT 
67.1 
64.4 
HPRT 
For: TGACACTGGCAAAACAATGCA 
Rev: GGTCCTTTTCACCAGCAAGCT 
67.5 
66.6 
MCT4 
For: CACAAGTTCTCCAGTGCCATTG  
Rev: CGCATCCAGGAGTTTGCCTC 
66.7 
69.2 
EGFR 
For: AAGACAGCTTCTTGCAGCGATA 
Rev: GGAGGAAGGTGTCGTCTATGCT 
65.1 
65.5 
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Table 13 cont. Primers used during the experimental work 
Methyl-pMCT1 
 
For1: GGAATTTAATATATTTTAG 42.5 
PCR; Automate sequencing 
 
For2: GGGTAGATTGTTTAGAGTT 49.6 
Rev1: AACTCTAAACAATCTACCC 49.6 
Rev2: CAACTCACCACTTTATCTAA 51.7 
Methyl-pLDHA 
 
For1: TTTGTGGTTGGAGGGTAGTAA 60.8 
For2: TAGTATAGTTGTTTTATTTA 41.0 
For3: AATTGTTTTTGGTTTTGTTG 56.6 
Rev1: TAAATAAAACAACTATACTA 41.0 
Rev2: CAACAAAACCAAAAACAATT 56.6 
Rev3: CACCTTAAAACCTATCATA 49.0 
Methyl-pLDHB 
For1:GAAATTTAAGAGGTTGTGG 
For2:GGTAGAGGGTAGTAGTTGTG 
For3: GAGGAGAAAGGTATTTAGATG 
Rev1: CACAACTACTACCCTCTACC 
Rev2: CATCTAAATACCTTTCTCCTC 
Rev3: CCCCAAACCCTTACTACAAC 
53.6 
52.7 
53.7 
52.7 
53.7 
59.8 
 
Tm: melting temperature 
qRT-PCR: quantitative Real Time-PCR 
 
 
3.5 Statistical analysis 
 
Student’s t test was used to evaluate the statistical significance of results, using OriginPro8 software 
(OriginLab Corporation). p<0.05 was considered statistically significant and p<0.001 highly statistically 
significant. 
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4. Results 
 
4.1 Role of EGF and NaLac in the regulation of LDHs (LDHA, LDHB, LDHC) and MCTs (MCT1, 
MCT4) expression  
 
4.1.1 LDHs and MCTs relative gene expression and protein levels in HeLa and SiHa cell 
lines 
 
The role of EGF in the regulation of LDHA, LDHB, LDHC, MCT1 and MCT4 gene expression in 
the presence and absence of NaLac in HeLa and SiHa cells was firstly evaluated by quantitative Real-
Time PCR (Figures 7 and 10). The regulation of LDHA, LDHB, (LDHC in SiHa cells), MCT1 and MCT4 
protein levels were evaluated through Western-blot (Figures 8 and 14) and Immunofluorescence (Figures 
9, 10, 12 and 13) in both cell lines. The designations, LDHA and LDHB protein levels, which were used in 
this thesis, correspond to the detection of LDH-M subunit and LDH-H subunit, respectively (as referred in 
3.1.3). 
In HeLa cells it was observed a statistically significant increase in LDHA and LDHB expression 
after NaLac treatment comparing to cells grown in control conditions (Figure 7a). For LDHA, the increase 
obtained at mRNA levels was reflected in LDHA protein levels assessed by western-blot (Figure 8) but 
not in LDHA protein levels assessed by immunofluorescence (Figure 9). Concerning LDHB, the increase 
was reflected in LDHB protein levels assessed by western-blot (Figure 8) and immunofluorescence 
(Figure 9).  
It was observed that EGF-stimulated HeLa cells exhibited higher (highly statistically significant) 
LDHA expression levels and LDHA protein levels (assessed by western-blot) comparing to unstimulated 
cells (Figures 7a and 8) and that this increase was even higher in stimulated cells grown in the presence 
of NaLac only at mRNA level (Figure 7a). In terms of LDHB expression levels, it was verified that EGF-
stimulated cells grown in presence of NaLac exhibited decreased levels comparing to cells grown in 
control conditions (Figure 7a) but this decrease was not reflected in LDHB protein levels assessed by 
western-blot (Figure 8).  
In SiHa cells grown in the presence of NaLac it was verified a statistically significant increase in 
LDHA and LDHB expression comparing to cells grown in control conditions (Figure 7b). This higher 
LDHA mRNA levels were not reflected in LDHA protein levels assessed through western-blot (Figure 8) 
and immunofluorescence (Figure 10). For LDHB the increase was reflected in LDHB protein levels 
assessed by western-blot (Figure 8) and immunofluorescence (Figure 10). In terms of LDHC expression, 
SiHa cells grown in the presence of NaLac showed decreased levels of it comparing to cells grown in 
control conditions (Figure 7b), however this decrease was not reflected in LDHC protein levels assessed 
by western-blot (Figure 8) and immunofluorescence (Figure 10). 
EGF-stimulated SiHa cells exhibited higher LDHA expression levels comparing to unstimulated 
cells grown in control conditions (Figure 7b) and these higher levels were maintained in stimulated cells 
grown in the presence of NaLac (Figure 7b).These increases observed at mRNA level were not reflected 
at protein level assessed by western-blot (Figure 8) and immunofluorescence (Figure 10). LDHB 
expression levels were higher in EGF-stimulated SiHa cells (Figure 7b) comparing to unstimulated cells 
and this increase was reflected in LDHB protein levels assessed by western-blot (Figure 8) and 
immunofluorescence (Figure 10). Besides that, EGF-stimulated cells grown in the presence of NaLac 
exhibited higher LDHB expression (highly statistically significant) (Figure 7b) and LDHB protein levels 
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(Figure 8) comparing to cells grown in control conditions but lower LDHB expression levels comparing to 
EGF-stimulated cells (Figure 7b). However this decrease at mRNA level was not reflected in LDHB 
protein levels (Figures 8 and 10). EGF-stimulated SiHa cells grown in the presence and absence of 
NaLac exhibited lower levels of LDHC expression comparing to cells grown in control conditions (Figure 
7b). However, LDHC protein levels were higher in EGF-stimulated cells grown either in the presence or 
absence of NaLac comparing to cells grown in control conditions (Figures 8 and 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 - Relative gene expression of lactate dehydrogenases (LDHs) in HeLa cells (a) and SiHa cells (b). Cells were 
grown in control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. 
Hypoxanthine phosphoribosyltransferase gene (HPRT) was used as endogenous control. Expression levels were normalized to 
those obtained for cells grown in control conditions. Data are mean ± standard deviation of biological triplicates.* p< 0.05  
**p<0.001 
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Figure 8 - LDHs protein levels in HeLa (LDHA and LDHB) and SiHa (LDHA, LDHB and LDHC) cells assessed by western-blot. 
Cells were grown in control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. 
Protein levels were normalized to β-actin and are relative to those obtained for cells grown in control conditions. 
HeLa SiHa 
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Figure 9 - Immunofluorescence for LDHA and LDHB in HeLa cells. Comparison between the protein levels of cells grown in control 
conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. Fluorescence microscopy 
(original magnification: 200x). Nuclei were stained with DAPI (blue). Scale bar 100 µm. 
 
 
The negative controls of the immunofluorescence assay are shown in figure A1 (Appendix II). 
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Figure 10 - Immunofluorescence for LDHA, LDHB and LDHC in SiHa cells. Comparison between the protein levels of cells grown 
in control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. Fluorescence 
microscopy (original magnification: 200x). Nuclei were stained with DAPI (blue). Scale bar 100 µm. 
Concerning MCTs expression, no differences were observed between MCT1 expression in HeLa 
cells grown in the presence of NaLac comparing to those grown in its absence (Figure 11a), however it was 
detected a decrease in MCT1 protein levels assessed by immunofluorescence (Figure 12). Nevertheless, 
HeLa cells grown in the presence of NaLac exhibited higher levels of MCT4 (Figure 11a) that was reflected in 
MCT4 protein levels (Figure 12).   
EGF stimulation of HeLa cells seems to promote MCT1 and MCT4 expression (Figure 11a) and that 
increase was reflected also at MCT1 and MCT4 protein levels assessed through immunofluorescence (Figure 
12). Concerning EGF-stimulated cells grown in the presence of NaLac, it was observed that MCT1 expression 
levels were lower comparing to stimulated cells grown in its absence (Figure 11a) and that was reflected at 
protein levels (Figure 12).  
In SiHa cells, also no significant differences were observed between MCT1 expression in cells grown 
in the presence of NaLac and in its absence (Figure 11b), but an evident increase in MCT1 protein levels was 
detected (Figure 13). SiHa cells grown in the presence of NaLac showed increased levels of MCT4 expression 
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comparing to those grown in its absence (Figure 11b) that was reflected in MCT4 protein levels (Figures 13 
and 14). In this cell line EGF stimulation only had a statistically significant effect on MCT4 expression (Figure 
11b) that seems to be potentiated by NaLac exposure of these cells (Figure 11b) what was also reflected at 
protein levels assessed by western-blot (Figure 14).  
 
Figure 11 - Relative gene expression of monocarboxylate transporters (MCTs) in HeLa cells (a) and SiHa cells (b). Cells 
were grown in control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. 
Hypoxanthine phosphoribosyltransferase gene (HPRT) was used as endogenous control. Expression levels were normalized to 
those obtained for cells grown in control conditions. Data are mean ± standard deviation of biological triplicates.* p< 0.05  
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Figure 12 - Immunofluorescence for MCT1 and MCT4 in HeLa cells. Comparison between the protein levels of cells grown in 
control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. Fluorescence 
microscopy (original magnification: 200x). Nuclei were stained with DAPI (blue). Scale bar 100 µm. 
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Figure 13 - Immunofluorescence for MCT1 and MCT4 in SiHa cells. Comparison between the protein levels of cells grown in control 
conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. Fluorescence microscopy 
(original magnification: 200x). Nuclei were stained with DAPI (blue). Scale bar 100 µm. 
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Figure 14 - MCT4 protein levels in SiHa cells assessed by western-blot. Cells were grown in control conditions, in the presence of 
NaLac and with EGF stimulation in the presence and absence of NaLac Protein levels were normalized to β-actin and are relative to 
those obtained for cells grown in control conditions. 
 
MCT1 protein levels in both cell lines were not assessed through western-blot due to technical 
problems involving anti-MCT1 antibody.  
In order to assess EGF receptor (EGFR) expression in HeLa and SiHa cells grown in the absence 
and presence of NaLac with and without EGF stimulation of these cells relative gene expression was 
evaluated through quantitative Real-Time PCR (Figure 15). In HeLa cells it was observed that EGFR 
expression was lower in cells grown in the presence of NaLac with or without EGF stimulation comparing to 
those obtained for cells grown in control conditions (Figure 15a). However, EGF-stimulated cells grown in the 
presence of NaLac showed higher (statistically significant) levels than those grown in its absence (Figure 15a).  
EGF-stimulated SiHa cells showed a statistically significant decrease in EGFR expression levels 
comparing to cells grown in control conditions (Figure 15b). However, as verified in HeLa cells, EGF-
stimulated cells grown in the presence of NaLac showed higher (statistically significant) levels than those 
grown in its absence (Figure 15b). 
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Figure 15 - Relative gene expression of EGF receptor (EGFR) in HeLa cells (a) and SiHa cells (b). Cells were grown in control 
conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. Hypoxanthine 
phosphoribosyltransferase gene (HPRT) was used as endogenous control. Expression levels were normalized to those obtained for 
cells grown in control conditions.  Data are mean ± standard deviation of biological triplicates. *p<0.05 
 
Aiming to evaluate if a chronically exposure of SiHa cells to NaLac would modify the regulation of 
LDHs and MCTs gene expression in this cell line, cells were chronically grown in the presence of NaLac and 
then relative gene expression was assessed by quantitative Real-Time PCR (Figure 16). The data revealed a 
statistically significant increase in LDHA and LDHB expression and a decrease (highly statistically significant) 
in LDHC levels comparing to cells grown in control conditions (Figure 16), as observed for acute exposure to 
NaLac (Figure 7b) . MCT4 levels was higher (although not statistically significant) after chronic exposure to 
NaLac comparing to cells not exposed to it, as verified for acute exposure to NaLac (Figures 16 and 11b). So, 
LDHs and MCTs gene expression in SiHa cells seems do not be changed by a chronically exposure to NaLac, 
comparing to an acute one. A statistically significant increase in EGFR mRNA levels were observed in SiHa 
cells chronically exposed to NaLac comparing the levels of those grown in the absence of it (Figure 16) while 
in SiHa cells exposed to NaLac (not chronically) this difference was not evident (Figure 15b).  
 
Regarding EGF stimulation of SiHa cells chronically exposed to NaLac, it was observed the same 
trend, in terms of LDHs and MCTs expression as in EGF-stimulated cells not chronically exposed to NaLac 
(Figures 16, 7b and 11b). However, a statistically significant increase in EGFR expression levels was observed 
in EGF-stimulated SiHa cells chronically exposed to NaLac comparing to cells grown in control conditions 
(Figure 16), while in EGF-stimulated SiHa cells exposed to NaLac (not chronically) this difference was not 
evident (Figure 15b). 
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4.1.2 Epigenetic regulation of LDHA, LDHB and MCT1 promoters 
 
In order to evaluate the epigenetic regulation of LDHA, LDHB and MCT1 promoters and to identify a 
potential role of NaLac by itself or in association with EGF on that regulation, the methylation pattern of 
specific CpG islands was determined using sodium bisulfite treatment of DNA. 
 
4.1.2.1 Methylation pattern of LDHA, LDHB and MCT1 promoters 
 
DNA was extracted from HeLa and SiHa cells in culture in the presence and absence of NaLac with 
and without EGF stimulation (culture conditions described at 3.1.1). Sodium bisulfite treatment of this DNA and 
subsequent analysis of the methylation pattern of specific CpG islands, revealed that all the CpG dinucleotides 
identified in the two CpG islands studied in LDHA promoter were unmethylated (Figure 17) in both cell lines. 
Besides that, all the CpG dinucleotides identified in the three CpG islands analyzed in LDHB promoter were 
unmethylated (Figure 18) in both cell lines. Finally, all the CpG dinucleotides identified in the CpG island 
analyzed in MCT1 promoter were unmethylated (Figure 19) in both cell lines. Additionally, the methylation 
pattern of the studied CpG islands of DNA extracted from cells grown in the various culture conditions 
(mentioned above and described at 3.1.1) was the same. 
 
 
 
Figure 16 - Relative gene expression in SiHa cells chronically exposed to NaLac (long term (LT) 
exposition) with and without EGF stimulation of these cells. Hypoxanthine phosphoribosyltransferase gene 
(HPRT) was used as endogenous control. Expression levels were normalized to those obtained for cells grown in 
control conditions. Data are mean ± standard deviation of biological triplicates. * p<0.05  ** p<0.001 
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So, in this setting, LDHA, LDHB and MCT1 promoters are not regulated by methylation and EGF 
stimulation and/or NaLac treatment of cells did not affect the methylation status of these promoters in these 
two cell lines. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 - Schematic representation of the methylation pattern of two LDHA promoter CpG islands in HeLa and SiHa 
cells. a) 18 CpG dinucleotides identified in LDHA promoter CpG island 1 b) 17 CpG dinucleotides identified in LDHA promoter 
CpG island 2. White circles denote unmethylated CpG sites.   
 
Figure 18 - Schematic representation of the methylation pattern of three LDHB promoter CpG islands in HeLa and SiHa 
cells. a) 19 CpG dinucleotides identified in LDHB promoter Island 1. b) 12 CpG dinucleotides identified in LDHB promoter Island 2. 
c) 11 CpG dinucleotides identified in LDHB promoter Island 3. White circles denote unmethylated CpG sites. 
 
Figure 19 - Schematic representation of the methylation pattern of one MCT1 promoter CpG island in HeLa and SiHa cells. 
a) 38 CpG dinucleotides identified in MCT1 promoter CpG island 1. White circles denote unmethylated CpG sites.  
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4.1.3 Activity of LDHA, LDHB and MCT1 promoters 
 
In order to evaluate the activity of LDHA and LDHB and MCT1 promoters after EGF stimulation of 
cells grown in the presence and absence of NaLac in SiHa and HeLa cell lines, different deletion constructs 
were generated using conventional molecular cloning techniques. After that promoter activity was detected 
using the Dual Luciferase Assay System.  
Firstly, it was evaluated which promoter deletion construct exhibited higher luciferase activity for both 
cell lines. It was observed that LDHA f2, LDHB f1 and MCT1 f2 deletion construct were those with higher 
luciferase activity in HeLa cells (Figures 20 and 21) while in SiHa cells LDHA f2, LDHB f1 and MCT1 f1 
exhibited the highest luciferase activity (Figures 20 and 21). 
Secondly, the luciferase of the various deletion constructs was assessed in HeLa and SiHa cells 
transfected in control conditions, in the presence of NaLac and with EGF stimulation in the presence and 
absence of NaLac (as described in 3.1.5.4). The levels were then compared to those obtained for cells 
transfected in control conditions (as described in 3.1.5.4) for both cell lines (Figures 20 and 21).  
In HeLa cells there were no statistically significant differences between the luciferase activity of LDHA 
and LDHB deletion constructs in cells exposed to NaLac comparing to cells grown in control conditions (Figure 
20). However, in EGF-stimulated HeLa cells grown in the presence of NaLac, the luciferase activity of LDHA f1 
deletion construct and LDHB f2 deletion construct was, respectively higher and lower than in those grown in 
control conditions (Figure 20). The luciferase activity of three LDHA deletion constructs and LDHB f1 deletion 
construct was higher in EGF-stimulated HeLa cells grown in the presence of NaLac than in stimulated cells 
grown in its absence (Figure 20).  
Relating to SiHa cells, it was observed a statistically significant increase in luciferase activity of the 
three LDHA deletion constructs in cells exposed to NaLac comparing to cells grown in control conditions 
(Figure 20). For LDHB deletion constructs, it was also observed an increase, which was statistically significant 
for f1 construct, in their luciferase activity in cells exposed to NaLac comparing to cells grown in control 
conditions (Figure 20).  
In EGF-stimulated SiHa cells grown either in the presence or absence of NaLac was observed a 
highly significant increase in luciferase activity of the three LDHA deletion constructs comparing to cells grown 
in control conditions (Figure 20). Besides that in EGF-stimulated SiHa cells the luciferase activity of the three 
LDHA deletion constructs was higher in cells grown in the presence of NaLac than in those grown in its 
absence (Figure 20). In EGF-stimulated SiHa cells grown either in the presence or absence of NaLac the 
luciferase activity of LDHB deletion constructs was also statistically significant higher than in those grown in 
control conditions (Figure 20). In addition, the luciferase activity of LDHB f1 deletion construct was higher in 
EGF-stimulated cells grown in the presence of NaLac whether the luciferase activity of LDHB f2 deletion 
construct was lower in these cells comparing to stimulated cells grown in its absence (Figure 20).  
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For MCT1 f1 deletion construct, it was observed higher (statistically significant) luciferase activity in 
SiHa and HeLa cells transfected in the presence of NaLac comparing to cells transfected in its absence 
(Figure 21). In SiHa cells this increment was also verified for MCT1 f2 deletion construct (Figure 21).  
MCT1 f1 deletion construct exhibited higher (highly statistically significant) luciferase activity in EGF-
stimulated HeLa and SiHa cells transfected either in the presence of absence of NaLac comparing to those 
transfected in control conditions (Figure 21). In SiHa cells, this increase was also verified for MCT1 f2 deletion 
construct (Figure 21). In EGF-stimulated HeLa cells transfected in the presence of NaLac both MCT1 deletion 
constructs exhibited higher luciferase activity comparing to those observed in stimulated cells transfected in its 
absence (Figure 21). While in EGF-stimulated SiHa cells transfected in the presence of NaLac, there was no 
difference between luciferase activity of both MCT1 deletion constructs comparing to those observed in 
stimulated cells transfected in its absence (Figure 21). 
 
 
 
Figure 20 - Luciferase activity of LDHA (f1, f2, f3) and LDHB (f1, f2) deletion constructs in transfected HeLa and SiHa cells. 
Cells were grown in control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac.         
* p< 0.05  ** p<0.001 
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Figure 21 - Luciferase activity of MCT1 (f1 and f2) deletion constructs in transfected HeLa and SiHa cells. Cells were grown in 
control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac.* p< 0.05  **p<0.001 
 
Finally, TFSEARCH database (ver.1.3) (http://www.cbrc.jp/research/db/TFSEARCH.html) was 
consulted in order to assess which transcription factors had putative binding sites at the specific regions of the 
LDHA, LDHB and MCT1 promoters that had been cloned in the generated deletion constructs. c-Myc was the 
elected transcription factor once LDHA f2, MCT1 f1 and MCT1 f2 deletion constructs included putative N-Myc 
binding sites and c-Myc has the same binding sequence of N-Myc. Besides that, this choice was based on the 
fact that c-Myc has an important role in the regulation of cancer cell metabolism (as referred in introduction) 
and it is involved in uterine cervix carcinogenesis. 
 
4.1.4 Role of c-Myc transcription factor in the regulation of LDHA and MCT1 expression 
 
In order to study c-Myc transcription factor role in the regulation of LDHA and MCT1 expression in the 
presence and absence of NaLac and/or after EGF stimulation of cells a c-Myc-antibody Chromatin 
Immunoprecipitation (ChIP) assay was performed for both cell lines (Figures 22 and 23). 
In HeLa cells, it was observed higher occupancy of c-Myc at MCT1 promoter in cells stimulated with 
EGF and grown in the absence of NaLac comparing to those grown in control conditions (Figure 22). For SiHa 
cells, it was detected higher occupancy of c-Myc at MCT1 promoter for EGF-stimulated cells grown in the 
presence of NaLac comparing to those grown in control conditions (Figure 23). SiHa cells grown in control 
conditions had shown high occupancy of c-Myc at MCT1 promoter while cells grown in the presence of NaLac 
and EGF-stimulated cells exhibited lower, or none, occupancy, respectively (Figure 23).  
In relation to LDHA promoter it was observed occupancy of c-Myc at this promoter in HeLa cells grown 
in the presence of NaLac and also in EGF-stimulated cells grown in its presence comparing to cells grown in 
control conditions (Figure 22). In SiHa cells occupancy of c-Myc at LDHA promoter was not evident and was 
not influenced by NaLac or EGF stimulation of cells (Figure 23). 
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Figure 22 - Relative occupancy of c-Myc factor at LDHA and MCT1 promoters (relative to IgG) in HeLa cells. Cells were grown in 
control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. 
 
 
Figure 23 - Relative occupancy of c-Myc factor at LDHA and MCT1 promoters (relative to IgG) in SiHa cells. Cells were grown in 
control conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac. 
 
  
0 
0,5 
1 
1,5 
2 
2,5 
3 
3,5 
4 
4,5 
5 
5,5 
LDHA F1R1 LDHA F2R2 MCT1 F1R1 
R
e
la
ti
ve
 o
cc
u
p
an
cy
 (
2
^C
tN
e
g-
C
tM
yc
) 
Control 
NaLac 
EGF 
NaLac EGF 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
LDHA F1R1 LDHA F2R2 MCT1 F1R1 
R
e
la
ti
ve
 o
cc
u
p
an
cy
(2
^C
tN
e
g-
C
tM
yc
) 
Control 
NaLac 
EGF 
NaLac EGF 
53 
 
4.2 Detection of c-Myc copy number by Fluorescent in situ hybridization (FISH)  
 
Once several studies had shown amplification or increased expression of c-Myc in many tumors, 
including uterine cervix carcinomas, a FISH for c-Myc was performed in HeLa and SiHa cell lines to evaluate 
c-Myc copy number in these cells.  
FISH analysis revealed that there is heterogeneity in terms of c-Myc copy number both in HeLa and 
SiHa cell nuclei (Table A1, Appendix II). Using 8q24 LSI MYC probe it was verified that 4 was most frequent c-
Myc copy number detected in both HeLa (92.59%) and SiHa (88.46%) cells (Table A1 and Figure A2, 
Appendix II), suggesting c-Myc amplification in these cell lines. 
Through complementary FISH analysis, using a control probe for the centromeric region at 
chromosome 8, it was verified that in HeLa cells nuclei 95.84% of total cell nuclei had 4 c-Myc copies 
(corresponding to 4 Orange (O) signals in FISH images) and 2 centromeric signals (corresponding to 2 Aqua 
(Aq) signals in FISH images) (Table14, Figures 24a and 24b), suggesting genetic c-Myc amplification. 
For SiHa cells, 77.30% of total cell nuclei had 4 c-Myc copies (corresponding to 4 Orange (O) signals 
in FISH images) and 4 centromeric signals (corresponding to 4 Aqua (Aq) signals in FISH images) (Table 14, 
Figures 24c and 24d), suggesting that aneuploidy is in the basis of the increased number of c-Myc copies, 
since SiHa cells have more than two chromosome 8, where c-Myc is located.  
 
Table 14 - Frequency (in percentage) of c-Myc copy number detected in SiHa and HeLa cells using FISH. c-Myc copy number 
and the number of centromeric signals were detected using LSI MYC SpectrumOrange (O) probe for 8q24 and SpectrumAqua (Aq) 
CEP8 probe (8p11.1-q11.1 CEP8 alpha satellite that serves as a control for chromosome 8), respectively, in SiHa and HeLa interphase 
nuclei.  
 
c-Myc copy number (O) + centromeric 
signals number (Aq) 
% 
 SiHa 
4O 4Aq 77.30 
5O 5Aq 21.99 
4O 5Aq 0.71 
 HeLa 
4O 2Aq 95.84 
3O 2Aq 3.33 
5O 3Aq 0.83 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Histological analysis 
 
Once previous studies referred MCT1 overexpression uterine cervix cancer, MCT1 immunodetection 
was performed in tissue microarrays of AC and SCC of the uterine cervix cases. Additionally, c-Myc 
amplification had also been described in this type of tumors, so, c-Myc copy number was also analyzed in 
these microarrays. Tissue microarrays of AC and SCC of the uterine cervix cases were analyzed by 
immunohistochemistry for MCT1 and FISH for Chromosome 8/c-Myc (Figures 25, 26 and 27). 
Concerning AC cases, only two were positive for MCT1 (Figure 25) and were diploid (normal) for 
chromosome 8 and c-Myc (Figures 25). Regarding SCC cases, it seems that the increase in c-Myc copy 
number is associated with increase in MCT1 immunodetection despite of the detection of c-Myc diploid 
(normal) cases expressing MCT1 with several intensity  (Figures 25 and 26). 
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Figure 24 - Copy number analysis of c-Myc through Fluorescent in situ hybridization (FISH). Representative experiments of 
FISH analysis of c-Myc in HeLa (a,b) and SiHa (c,d) cells are shown. The probe used for c-Myc detection was the LSI IGH/MYC, CEP8 
Tri-color, Dual Fusion Translocation Probe that includes the SpectrumAqua CEP8 probe (8p11.1-q11.1 CEP8 alpha satellite that 
serves as a control for chromosome 8) (located at the centromere), the LSI MYC SpectrumOrange probe for 8q24 and the LSI IGH 
SpectrumGreen probe for 14q32 whose information was not used in this context. Nuclei in interphase were counterstained with DAPI. 
Figure 25 - Percentage of MCT1 positive (+) and negative (-) AC cases with 
disomy or aneusomy for chromosome 8 and c-Myc. AC: Adenocarcinoma 
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Figure 26 - Percentage of MCT1 positive (from +/- to +++) and negative (-) SCC cases with disomy, trisomy, aneusomy or 
aneusomy and amplification for chromosome 8 and c-Myc. SCC: Squamous cell carcinoma. 
 
 
Figure 27 - Percentage of MCT1 positive (+) and negative (-) SCC cases with disomy, trisomy, aneusomy or aneusomy and 
amplification for chromosome 8 and c-Myc. SCC: Squamous cell carcinoma. 
 
MCT1 immunohistochemistry analysis also revealed important differences between normal ectocervix 
(Figure 28) and normal endocervix (Figure 29), in terms of MCT1 immunodetection. It was verified that normal 
ectocervix samples were mainly positive for MCT1 while normal endocervix ones were mainly negative. 
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Figure 28 - MCT1 immunodetection in SCC, CIN and normal ectocervix. Representative images of MCT1 immunodetection in 
SCC, CIN cases and in normal ectocervix are shown.  MCT1 negative (-) and positive (++, +++) cases are represented. SCC: 
squamous cell carcinoma. CIN3: cervical intraepithelial neoplasia grade 3.  
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Figure 29 - MCT1 immunodetection in AC and normal endocervix. Representative images of MCT1 immunodetection in AC cases 
and in normal endocervix are shown.  MCT1 negative (-) and positive (+++) cases are represented. AC: Adenocarcinoma. 
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4.4 Role of NaLac and EGF in cell migration, cell cycle regulation  and proliferation in vitro 
 
4.4.1 Cell migration 
Since EGF has been described as an important growth factor in uterine cervix carcinogenesis in vitro 
Wound Healing assay was performed to investigate a possible role of NaLac by itself or in association with 
EGF stimulation of SiHa cells on their migration rate (Figure 30). The migration rate was evaluated at the 
following time points: 0, 8, 24 and 32 hours (Figures 30 and 31). 
 
Figure 30 - In vitro Wound Healing assay in SiHa cells. Mitomycin-treated cells were grown in control conditions, in the presence of 
NaLac and with EGF stimulation in the presence or absence of NaLac. Wound closure was photographed when the scrape wound was 
introduced (t=0 hours) and at designated times after wounding (t=8hours, t=24hours, t=32hours). Phase microscopy (original 
magnification: 200x). 
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It was verified a higher cell migration rate (faster wound closure) in cells grown in the presence of 
NaLac comparing to cells grown in control conditions (Figures 30 and 31). EGF stimulation of cells grown in 
the presence of NaLac seems to promote cell migration once wound closure was faster than in cells grown 
only in presence of NaLac and in control conditions too (Figures  30 and 31). 
 
 
 
 
 
 
 
 
 
Once Mitomycin was used in in vitro wound healing assay to inhibit cell proliferation a proliferation 
curve of SiHa cells grown in the presence and absence of this anti-proliferative agent was performed (Figure 
32). It was observed that 5 µg/mL of Mitomycin was appropriate to inhibit SiHa cells proliferation during 32 
hours (Figure 32). 
 
Figure 32 - Proliferation curve of SiHa cells after treatment with anti-proliferative agent Mitomycin (5µg/mL). Number of cells 
(x104)/mL was determined at 0, 8, 24 and 32 hours. Data are mean ± standard deviation. 
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Figure 31 - Quantification of wound closure in SiHa cells. Mitomycin-treated cells were grown in control conditions, in the presence 
of NaLac and with EGF stimulation in the presence or absence of NaLac. Data were collected 0 hours, 8 hours, 24 hours and 32 hours 
after scratching.   
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4.4.2 Cell  cycle regulation and proliferation in vitro 
 
Once several data indicated that EGF plays an important role in the regulation of cell growth 
and proliferation, cell cycle analysis and a proliferation curve was performed to investigate a possible role 
of NaLac by itself or in association with EGF stimulation of SiHa cells on cell cycle regulation and on their 
proliferation in vitro. 
 
4.4.2.1 Cell cycle analysis 
 
Cell cycle analysis of SiHa cells was performed by flow cytometry (Figure 33). 
 
Figure 33 - Flow cytometric analysis showing the cell cycle distribution of SiHa cells (PI staining). Cells were grown in control 
conditions, in the presence of NaLac and with EGF stimulation in the presence and absence of NaLac for 6 hours and 24 hours. Data 
are means of triplicates. 
 
Firstly, cell cycle analysis of SiHa cells, revealed that the majority of the cells were in G1 phase 
despite of culture conditions of these cells (Figure 33). 
It was observed a statistically significant increase in the percentage of cells in G1 phase after 6 hours 
in EGF-stimulated cells (86.81%) comparing to cells grown in control conditions (84.45%) and a statistically 
significant decrease in the percentage of cells in S (5.13%) and G2/M phases (6.73%) comparing to cells 
grown in control conditions (6.31% and 8.36%, respectively) (Figure 33). The same tendency was verified in 
EGF-stimulated cells grown in the presence of NaLac, after 6 hours. 
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In EGF-stimulated cells grown in the presence of NaLac was verified a statistically significant 
decrease in the percentage of cells in S (5.15%) and G2/M (7.57%) phases comparing to cells grown in control 
conditions (6.31% and 8.36%, respectively), after 6 hours (Figure 33). It was also verified an increase, 
although not statistically significant, in the amount of cells in G1 phase (86.18%) for this condition (Figure 33). 
In EGF-stimulated cells grown in the presence of NaLac was seen a statistically significant decrease 
in the percentage of cells in G1 phase (76.39%) and an increase in those in S phase (10.67%) and G2/M 
(12.28%) (not statistically significant) comparing to cells grown in control conditions (82.22%, 7.84% and 
9.25%, respectively) (Figure 33), after 24 hours. At this time point, it was observed that EGF-stimulated cells 
exhibited a statistically significant higher percentage of cells in S phase (12.78%) comparing to cells grown in 
control conditions (7.84%) (Figure 33). In EGF-stimulated cells grown in the presence of NaLac it was 
observed a statistically significant decrease in the percentage of cells in S phase (10.67%) comparing to EGF-
stimulated cells grown in its absence (12.78%) (Figure 33). 
4.4.2.2 Proliferation curve 
A proliferation curve of SiHa cells was done aiming to evaluate a possible role of EGF in the in vitro 
proliferation of this cell type in the presence and absence of NaLac (Figure 34). The number of cells per mL 
was determined at 0,3,6,12,24 and 30 hours (Figure 34). 
 
 
Figure 34 - Proliferation curve for SiHa cells. Cells were grown in control conditions, in the presence of NaLac and with EGF 
stimulation in the presence and absence of NaLac. Data were acquired at 0,3,6,12,24 and 30 hours after 12-16h of serum starvation 
and are mean ± standard deviation of four cell counts.* p< 0.05 
 
After 3 hours of EGF stimulation in the presence or absence of NaLac, it was observed a statistically 
significant lower number of cells per mL comparing to the cell number obtained in control conditions (Figure 
34). After 6 hours, the proliferation curve had the same trend but, after 12 hours, there were higher number of 
cells per mL in EGF-stimulated cells and also in stimulated cells grown in the presence of NaLac (Figure 34) 
comparing to the cell number obtained in control conditions. After 24 hours of EGF stimulation of cells in the 
presence of NaLac, it was seen a statistically significant higher number of cells per mL than in control 
conditions (Figure 34).   
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5. Discussion 
Emerging evidence indicates that impaired cellular energy metabolism is the defining characteristic of 
nearly all cancers regardless of cellular or tissue origin (Seyfried & Shelton, 2010). Tumor cells reprogram their 
metabolic pathways to accomplish their higher energy demanding (Tennant et al., 2010). Recently, Porporato 
et al., 2011 pointed out that the shift to self-autonomous aerobic glycolysis is driven by genetic and epigenetic 
changes (Porporato et al., 2011). The study of metabolic alterations and adaptations of cancer cells that 
contribute to alter the flux along key metabolic pathways such as glycolysis and glutaminolysis must consider 
all the intervenients in metabolomic plateau. Several authors proposed that lactate acts as a paracrine signal 
in carcinogenesis by optimizing the microenvironment for tumor growth (Hussien & Brooks, 2011; Hsu & 
Sabatini, 2008). Additionally, lactate has been considered as a signaling molecule that could not only mirrors 
tumor malignancy but also enhance that (Walenta & Mueller-Klieser, 2004). As a consequence also the 
enzymes involved in lactate production/consumption (LDHs) and lactate transporters (MCTs) had been linked 
to tumor development and progression in recent reports ( Pinheiro et al., 2008; Sonveaux et al., 2008; Fang et 
al., 2006 Walenta & Mueller-Klieser, 2004; Lewis et al., 2000). So, the characterization of the metabolic profile 
of two uterine cervix cancer cell lines from two different histological types, adenocarcinoma (HeLa) and 
squamous cell carcinoma (SiHa), namely the role of LDHA, LDHB, LDHC, MCT1 and MCT4 in the metabolic 
switch verified in uterine cervix cancer was chosen as main objective of the present thesis.  
In order to evaluate a potential role of EGF and NaLac in the regulation of LDHs and MCTs 
expression, LDHA, LDHB, (LDHC in SiHa cells), MCT1 and MCT4 relative gene expression were quantified for 
each cell line grown in the presence of NaLac with and without EGF-stimulation of cells and compared to the 
levels obtained for cells grown in control conditions (Figures 7 and 11).  
Concerning LDHs expression, it was observed, for both cell lines, a statistically significant increase in 
LDHA expression levels in cells grown in the presence of NaLac and EGF-stimulated cells grown in its 
presence and absence comparing to cells grown in control conditions (Figures 7a and 7b). In HeLa cells grown 
in the presence of NaLac the observed increase at mRNA levels was reflected in LDHA protein levels 
assessed by western-blot (Figure 8) but not by immunofluorescence (Figure 9). EGF-stimulated HeLa cells 
exhibited higher LDHA expression and LDHA protein levels (assessed by western-blot) comparing to 
unstimulated cells (Figures 7a and 8) and that this increase was even higher in stimulated cells grown in the 
presence of NaLac only at mRNA level (Figure 7a). EGF stimulation of cells grown in the presence of NaLac 
seems to promote LDHA expression and that could be explained by c-Myc binding to LDHA promoter and its 
activation in the referred culture conditions (as discussed later). 
In SiHa cells grown in the presence of NaLac and EGF-stimulated cells grown in its presence and 
absence the higher LDHA mRNA levels were not reflected in LDHA protein levels assessed through western-
blot (Figure 8) and immunofluorescence (Figure 10).  The absence of correlation between the level of LDHA 
mRNA and protein levels in SiHa cells could be due to diverse post-transcriptional mechanisms involved in 
turning mRNA into protein (as mRNA degradation) or the different in vivo half-lives of proteins as the result of 
varied protein synthesis and degradation (Greenbaum et al., 2003). 
Recent data indicated that renal cell carcinoma specimens revealed a highly significant increase in 
the expression of LDHA compared to the corresponding normal kidney tissue on mRNA level (Singer et al., 
2011).  
The observed increase in LDHA expression in both HeLa and SiHa cells lines is in concordance with 
the analysis of the methylation pattern of LDHA promoter which revealed unmethylated CpG islands (Figure 
17). However, previous data had revealed hypermethylation of CpG islands in the LDHA promoter region 
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leading to transcriptionally silencing of the somatic LDHA in R51 cells (a retinoblastoma cell line) (Maekawa et 
al., 2002).   
Concerning LDHB expression, it was observed, for both cell lines, a statistically significant increase in 
LDHB expression levels in cells grown in the presence of NaLac and EGF-stimulated cells comparing to cells 
grown in control conditions (Figures 7a and 7b). In cells grown in the presence of NaLac, the increase was 
reflected in LDHB protein levels assessed by western-blot (Figure 8) and immunofluorescence (Figures 9 and 
10) in both cell lines. This result is not corroborated by a previous report that demonstrated LDHB silencing by 
promoter hypermethylation in human prostate cancer (Leiblich et al., 2006). Nevertheless, the observed 
increase in LDHB expression is in concordance with the analysis of the methylation pattern of LDHB promoter 
which revealed unmethylated CpG islands (Figure 18). Other authors, however, had detected promoter 
methylation of LDHB in four gastric cancer cell lines and one pancreatic cancer cell line (Maekawa et al., 
2003). Accordingly to these authors, promoter methylation of LDHB was observed in 3 of 20 gastric cancer 
tissues and in none of the corresponding healthy mucosa. Besides that, none of 25 colorectal cancer tissues 
and corresponding healthy mucosa had promoter methylation in LDHB. Therefore, the authors concluded that 
LDHB promoter was methylated in 5 of 12 cancer cell lines and in 3 of 45 cancers, suggesting that methylation 
of LDHB promoter is a relatively uncommon mechanism for the frequent increase of cathodal LDH isoenzymes 
in gastric and colorectal cancer patients (Maekawa et al., 2003). 
However, EGF-stimulated HeLa cells grown in the presence of NaLac exhibited decreased LDHB 
expression levels comparing to cells grown in control conditions (Figure 7a) but this decrease was not 
reflected in LDHB protein levels assessed by western-blot (Figure 8).  
Recent data revealed that LDHA was overexpressed in neoplastic cells and the expression of LDHB 
was downregulated (Singer et al., 2011). 
In HeLa cells LDHC expression was not evaluated once there is data suggesting that this cell line do 
not express this gene (Tang & Goldberg, 2009). In SiHa cells LDHC expression was evaluated and it was 
verified that cells grown in the presence of NaLac and EGF-stimulated cells grown in its absence or presence, 
showed decreased levels of it comparing to cells grown in control conditions (Figure 7b), however this 
decrease was not reflected in LDHC protein levels assessed by and western-blot (Figure 8) and 
immunofluorescence (Figure 10). This absence of correlation could be due to post-translational modification of 
the enzyme (activation). Other authors had proposed that LDHC might be post-transcriptionally regulated by 
an inhibition of translation or an increase of mRNA stability through the regulation of transcript levels with non 
coding RNAs as microRNAs (Goldberg et al., 2010). 
The expression of this human testis-specific lactate dehydrogenase has been recently reported in a 
broad spectrum of tumors with relatively high frequency in lung cancer, melanoma, and breast cancer, and in 
some prostate cancers (Tang & Goldberg, 2009; Koslowski et al., 2002). The observed decrease in LDHC 
mRNA levels could be explained by promoter hypermethylation. However, in this study, the methylation status 
of LDHC promoter was not evaluated. This hypothesis is in concordance with a previous study by Tang & 
Goldberg, 2009. These authors verified that LDHC expression in cancer cells was regulated by transcription 
factor Sp1 and CREB and promoter methylation (Tang & Goldberg, 2009). 
Regarding MCTs expression, in HeLa cells was not observed a substantial difference between MCT1 
expression levels of cells grown in the presence of NaLac comparing to those grown in its absence (Figure 
11a). However, it was observed a decrease in MCT1 protein levels verified by immunofluorescence analysis 
(Figure 12). This discrepancy between MCT1 mRNA and protein expression is not uncommon (Kang et al., 
2009). In the basis of that discrepancy could be the recognized different, and independent, mechanisms of 
transcriptional and translational regulation.  Accordingly to Greenbaum et al., 2003 the absence of correlation 
65 
 
may be due to the complicated and varied post-transcriptional mechanisms involved in turning mRNA into 
protein and/or the fact that proteins may differ substantially in their in vivo stability (Greenbaum et al., 2003). 
Other authors had also reported little correlation between the mRNA levels and the protein expression of this 
monocarboxylate transporter, suggesting that post-transcriptional mechanisms may be involved in regulation 
of MCT1 expression (Jackson et al., 1997). 
However, EGF-stimulated HeLa cells exhibited an increase in MCT1 expression levels (Figure 11a) 
comparing to cells grown in control conditions that was reflected in protein levels assessed by 
immunofluorescence (Figure 12). EGF-stimulated cells grown in the presence of NaLac exhibited a decrease 
in MCT1 expression both at mRNA (Figure 11a) and protein levels (Figure 12) comparing to those of EGF-
stimulated cells.  
Taking into account the lower MCT1 expression and protein levels in HeLa cells grown in the 
presence of NaLac and in EGF-stimulated cells grown in its presence, we proposed that NaLac regulates 
negatively MCT1 expression. This action could be mediated by c-Myc binding to MCT1 promoter, with c-Myc 
acting, in this context, as a repressor (as described later). 
SiHa cells grown in the presence of NaLac exhibited an increase in MCT1 expression levels (Figure 
11b) that was reflected in MCT1 protein levels confirmed by immunofluorescence analysis (Figure 13). 
Hashimoto & Brooks, 2008 had shown that lactate stimulates the overexpression of mitochondrial MCT1 
(Hashimoto & Brooks, 2008). Additionally, Sonveaux et al., 2008 showed that, in SiHa cells, MCT1 is mainly 
responsible for lactate uptake in cells exposed to exogenous lactate (Sonveaux et al., 2008). Accordingly to 
these authors, SiHa cells grown in the presence of glucose and lactate switch from glucose to lactate uptake 
(Sonveaux et al., 2008). 
Recent data reported upregulation of MCT1 in breast cancer (Pinheiro et al., 2010) and the same 
observation was verified in the present thesis for SiHa cells exposed to NaLac. This result is not corroborated 
by a previous report pointing to a possible silencing of MCT1 expression by gene promoter hypermethylation 
(Asada et al, 2003) Besides that, our analysis of the methylation pattern of this promoter had revealed that all 
CpG dinucleotides in the studied CpG island were unmethylated (Figure 19).  
Moreover, Hussien & Brooks, 2011 had suggested that the high amount of lactate produced by 
cancer cells acts as a signaling molecule that increases the expression of MCT1 and causes mitochondrial 
biogenesis in stroma cells surrounding tumors.  This increased MCT1 expression and oxidative capacity of 
stroma cells would encourage them to use lactate as their energy source and spare the glucose for the tumor 
cells (Hussien & Brooks, 2011). An increase of 10–15% in pyruvate and lactate uptake was seen in the cancer 
cell line MDA-MB-231 when transfected with plasmid containing MCT1 gene and this uptake was accelerated 
at acidic pH and with an increase in lactate or pyruvate concentration in the incubation media (Garcia et al., 
1994).  
Also in a non tumoral context, recent data, had shown that incubation of rat muscle cell line L6 with 
lactate increased the expression of MCT1 (Hussien & Brooks, 2011). 
EGF stimulation of SiHa cells grown either in the presence or absence of NaLac seems do not 
influence MCT1 expression both at mRNA and protein levels (Figures 11b and 13). 
Concerning MCT4, it was observed that HeLa and SiHa cells grown in the presence of NaLac and 
EGF-stimulated cells grown in its presence and absence exhibited higher levels of MCT4 expression 
comparing to cells grown in control conditions (Figures 11a and 11b) that were reflected in MCT4 protein 
levels assessed by western-blot, in SiHa cells, (Figure 14) and immunofluorescence analysis (Figures 12 and 
13) in both cell lines. As previously referred, most cancer cells rely on high rate of aerobic glycolysis to obtain 
ATP in a hypoxic microenvironment (Vander Heiden et al., 2009). As a result lactate is abundantly synthesized 
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from pyruvate (Feron, 2009) and cancer cells increase proton efflux, in order to avoid apoptosis triggered by 
cellular acidosis, by upregulating, for instance, H+-linked monocarboxylate transporters (Izumi et al., 2003). 
Other authors had shown that MCT1, but not MCT4, was expressed at the plasma membrane of 
oxidative SiHa tumor cells (Sonveaux et al., 2008). 
EGF plays an important role in the regulation of cell growth, proliferation and differentiation by binding 
to its receptor EGFR (Carpenter & Cohen, 1990). So, in the present work EGFR expression levels were also 
evaluated in both cell lines. In HeLa cells, it was observed that EGFR expression was lower in cells grown in 
the presence of NaLac with or without EGF stimulation comparing to those grown in control conditions (Figure 
15a). However, EGF-stimulated cells grown in the presence of NaLac showed higher (statistically significant) 
levels than those grown in its absence (Figure 15a).  
EGF-stimulated SiHa cells showed a statistically significant decrease in EGFR expression levels 
comparing to cells grown in control conditions (Figure 15b). However, as verified in HeLa cells, EGF-
stimulated cells grown in the presence of NaLac showed higher (statistically significant) levels than those 
grown in its absence (Figure 15b). These results suggested that EGF stimulation of cells, by itself, do not 
promote EGFR expression. However, increased EGFR activation could result from  gene amplification, protein 
overexpression or mutations of the EGFR (Brand et al., 2011). It has been shown that treatment of murine 
osteoblast cells with EGF increased the production of prostaglandin E2 (PGE2) resulting in the activation of 
EGFR (Narayanan et al., 2012).  
 
Regarding chronically exposure of SiHa cells to NaLac, LDHs and MCTs gene expression seems do 
not be changed by a chronically exposure to NaLac comparing to an acute one (Figures 16, 7b and 11b). A 
statistically significant increase in EGFR mRNA levels were observed in SiHa cells chronically exposed to 
NaLac comparing the levels of those grown in the absence of it (Figure 16) while in SiHa cells exposed to 
NaLac (not chronically) this difference was not evident (Figure 15b).  
In EGF-stimulated SiHa cells chronically exposed to NaLac, it was observed the same trend, in terms 
of LDHs and MCTs expression, as in EGF-stimulated cells not chronically exposed to NaLac (Figures 16, 7b 
and 11b). However, a statistically significant increase in EGFR expression levels was observed in EGF-
stimulated SiHa cells chronically exposed to NaLac comparing to cells grown in control conditions (Figure 16), 
while in EGF-stimulated SiHa cells exposed to NaLac (not chronically) this difference was not evident (Figure 
15b).  
Taking into account the increase in EGFR mRNA levels in SiHa cells chronically exposed to NaLac 
and in EGF-stimulated ones grown in this conditions, and once chronically exposure to NaLac reflects better 
the acidic microenvironment of tumor regions, we proposed that NaLac indirectly could contribute to EGFR 
overexpression that has been reported to be frequent in uterine cervix cancer ( Shen et al., 2008; 
Kersemaekers et al., 1999; Hale et al., 1993), specifically in squamous cell carcinoma (Lee et al., 2004).  
 
 Once epigenetic regulation of LDHA, LDHB and MCT1 promoters by methylation revealed that, in this 
setting, they are not regulated by this mechanism and EGF stimulation and/or NaLac treatment of cells did not 
affect the methylation status of these promoters in HeLa and SiHa cell lines, different deletion constructs were 
generated in order to evaluate their activity. This assay revealed that LDHA f2, LDHB f1 and MCT1 f2 deletion 
construct were those with higher luciferase activity in HeLa cells (Figures 20 and 21) while in SiHa cells LDHA 
f2, LDHB f1 and MCT1 f1 exhibited the highest luciferase activity (Figures 20 and 21).  
Focusing on LDHA f2 deletion construct in HeLa cells, it was observed that its luciferase activity was 
higher in EGF-stimulated cells grown in the presence of NaLac than in stimulated cells grown in its absence 
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(Figure 20). This could be explained by the higher relative occupancy of c-Myc at this locus in cells grown in 
the same conditions (Figure 22).  Previous data pointed out that c-Myc is able to transactivate the LDHA 
promoter and directly increase LDHA expression (Shim et al., 1997). So, c-Myc binding to LDHA promoter 
could explain the higher LDHA expression levels observed in EGF-stimulated HeLa cells grown in the 
presence of NaLac (Figure 7a). EGF-stimulation, by itself, of HeLa cells seems do not promote c-Myc binding 
to LDHA promoter (Figure 22), and the activity of LDHA f2 decrease (Figure 20), suggesting that this 
association is dependent of NaLac presence. 
In SiHa cells occupancy of c-Myc at LDHA promoter was not evident and not influenced by NaLac or 
EGF stimulation of cells (Figure 23). However, LDHA f2 deletion construct exhibited higher luciferase activity in 
cells grown in the presence of NaLac, either EGF stimulated or not, comparing to cells grown in control 
conditions (Figure 20). This increment in promoter activity was reflected at LDHA mRNA levels (Figure 7b) but 
not in protein levels (as previously referred). This increase could be explained by USF binding to LDHA 
promoter region, once this construct includes USF putative binding sites. Hu et al., 2011 had shown 
transactivation of the LDHA gene by USFs, in oxygenated cells, implying these transcription factors as 
candidate drivers of aerobic glycolysis in cancer cells (Hu et al., 2011). 
Regarding MCT1 f2 deletion construct in HeLa cells, it was observed that its luciferase activity was 
lower in EGF-stimulated cells grown in absence of NaLac comparing to cells grown in controls conditions 
(Figure 21). This could be explained by the higher relative occupancy of c-Myc at this locus in cells grown in 
the same conditions comparing to cells grown in control conditions (Figure 22) if c-Myc acts, in this specific 
scenario, to decrease promoter activity. However, this decrease is not reflected at mRNA levels (Figure 11) 
neither at protein levels. In HeLa cells grown in the presence of NaLac this deletion construct also exhibited 
lower luciferase activity comparing to cells grown in control conditions (Figure 21). This could result from the 
higher relative occupancy of c-Myc at MCT1 promoter locus in cells grown in the presence of NaLac 
comparing to cells grown in control conditions (Figure 22) if c-Myc acts, in this setting, to decrease promoter 
activity (act as a repressor). This decrease was reflected in MCT1 protein levels (Figure 12) (as previously 
referred). Previous data indicated that MCT1 protein expression appeared to be upregulated by c-Myc 
overexpression (Kang et al., 2009). However, Si et al., 2010 demonstrated c-Myc repression of the 
CCAAT/Enhancer Binding Protein δ (C/EBPδ) promoter in a Miz1 and Max-dependent manner, two c-Myc 
interacting proteins that are constitutively associated with C/EBPδ proximal promoter (Si et al., 2010). Other 
authors had shown that the activity of the minimal promoter of BRD7 (a bromodomain-containing gene 
identified from Nasopharyngeal carcinoma cells) was inversely related to c-Myc expression (Liu et al., 2008). 
Accordingly to them, c-Myc negatively regulates the promoter activity and endogenous mRNA expression of 
BRD7 gene (Liu et al., 2008). So, and as reviewed by McMahon, 2010, c-Myc functions not only as an 
activator of transcription but in some settings as a repressor (McMahon, 2010). 
 Regarding SiHa cells grown in control conditions, they exhibited low MCT1 f2 deletion construct 
activity (Figure 21) and high relative c-Myc occupancy at this promoter (Figure 23) suggesting that, in this 
setting, c-Myc could act as a repressor. This observation could be validated considering the low MCT1 protein 
levels observed in cells grown in these conditions (Figure 13). By its turn, in the presence of NaLac, it was 
observed less c-Myc interaction with the MCT1 promoter region (Figure 23) which could contribute to the 
higher luciferase activity observed for MCT1 f2 deletion construct in cells grown in the presence of NaLac 
comparing to those grown in its absence (Figure 21). This higher MCT1 promoter activity was reflected in 
higher MCT1 expression and protein levels (Figures 11b and 13) comparing to those obtained in cells grown in 
control conditions. On the other hand, in the basis of this increased MCT1 expression could be the action of c-
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Myc, in this specific setting, as an activator, as other authors had proposed (Kang et al., 2009). The elucidation 
of c-Myc transcriptional activator or repressive effects will result from the study of its partners. 
The luciferase activity of LDHB deletion constructs and, consequently, LDHB promoter activity could 
not be explained by the interaction with c-Myc transcription factor since the search in TFsearch database 
revealed the lack of N-Myc/c-Myc putative binding sites at this promoter. In HeLa cells grown in the presence 
of NaLac, it was observed a slight increase in the activity of LDHB f1 deletion construct (Figure 20) and this 
was reflected at mRNA and protein levels (Figures 7a, 8 and 9). However in EGF-stimulated HeLa cells the 
activity of this construct was lower than in unstimulated cells (Figure 20) but their grown in the presence of 
NaLac promoted its increase (Figure 20). This increase was not reflected at mRNA neither at protein levels 
(Figures 7a and 8). 
In SiHa cells grown in the presence of NaLac it was observed an increase in the activity of LDHB f1 
deletion construct (Figure 20) that was reflected at mRNA (Figure 7b) and protein levels (Figures 8 and 10). In 
EGF-stimulated SiHa cells this increase was even higher (Figure 20) and was also reflected at mRNA (Figure 
7b) and protein levels (Figures 8 and 10). NaLac seems to potentiate the activator effect of EGF once the 
activity of this promoter was even higher when EGF-stimulated cells were grown in its presence (Figure 20) 
and, despite of not being reflected at mRNA levels, at protein levels this was evident (Figure 8). Recent data 
revealed transactivation of LDHB gene expression by a signal transducer and activator of transcription 3 
(STAT3), a key tumorigenic driver in many cancers that acts as a downstream mTOR effector in human cancer 
cells (Zha et al., 2011). Regarding a potential EGF-mediated activation of LDHB, previous data had shown that 
purified EGFR kinase phosphorylates key regulatory enzymes of the glycolytic pathway, such as 
phosphofructokinase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in an EGF-dependent 
manner, but not LDH (Reiss et al., 1986). 
Gene amplification is an important mechanism of oncogene activation and is crucial for the 
development and progression of cancer. The identification of frequent copy number change in certain 
chromosomal regions can lead to identification of functional important genes in carcinogenesis and can be 
used as prognostic markers (Kornegoor et al., 2012). The c-Myc gene has long been known to be altered by 
chromosomal translocations and gene amplification in human cancers (Dang et al., 2009). 
 In HeLa cells, it was detected genetic c-Myc amplification, being duplication the most frequently 
detected alteration, by FISH analysis (Figures 24a, 24b and Table 14). Four Myc gene copies would 
theoretically be present in nuclei in the process of DNA synthesis before mitosis, however the number of 
centromeric signals is reportedly unchanged throughout the cell cycle (Takahashi et al., 1998). Previous data 
indicated that c-Myc gene sequence amplification was most likely triggered by HPV 18 viral insertion at a 
single integration site in HeLa cells (Macville et al., 1999). Accordingly to these authors FISH localization of 
HPV 18 integration at the c-Myc locus in HeLa cells is common and representative for advanced stage cervical 
cell carcinomas (Macville et al., 1999). c-Myc gene amplification has been identified as one of the critical early 
events in the progression of uterine cervical lesion (Aoyama et al., 1998). However, other authors concluded 
that there was no significant difference in c-Myc gene amplification in samples with some type of CIN or cancer 
compared to those from normal cytology, only a slight gain of 12% for cancer samples when compared with 
samples from patients with a normal cytology result (García et al., 2011). 
Considering FISH analysis it was possible to conclude that, in SiHa cells, aneuploidy is in the basis of 
increased number of c-Myc copies (Figures 24c, 24d and Table 14). Previous data reported that numerical 
abnormalities involving chromosome 8, in which c-Myc is located, have been suggested as a mechanism 
accounting for the increased c-Myc copy number (Takahashi et al., 1998). 
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Additionally, FISH results obtained for SiHa cells (Figure 24c,24d and Table14 and tableA1, Appendix 
II) were in concordance with previous data that showed, also through FISH, that the distribution of c-Myc copy 
number ranged from 3 to 5 copies in SiHa cells (Harris et al., 2003). 
The c-Myc oncogene seems to be fundamental in the carcinogenesis process. Thus, the increase of 
the number of alleles of the proto-oncogene c-Myc is directly related to the degree of aggressiveness of the 
tumor, considering that the more copies of it there are, the higher level of its expression (Calcagno et al., 
2005). 
Given the results of c-Myc analysis by FISH and the existence of previous reports indicating an 
association between c-Myc amplification and malignant phenotypes (Hale et al., 1993; Pfeiffer et al., 1989) 
tissue microarrays of AC and SCC of the uterine cervix cases were analyzed through c-Myc/Chromosome 8 
FISH. Besides that, considering the previously referred MCT1 overexpression detected in uterine cervix cancer 
(Pinheiro et al., 2009) and the proposed c-Myc regulation of MCT1 expression, these tissue microarrays were 
also analyzed by immunohistochemistry for MCT1.  
MCT1 immunohistochemistry analysis revealed important differences between normal ectocervix 
(Figure 28) and normal endocervix (Figure 29), in terms of MCT1 immunodetection. It was verified that normal 
ectocervix samples were mainly positive for MCT1 while normal endocervix ones were mainly negative. These 
observations pointed out the crucial role of microenvironment on gene expression regulation. The squamous 
epithelium of the ectocervix is nearer to the lactate-enriched microenvironment and this seems to have 
important consequences at the regulation of MCT1 expression, increasing it.  By its turn, the glandular 
endocervical epithelium is distant from the lactate-enriched microenvironment what could contribute to the 
decreased MCT1 expression.  
Additionally, the analysis of tissue microarrays of AC and SCC of the uterine cervix cases revealed 
that, concerning AC cases, only two were positive for MCT1 and are diploid (normal) for c-Myc (Figures 25,26 
and 27). Regarding SCC cases, it seems that the increase in c-Myc copy number is associated with increase 
in MCT1 immunodetection despite of the detection of c-Myc diploid (normal) cases expressing MCT1 with 
several intensity Figures 28 and 29). Accordingly to Policht et al., 2010, in SCC, c-Myc positivity rate (that is c-
Myc gain) was 100% (Policht et al., 2010). Additionally, it has been revealed that MCT1 protein expression 
appeared to be upregulated by c-Myc overexpression (Kang et al., 2009).  
Comparing to AC cases, SCC cases revealed higher, and with different intensities, MCT1 
immunodetection what is not in concordance with a previous study by Pinheiro et al., 2009. These authors had 
described that MCT1 was not differentially expressed among the three histological types of uterine cervix 
cancer studied (SCC, AC and adenosquamous carcinoma) (Pinheiro et al., 2009). 
 The analysis of SCC cases by FISH had shown that, in terms of c-Myc altered copy number, 
aneuploidy (22.7%) was the most frequently detected as shown in FISH analysis of SiHa cells. FISH analysis 
of AC cases revealed aneuploidy (2 cases in a total of 14 AC cases) in c-Myc copy number while the same 
analysis performed in HeLa cells did not revealed it.  
AC and SCC microenvironment is quite different and this could explain the differences obtained, in 
terms of MCT1 expression, in both types of uterine cervix cancer. It has been described that high lactate 
concentration is one of the defining characteristics of the physiological microenvironment of locally advanced 
squamous cell carcinomas of the uterine cervix (Schwickert et al., 1995). 
Integrating the results from MCT1 immunodetection in SCC and those obtained for MCT1 expression 
in SiHa cells (obtained from squamous cell carcinoma) the lactate-enriched microenvironment where SCC 
develops seems to contribute to the upregulation of MCT1. These observations suggest that tumor 
microenvironment can play a role in cancer cells selection and tumor progression.  In the oxidative context 
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where SCC cancer cells develop, the upregulation of MCT1 confer crucial advantages to these cells, given its 
importance in lactate uptake. Additionally, this upregulation could be in the basis of a switch from glucose to 
lactate consumption in SCC tumors as described in SiHa cells (previously referred). The crucial role of tumor 
microenvironment had also been pointed out in a report by Sonveaux et al., 2008, where the authors revealed 
that microenvironmental influences can stimulate MCT1-mediated lactate consumption, which is otherwise 
nonexistent in vitro (Sonveaux et al., 2008). 
In HeLa cells (obtained from adenocarcinoma) we proposed that MCT1 expression could be 
negatively regulated by c-Myc in cells grown in the presence of NaLac. However, considering AC cases 
analysis, and due to the low lactate concentration found in the microenvironment where this type of tumor 
develop, our observation cannot be transposed to this scenario. In AC cases, the low lactate levels, seems 
promote MCT1 downregulation. Or we can think in a different way: the low lactate levels presented in the 
microenvironment where this type of tumor develops select tumor cells expressing low MCT1 given their lower 
requirement of lactate uptake, comparing to SCC tumor cells. 
Metastatic spread of malignant cells via migration and invasion to distant area such as pelvic lymph 
node is the primary cause of treatment failure and subsequent death in uterine cervix cancer patients (Chiang 
et al., 2008). So, in the present thesis it was also evaluated SiHa cell migration in different culture conditions. 
The study of SiHa cell migration, assessed by in vitro Wound Healing assay (Figures 31 and 32) 
revealed higher cell migration rate in cells grown in the presence of NaLac comparing to cells grown in its 
absence (Figures 31 and 32). This is in concordance with previous data that had shown a link between lactate 
accumulation in tumors and enhancement of tumor cell migration (Walenta & Mueller-Klieser, 2004). Besides 
that, data from Bonuccelli et al., 2010 evidenced that L-lactate functioned as chemo-attractant, stimulating the 
migration of epithelial cancer cells, in transwell assay So, accordingly to these authors, the metabolic products 
of aerobic glycolysis can function as chemo-attractant for cancer cells, probably via a form of nutrient sensing 
(Bonuccelli et al., 2010). Additionally, Végran et al., 2011 found that lactate could enter endothelial cells 
through MCT1, trigger the phosphorylation/degradation of IkBα, and then stimulate an autocrine NF-kB/IL-8 
(CXCL8) pathway driving cell migration and tube formation (Végran et al., 2011). 
Wound healing in vitro assay also revealed that EGF stimulation of SiHa cells grown in the presence 
of NaLac seems to promote cell migration (Figures 31 and 32). This result is in concordance with previous 
results from Shen et al., 2006 that had shown that EGF is a potent stimulator of uterine cervix cancer cell lines 
(SiHa and CaSki) migration and invasiveness (Shen et al., 2006).  Moreover, in a non tumoral context, Zhuang 
et al., 2004 had proposed that EGFR mediates RPTC migration following injury and in response to EGF 
(Zhuang et al., 2004). 
Some mechanisms that could be in the basis of the EGF-mediated uterine cervix cancer cells 
migration had been proposed. Chiang et al., 2008 revealed that uterine cervical cancer cells benefit some 
enhanced cellular functions from Na+/H+ exchanger 1 (NHE1) abundance, such as cell volume regulation, 
migration, and invasion (Chiang et al., 2008). These authors had shown colocalization of NHE1 with EGF in 
uterine cervical cancer tissues (Chiang et al., 2008). Besides that, studies in cell culture systems indicated that 
EGF upregulates NHE1 abundance in a time-dependent manner by post-translational regulation (Chiang et al., 
2008). So, accordingly to these authors, NHE1 activity is necessary for EGF-mediated cancer cell migration 
and invasiveness (Chiang et al., 2008). 
Additionally, EGF plays an important role in the regulation of cell growth and proliferation (Carpenter 
& Cohen, 1990). It is known that EGF is a mitogen for estrogen receptor (ER). It has been recently proven that 
this growth factor occasionally mimics estrogen action and cross-talk with ER-α to exert its activity (Narayanan 
et al., 2012).  
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Previous data had indicated that the malignant transformation of the SCC of the uterine cervix is 
associated with several molecular events, including cell cycle aberration (Clarke & Chetty, 2001). So, SiHa cell 
cycle analysis was performed trying to establish a potential role of NaLac and/or EGF on cell cycle regulation. 
Cell cycle analysis of SiHa cells revealed that the majority of the cells were in G1 phase despite of 
culture conditions (Figure 33) of these cells. This could be result from deficient synchronization of cells. Other 
authors also promote cell synchronization by serum starvation however, for a period of 48 hours (Nicolas et al., 
2003). Another study suggests serum starvation for two days followed by a treatment with 5 µM aphidicolin for 
16 hours for chemical synchronization of SiHa cells (Shen et al., 2000).  
Besides that, it was observed a statistically significant increase in the percentage of cells in G1 phase 
after 6 hours in EGF-stimulated cells comparing to cells grown in control conditions and a statistically 
significant decrease in the percentage of cells in S and G2/M phases (Figure 33).  The decrease in the 
percentage of cell in the S phase indicates a decrease in the rate of DNA synthesis indicating cell cycle arrest. 
The same tendency was verified in EGF-stimulated cells grown in the presence of NaLac, after 6 hours (Figure 
33). However, after 24 hours it was seen a statistically significant decrease in the percentage of cells in G1 
phase and an increase in those in S phase and G2/M (not statistically significant) in cells stimulated with EGF 
and grown in the presence of NaLac comparing to cells grown in control conditions (Figure 33). Besides that, 
at this time point, it was observed a statistically significant increase in the percentage of cells in S phase in 
cells stimulated with EGF comparing to cells grown in control conditions (Figure 33). This data suggests that 
EGF-stimulated cells undergo an increase in the rate of DNA synthesis (as indicated by the increase in the 
percentage of cells in the S phase) leading to cell cycle progression. This observation is in concordance with 
recent data in HeLa cells (Narayanan et al., 2012). 
Accordingly to Narayanan et al, 2012, an exogenous EGF stimulation may enhance HPV-related 
uterine cervical cancer cell proliferation by activating EGFR and cyclin D1 that is independent of COX-2 levels 
(Narayanan et al., 2012). Previous data, in a human prostate cancer cell line, also showed that EGF induces 
cyclin D1, a protein required for cell cycle progression from G1 (Perry et al., 1998).  
 Considering cell cycle analysis data, and in order to evaluate SiHa cell proliferation in the various 
culture conditions, a proliferation curve was performed (Figure 34). This assay revealed that after 24 hours of 
EGF stimulation in the presence of NaLac it was seen a statistically significant higher number of cells per mL 
comparing to the cell number obtained in control conditions (Figure 34). Through this analysis it was possible 
to suggest that EGF promotes cellular proliferation which is in accordance with cell cycle progression 
previously referred.  
 So, in SiHa cells EGF stimulation of cells grown in the presence of NaLac seems to promote cell 
migration and cell cycle progression and proliferation. In SiHa cells, the identification of increased c-Myc copy 
number (as result of aneuploidy) and given the important role of c-Myc in, not only, the regulation of cell 
metabolism but also the induction of cell proliferation, this phenotype could be mediated by this crucial 
oncogene. Other authors proposed that c-Myc acts pleiotropically to transform cells by upregulating 
components of the cell cycle machinery such as CDC25A (Galaktionov et al., 1996), stimulating the production 
of biosynthetic enzymes such as ornithine decarboxylase (Bello-Fernandez et al., 1993) to prepare cells for S-
phase entry, and activating the expression of metabolic enzymes such as LDHA to ensure an adequate supply 
of energy or signals for cell proliferation (Shim et al., 1997). However, we proposed that c-Myc role in inducing 
cell proliferation and migration could be, in this context, via MCT1. This could be supported by previous data 
suggesting that MCT1 have an important role in tumor progression since it was shown that inhibition of MCT1, 
either pharmacologically or using RNA interference (RNAi), results in the inhibition of xenograft tumor growth 
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(Tennant et al., 2010; Sonveaux et al., 2008) and also by the recent observation that high expression of both 
MCT1 and MCT4 correlates with the invasiveness of lung cancer cells (Izumi et al., 2011).  
While some early reports on c-Myc targets suggested that individual genes might be critical to 
mediate c-Myc’s ability to transform cells, our results are in concordance with more recent models assuming 
that it is the combinatorial effect on different c-Myc target genes and their products that control cell 
transformation. So, the knowledge about the potent role of c-Myc in tumorigenesis but also as a regulator of 
many cellular processes, including basic aspects of metabolism, cell cycle control, differentiation, and 
apoptosis, suggests that this oncoprotein must be precisely and decisively regulated (Lüscher, 2012). 
 Taking into consideration all the results obtained during this experimental work, it is important to 
underline the crucial role of NaLac either in association with EGF or not in the regulation of critical steps of 
central metabolic pathways essential to cell survival, maintenance and proliferation. Our data pointed out the 
necessity of consider all intervenients in the metabolomic plateau in the study of cancer metabolism and our 
study aim to illustrate the several metabolic alterations and adaptations of tumor cells that can contribute, 
ultimately to the establishment of new therapeutic targets.  
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6. Future perspectives 
 
In order to better understand c-Myc regulation of LDHA and MCT1 expression, as future perspectives, 
it would be important to generate mutated promoter constructs, by site mutation, abolishing c-Myc binding to 
this region and evaluate promoter activity.  It would be also important to clarify the context of gene expression 
regulation by c-Myc, namely through the identification of its partners in the different conditions, given its dual 
role in gene expression regulation. 
Besides that, the evaluation of LDHB expression regulation by STAT3, either in the presence and 
absence of NaLac and EGF stimulation, would contribute to validate the proposed role of this transcription 
factor on that regulation.  
It would be also important to generate MCT4 deletion constructs and perform chIP analysis for c-Myc 
in order to assess if this transcription factor could be in the basis of MCT4 upregulation in cells grown in the 
presence of NaLac. 
Additionally, the establishment of in vivo models namely to perform the inhibition of MCT1 and to 
evaluate the consequences for tumor growth constitutes an important future approach. 
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7. Conclusions 
Emerging evidence indicates that impaired cellular energy metabolism is the defining characteristic of 
nearly all cancers regardless their cellular or tissue origin. Frequently, tumor cells have a remarkably different 
metabolism from that of the tissues from which they are derived. Although NaLac is generally considered a 
waste product, several studies show that it is a prominent substrate that fuels the oxidative metabolism of 
some oxygenated tumor cells. In uterine cervix, mainly ectocervix, the NaLac rich microenvironment may play 
a role in cancer cells selection due to their ability of consuming lactate as carbon and energy source. The 
study of the enzymes involved in lactate production (LDHA) and consumption (LDHB), as well as its 
transporters (MCTs), will help to define new therapeutic targets. 
Our findings suggested c-Myc activation of LDHA expression in HeLa cells grown in the presence of 
NaLac and gene amplification of c-Myc in this cell line. Regarding SiHa cells it was observed LDHA 
upregulation, at mRNA level, by NaLac however, not c-Myc-mediated.  
Additionally, our data indicated that, in both cell lines, NaLac promotes LDHB expression. In SiHa 
cells EGF stimulation also promotes LDHB expression, being this activator effect increased by NaLac 
presence. We proposed NaLac-mediated c-Myc repression of MCT1 expression in HeLa cells. In SiHa cells 
we suggested that in the presence of NaLac there is a decrease in c-Myc interaction with MCT1 promoter 
region (as a repressor), promoting MCT1 expression, or an alternative role of c-Myc as an activator of MCT1 
gene expression in this context. The elucidation of c-Myc transcriptional activator or repressive effects will 
result from the study of its partners. 
The data from SCC and SC cases pointed out the crucial role of tumor microenvironment in tumor 
cells selection. In the oxidative context where SCC cancer cells develop, the upregulation of MCT1 confer 
crucial advantages to these cells, given its importance in lactate uptake. Additionally, this upregulation could 
be in the basis of a switch from glucose to lactate consumption in SCC tumors as described in SiHa cells. In 
AC cases, the low lactate levels, seems to promote MCT1 downregulation, or, by another hand, select tumor 
cells expressing low MCT1 given their lower requirement of lactate uptake, comparing to SCC tumor cells. 
Finally, considering all the results obtained during this experimental work, it is important to underline 
the crucial role of NaLac either in association with EGF or not in the regulation of critical steps of central 
metabolic pathways essential to cell survival, maintenance and proliferation. 
Summing up, we observed that NaLac, EGF and c-Myc regulate the expression of MCT1 in both 
HeLa and SiHa cells. In vitro, c-Myc plays a role in MCT1 expression both as activator and as repressor, 
depending on culture conditions and on cytogenetic alterations. In tissue arrays, we also observed in SSC a 
trend between the number of chromosome 8 and the expression of MCT1, in 23 cases with cytogenetic 
alterations, 17 (74%) are positive for MCT1. In SCC, MCT1 can be a suitable therapeutic target, since it is 
expressed in the majority of cases and, as we observed in vitro, there is a trend between the expression of 
MCT1 and the proliferation rate of cells. 
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Schematic representations of LDHA, LDHB, MCT1 and MCT4 gene expression regulation in HeLa 
and SiHa cells are presented in figure 35 and 36, respectively. 
 
 
Figure 35 - Schematic representation of LDHA, LDHB, MCT1 and MCT4 gene expression regulation in HeLa cells. In HeLa cells 
it was detected c-Myc genetic amplification. MCT1 expression is negatively regulated by c-Myc in cells grown in the presence of NaLac. 
LDHA expression is activated by c-Myc interaction with LDHA promoter in cells grown in the presence of NaLac. NaLac also promotes 
MCT4 expression. Both NaLac and EGF promote LDHB gene expression that could be regulated by STAT3.  
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Figure 36 - Schematic representation of LDHA, LDHB, MCT1 and MCT4 gene expression regulation in SiHa cells. SiHa cells are 
aneusomic (more than 2 copies) for chromosome 8, where c-Myc is located. c-Myc regulates negatively MCT1 expression in the 
absence of NaLac and this effect is reverted in the presence of NaLac. NaLac promotes LDHA upregulation, at mRNA level, in a non-c-
Myc mediated manner. EGF stimulation of cells promotes LDHB expression, being this activator effect increased by NaLac presence, 
and possibly mediated by STAT3. NaLac also promotes MCT4 expression.  
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Appendix I 
Solutions prepared for the experimental work:  
Luria-Bertani (LB) medium (Sambrook & Russel, 2001) 
For 1L:  
10g Tryptone (L42, Oxoid) 
5g Yeast extract (403 687,Cultimed) 
10g NaCl (106404, Merck) 
ddH2O to 1L 
 
10X PBS (pH 7.4-7.6) (Sambrook & Russel, 2001) 
For 1L: 
80g NaCl (1.37M) (106404, Merck) 
2g KH2PO4 (14.7mM) (104873, Merck) 
11.1g Na2HPO4 (78.1mM) (S-0876, Sigma) 
2g KCl (26.8mM) (104936, Merck) 
ddH2O to 1L 
 
10X TBS (pH 7.4-7.6)  
For 1L:  
8g NaCl (106404, Merck) 
0.63g Tris (15504-038, Gibco BRL) 
4.4 mL hydrochloric acid (1M)  
ddH2O to 1L  
 
5X SDS gel loading buffer (Sambrook & Russel, 2001) 
250 mM Tris HCl (pH 6.8) (0.5M 161-0799, Bio-rad) 
10% SDS (V6551, Promega) 
0.5% bromophenol blue 
50% glycerol (1.04094.1000, Merck) 
 
Transfer buffer (Sambrook & Russel, 2001) 
For 5L: 
75g glycine (US16407, USB) 
15g Trizma-base (T-8524, Sigma)  
ddH2O to 4L 
1L absolute ethanol (100983, Merck) 
5mL 10% SDS (V6551, Promega) 
 
15% resolving gel and 5% stacking gel for Tris-glycine SDS-Polyacrylamide Gel Electrophoresis prepared 
accordingly to Sambrook & Russel, 2001 
PBS 0.1% (v/v) Tween 20 
For 1L: 
1mL Tween 20 (20605, USB) 
1X PBS to 1L 
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PBS 0.2% (w/v) BSA  
0.4g BSA (A9647, Sigma) 
200 mL 1X PBS 
 
PBS 0.2% (w/v) BSA 0.1% (v/v) Triton X-100 
For 4mL: 
3.96 mL PBS 0.2% (w/v) BSA  
40 µL 10% Triton X-100 diluted in ddH2O (100% Triton X-100, T8787, Sigma) 
 
3% (w/v) skim milk in PBS 0.1% (v/v) Tween 20 
3g skim milk (Molico, Nestlé) 
100 mL PBS 0.1% (v/v) Tween 20 
 
RIPA buffer 
For 10 mL: 
20 mM Tris-HCl pH 7.5 
150 mM NaCl  (106404, Merck) 
5mM KCl  (104936, Merck) 
5mM MgCl2 (M-8266, Sigma) 
1% Triton X-100 (T8787, Sigma) 
ddH2O to 10 mL 
1 Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablet (11836170001, Roche) 
1 mM Orthovanadate (Na3VO4) 
 
50 µg/mL Propidium Iodide (PI) solution  
For 50 mL: 
1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in 1X PBS) 
49 mL 1X PBS 
0.1 mg/mL RNase A (Easy spin kit, Citomed) 
0.05% Triton X-100 (T8787, Sigma) 
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Appendix II 
 
Figure A1 - Negative controls of immunofluorescence for SiHa and HeLa cells. Fluorescence microscopy (original magnification: 
200x). Nuclei were stained with DAPI (blue). Scale bar 100 µm. 
 
 
 
 
Figure A2 - Copy number analysis of c-Myc with Fluorescent in situ hybridization (FISH). Representative experiments of FISH 
analysis of c-Myc in HeLa (a,b) and SiHa (c,d) cells are shown. The probe used for c-Myc detection was the LSI MYC Dual Color, 
Break apart rearrangement probe that is a mixture of two probes that hybridizes to opposite sides of the region located 3’ of MYC (8q24 
LSI MYC SpectrumOrange, SpectrumGreen). Nuclei in interphase were counterstained with DAPI. 
Table A1 - Frequency (in percentage) of c-Myc copy number detected in 
SiHa and HeLa cells assessed by FISH, using 8q24 LSI MYC probe. 
 
